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Abstract 
 
A library of potentially bioactive peptidomimetic compounds has been created using the Ugi and 
Passerini multi-component reactions. The products were isolated as racemic mixtures which we aimed 
to separate by enzymatic means.  
The Ugi enantiomers were obtained in exceedingly low yields due to considerable byproduct 
formation encountered with the use of ammonia as reactant and methanol as solvent. A threefold 
increase in the yields was achieved when employing the less nucleophilic 2,2,2-trifluoroethanol as 
solvent. An endeavour to resolve the racemates using proteases and penicillin G acylase proved 
unsuccessful, possibly attributable to the poor solubility of the Ugi products in a broad range of organic 
solvents. 
Enantiomers obtained from the Passerini reaction were efficaciously hydrolysed by lipase enzymes. 
Hence, the enantioselectivity of the hydrolysis reactions was explored by the employment of chiral 
HPLC and Mosher ester analysis. The biocatalysts displayed adequate selectivity for one of the 
adducts, making prospective separation of the racemic mixture viable. 
An investigation into the diastereoselectivity of the Passerini reaction was also performed. The 
application of phenylalanine-derived chiral starting materials in the reaction was seen to have a slight 
effect on reaction diastereoselectivity, giving on average a 2:1 diastereomeric ratio. Slightly greater 
d.r. values were obtained when bulkier isocyanides were employed. The diastereomeric mixtures 
were effectively separated via preparative HPLC to obtain pure compounds. 13C NMR spectroscopy 
indicated a trend in the chemical shift values for the newly formed stereogenic carbon centres for 
most of the two separated diastereomers. The C-2 values of most of the minor diastereomers 
appeared more downfield in comparison to the major diastereomers. Distinguishing the 
stereochemistry of the major and minor diastereomers through X-ray crystallography was not possible 
as the compounds were non-crystalline. Thus the configurations of the newly formed stereogenic 
centres of the major compounds were assigned by analogy with similar compounds previously 
identified in our laboratory. The major compounds were described as R at the newly formed 
stereogenic centre when L-phenylalaninal was used, and the minor products S. When D-phenylalaninal 
was used, the major diastereomer was assigned an S configuration at the newly formed stereocentre 
and the minor one was assigned R. The formation of the major diastereomer could be explained using 
a Felkin-Anh chelation controlled model, which has been observed in other reactions of mono-
protected amino aldehydes. 
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Chapter 1: Introduction 
 
1.1 Peptidomimetic Compounds 
 
Proteins and peptides are bioactive molecules that are central to a multitude of physiological 
processes. They fulfil both structural roles - strengthening and preserving cells and tissues, and 
functional roles.1-3 As enzymes, hormones and neurotransmitters, peptides can catalyse reactions, 
regulate gene expression and participate in cell signalling and transduction. Peptides are also involved 
in the advancement of several diseases, hence scientists have gained interest in developing these 
molecules as therapeutic agents against HIV, cancer and a range of other diseases.4, 5 However, the 
potential of these biomolecules as drug candidates is severely limited by their unfavourable 
pharmacological properties. Peptides and proteins are ordinarily poorly absorbed, rapidly degraded 
and exhibit low specificity which leads to undesirable side effects.6-8 Subsequently, peptidomimetic 
compounds have been synthesised to overcome these drawbacks.  
 
A peptidomimetic compound is an organic molecule that resembles the structure and biological 
activity of a natural peptide or protein, but has superior properties that lead to its function as a drug.9-
11 This is achieved by structurally altering existing peptides, predominantly through incorporating 
unnatural amino acids into their backbone and by modification of side chains which results in 
enhanced stability against protease degradation, improved specificity and bioavailability and a 
considerable increase in activity. This holds peptidomimetics as a valuable tool for the progression of 
novel anti-viral, anti-malarial, anti-tumour and immunosuppressant drugs.2, 12 
 
Lopinavir, ritonavir and saquinavir (Figure 1) are some well-known examples of successfully 
synthesised peptidomimetic drugs that are FDA-approved as HIV protease inhibitors. HIV protease 
inhibitors (PIs) are compounds that inhibit the function of the HIV protease enzyme, making it an 
effective treatment for HIV/AIDS sufferers.13 These drugs structurally mimic the natural substrate of 
the virus’ enzyme but contain a non-scissile hydroxyethylamine moiety in place of the normal amide 
group of the viral peptide (Figure 1). These compounds inhibit the enzyme’s ability to cleave 
polypeptides into functional proteins which is crucial for replication of the virus, rendering HIV 
inactive.13-17 
 
13 
 
 
Figure 1: Scissile bond of the viral polypeptide versus the non-cleavable hydroxyethylamine core of 
the HIV PIs.18 
 
Another renowned class of peptidomimetics are angiotensin-converting enzyme (ACE) inhibitors 
which are used to treat hypertension. ACE is a metalloprotease that operates analogously to HIV 
protease and is responsible for the cleavage of the peptide angiotensin I to angiotensin II which both 
directly and indirectly increase blood pressure.19 Thus ACE inhibitors like captopril and enalapril 
disturb this cascade of reactions, normalising blood pressure with enhanced bioavailability and less 
side-effects than non-peptidic antihypertensive drugs. Additionally these inhibitors are also active 
diabetic nephropathy and congestive heart failure medications.20-23 The structure of captopril was 
based on a nanopeptide, teprotide (Figure 2) contained in the venom of the poisonous snake Bothrops 
jararaca. This peptide is a powerful inhibitor of ACE and results in an instantaneous decrease in blood 
pressure, making it a fascinating tactic for the snake to capture it’s prey. Although the activity of 
teprotide was undeniable, it was costly and not orally bioavailable. Scientists deduced that the proline 
residue at the terminus was responsible for the activity of this peptide, hence after considerable 
modification they designed captopril which retained the vital amino acid and included a sulfhydryl 
functionality which led to an astounding increase in activity of a thousand-fold.24, 25 
14 
 
 
 
Figure 2: Peptidomimetic ACE inhibitors. 
 
The initial strategy for synthesising peptide mimics entails identification of essential amino acid 
residues mandatory for bioactivity through structure/conformation/activity relationships of the native 
peptide.26, 27 Scaffolds are then designed to modify the peptide by introducing non-hydrolysable amide 
bond isosteres or conformational restraints until a hit compound is found. Syntheses of these 
analogues typically involves a series of time-consuming linear reactions and is often not simple to 
achieve libraries of structurally diverse compounds.27-30 For instance Merck designed an anti-HIV drug 
Raltegravir (Scheme 1), which contains a 1,3,4-oxadiazole five-membered heterocyclic ring.31 The 
synthetic route is lengthy, comprising of six linear reactions with protection and deprotection steps. 
The complete synthesis requires over 100 hours of reaction time excluding chromatographic 
purification.31 Hence, the development of more straightforward reactions that can be used in a “model 
synthesis” is imperative. 
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Scheme 1: Synthesis of Raltegravir. 
 
1.2 Multicomponent Reactions 
 
A “model chemical synthesis” is one in which the anticipated product is attained in close to a 100% 
yield from a reaction comprising the minimal number of steps. The experimental procedure should be 
safe, effortless and fast whilst utilising inexpensive materials and techniques which pose no harm to 
the environment.32, 33   
 
Multi-component reactions (MCRs) first established by Laurent and Gerhardt in 1838 closely reflect a 
“model chemical synthesis”.32 MCRs are one-pot reactions in which three or more reactants combine 
to form a single composite product.34, 35 The reaction occurs in a series of fundamental steps which 
proceeds to the final irreversible reaction where the compound is obtained.36 Since a variety of 
starting materials with diverse functional groups can be incorporated, a vast library of compounds can 
be created to be screened for use as possible therapeutic agents.37-39  
 
MCRs are atom-economical in that most of the reactant material is included in the product (Figure 3). 
The amount of solvent used is also lessened as the process is completed in one step, deeming it 
efficient and environmentally-friendly. The formation of by-products is negligible which results in a 
higher yield as compared to a multistep synthesis. Perhaps the most advantageous feature of MCRs is 
post-transformation and modification of the products which leads to increasingly structurally complex 
compounds with potential bioactivity.34, 40 
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Figure 3: Illustration of a stepwise (multistep) reaction in comparison to a multicomponent reaction 
(MCR) which occurs in a single step.41 
 
1.2.1 Ugi Reaction 
 
The Ugi reaction accomplished by Ugi et al. in 1959 is an example of an isocyanide model of a MCR 
that is often used in medicinal and heterocyclic chemistry.42 Amongst its variations is the Ugi-four 
component reaction (U-4CR) which includes condensation of a carboxylic acid, aldehyde (or ketone), 
primary or secondary amine and an isocyanide to generate a stereogenic centre in the α-
acylaminocarboxamide product 1 (Scheme 2).43 
 
 
Scheme 2: Ugi-four component reaction in methanol. 
 
The U-4CR mechanism depends on the resonance of the isocyanide which converts from the C2 to the 
stable C4 form, allowing the C- to uniquely function as both an electrophile and a nucleophile.32 The 
reaction is usually performed at room temperature in polar, aprotic solvents; but success with 
methanol (and trifluoroethanol) as well as in aqueous media was reported by Thompson et al. and 
Mironov et al., respectively.40, 44 Scheme 3 outlines the U-4CR mechanism in which the carbonyl 
compound (aldehyde or ketone) and the amine initially precondense to form the Schiff base (imine) 
with the release of water. The carboxylic acid then protonates the imine nitrogen in the next step. The 
17 
 
third step involves the isocyanide reacting with the electrophilic iminium cation to give the nitrilium 
intermediate, which in turn reacts with the nucleophilic acid anion. The resulting intermediate then 
irreversibly undergoes intramolecular rearrangement to generate the final Ugi product.32 
 
 
Scheme 3: Mechanism of the U-4CR. 
 
Mironov et al. aimed to achieve a procedure for compound library production that is both easy and 
eco-friendly.44 Taking into account that high-throughput screening of biomolecules is conducted in 
water at physiological pH and room temperature, they prepared organic compounds via the U-4CR in 
an aqueous medium rather than using regular organic solvents. Although water is considered a poor 
solvent for the majority of organic molecules, its extraordinary properties can lead to advantageous 
results in synthetic chemistry. For instance, organic compounds aggregate in certain regions in water 
18 
 
owing to their hydrophobic nature. These regions are greatly concentrated and thus collisions 
between particles are quicker, resulting in faster addition reactions. Also aggregation of organic 
particles occurs in particular orientations which results in notable product selectivity.44, 45 
 
Using levulinic acid with several amines and isocyanides, Mironov et al. demonstrated that the Ugi 
reaction is successfully performed in aqueous conditions in good yields provided that the 
concentration of reactants are in the high range of 0.5 – 2.0 M.44 For starting materials that exhibited 
poor solubility in water, supersaturated solutions and surfactants were used and equally good results 
were obtained. Hence the feat of the Ugi reaction depends not only on the type of solvent used but 
also on the concentration of starting material present.44   
 
To obtain a collection of 5-aminothiazole and oxazole derivatives, Thompson and Chen executed the 
U-4CR with ammonia as the primary amine constituent.40 Exceptionally low yields were obtained in 
methanol solvent due to a large number of byproducts gained from side reactions often experienced 
when using ammonia in the Ugi reaction. This is due to the involvement of the alcoholic solvent in the 
presence of excess aldehyde via a six-component coupling (6-CC) reaction which leads to the 
formation of the most predominant byproduct 2 (Figure 4). In earlier research, Kazmaier et al. realised 
that since 2 was obtained using methanol, a less nucleophilic solvent like 2,2,2-trifluoroethanol would 
prevent possible side reactions thus leading to increased yields.40, 46, 47 Thompson and Chen proved 
this to be true and achieved nearly a twofold increase in the yields using 2,2,2-trifluoroethanol in 
comparison to methanol.40 In addition the protocol was simplified as fewer purification steps were 
required since generation of byproducts was almost negligible.  
 
 
 
Figure 4: Major byproduct 2 obtained with the U-4CR using ammonia and methanol. 
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1.2.2 Passerini Reaction 
 
The Passerini reaction is another isocyanide-type MCR akin to the U-4CR but features only three 
components, namely an acid, aldehyde (or ketone) and isocyanide which forms α-
hydroxycarboxamide compounds 3 (Scheme 4). To date there has been extensive use of both these 
MCRs in drug design and production of substantial compound libraries.48-51 
 
 
Scheme 4: Passerini reaction performed in dichloromethane. 
 
The Passerini reaction can be carried out in polar solvents, but was originally believed to occur more 
rapidly in aprotic solvents such as CH2Cl2 (Scheme 4). The latter route may follow a concerted non-
ionic pathway (Scheme 5) which involves H-bonding between the aldehyde and carboxylic acid. The 
isocyanide carbon acts as a nucleophile and electrophile to form a non-isolatable 5-membered 
transition state ring. An intramolecular acyl transfer to the adjacent hydroxyl group leads to 
rearrangement to the stable Passerini product 3.52 
 
 
 
Scheme 5: Mechanism of the Passerini reaction in aprotic solvents. 
 
Just as with the U-4CR, Pirrung et al. also proved the effectiveness of conducting the Passerini reaction 
in aqueous media.53 The reaction demonstrated in Scheme 6 was performed in both dichloromethane 
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and water. In contrast to previous reports, Pirrung found that the rate of the reaction was accelerated 
18-fold in water with 100% conversion achieved in only 3.5 hours.53 Dichloromethane afforded a 45% 
yield of the product after 18 hours as opposed to the excellent yield of 95% obtained in aqueous media 
at room temperature. The experiment was also carried out in water at 4 and 50 ˚C and outstanding 
yields were likewise noted as compared to organic solvents. Recent reports have credited the superior 
reaction rates of this MCR in water to the improved H-bonding in the transition state (Scheme 5) as 
well as the hydrophobic effect. This finding not only provides an efficient method for the Passerini 
reaction, but also presents an eco-friendly approach to complex organic molecules.53 
 
 
 
Scheme 6: Passerini reaction performed in dichloromethane and water. 
 
1.2.3 Application of MCRs 
 
Synthesis of the substructure 4-aminopiperidine-4-carboxylic acid present in carfentanil and 
remifentanil (Scheme 7) - opioid analgesics used for large animals and humans, respectively, typically 
comprises of 8 steps.54 Malaquin and co-workers attempted a simpler approach to this preparation 
using the Strecker multicomponent reaction but obtained the desired compound in very poor yields.37 
They later demonstrated that the Ugi reaction was more synthetically efficient and yielded no side-
products owing to the stable α-acylaminocarboxamide product formed (Scheme 7).37   
 
 
 
Scheme 7: Preparation of 4-aminopiperidine-4-carboxylic acid derivatives. 
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Merck has similarly employed the U-4CR (with subsequent enantioselective hydrogenation) in the 
manufacture of indinavir (CrixivanTM), another potent HIV protease inhibitor approved by the FDA in 
1996 (Scheme 8). Indinavir is a peptidomimetic compound which would conventionally be prepared 
in a 20-step synthesis, hence introduction of the U-4CR resulted in faster production, ultimately 
leading to a more affordable consumer product.32, 55 
 
 
 
Scheme 8: Synthesis of CrixivanTM, an approved HIV protease inhibitor using the U-4CR. 
 
The Passerini reaction has also been utilised in many instances. One notable application is the 
preparation of a phthalideisoquinoline alkaloid, hydrastine, which naturally occurs in the Hydrastis 
canadensis plant species, more commonly known as goldenseal (Scheme 9).56 This alkaloid has several 
pharmacological properties which include treatment of upper respiratory tract infections and 
postpartum haemorrhage.57 A four-step complete synthesis of hydrastine was described in 1981 by 
Falck et al. of which an intramolecular Passerini reaction was the pivotal step.58 The preparation 
started with an alkylation reaction which yielded 3,4-methylenedioxyphenethylisocyanide. This in turn 
reacted with opianic acid that functions as both the acid and aldehyde component of the MCR, 
followed by ring-closure, hydrogenation and reductive amination to form the final compound.58 
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Scheme 9: Synthesis of hydrastine. Reagents: a) CH2Cl2 b) POCl3, MeCN, PtO2, H2 c) NaBH3CN, COH2. 
 
The Hepatitis C virus (HCV) impacts more than 200 million people globally. It has become a major 
health concern as it can lead to cirrhosis, liver failure and cancer. Presently there are no vaccines for 
this infection, but treatment comprises of HCV NS3 protease inhibitors. The Passerini reaction is 
involved in the complete synthesis of the HCV PI telapravir (Scheme 10), a large molecule with complex 
stereochemistry. The reaction gives rise to diastereomers by coupling of a chiral aldehyde, cyclopropyl 
isocyanide and acetic acid with a favourable d.r. of 78:22.59, 60 
 
 
Scheme 10: Diastereomeric Passerini reaction as part of the total synthesis of telaprevir. 
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1.2.4 Diastereoselectivity of MCRs 
 
When starting with achiral reactants these isocyanide-MCRs lead to a 50:50 mixture of enantiomers 
as a new stereogenic centre is formed during the course of the reaction. If one of the starting materials 
already contains a stereogenic centre, a mixture of diastereomers will then be obtained. As a result 
enantiomerically/diastereomerically pure compounds are not achieved. This has a negative 
consequence, especially in drug design where only one enantiomer will exhibit activity and the other 
may be inactive or even harmful. However numerous post-modification processes, including 
enzymatic resolution which will be discussed later, can be applied to the products to overcome this 
matter.61 
 
Various studies have been done on the diastereoselectivity of both the Ugi and Passerini reactions. 
Chiral isocyanides and carboxylic acids have been found to have no momentous effect on the 
selectivity of the U-4CR, affording mostly 1:1 ratios of diastereomeric mixtures. Chiral aldehydes, 
especially α-alkyl-containing compounds, exhibit low configurational stability during the Ugi reaction 
and racemize relatively easily. On the other hand, amines containing a fixed stereogenic centre offer 
the greatest selectivity in comparison to the other starting materials of the U-4CR, but in most cases 
the d.r. values are still not exceptional.62 
 
In the early 1970s Ugi et al. first described the employment of chiral (+)-α-ferrocenylalkylamines in 
diastereomeric U-4CRs with benzoic acid, iso-butyraldehyde and t-butylisocyanide. 63, 64 Changes in the 
diastereoselectivity were seen under various solvent and temperature conditions, as well as with the 
alkyl substituent of the amine. When R = methyl (Scheme 11), a fair d.r. of 79:21 was observed in a 
yield of 90% at 0 ˚C in a methanolic solvent. Later studies reported an outstanding d.r. of 99:1 when 
using bulkier ferrocenylamines (R = isopropyl) at –78 ˚C. Regardless of the great selectivity, the use of 
these chiral amines have not been further examined due to instability and low recovery of these 
compounds.63, 64 
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Scheme 11: Diastereoselective Ugi reaction with chiral ferrocenylalkylamines. 
 
Mandai et al. investigated the diastereoselectivity of the U-4CR with α-amino acids and chiral DMAP-
derived aldehydes in methanol.65 Two aldehydes were utilised, 4-(dimethylamino)-2-
pyridinecarboxaldehyde and 4-(dimethylamino)-3-pyridinecarboxaldehyde (Figure 5) which delivered 
2- and 3-substituted DMAP analogues, respectively. Using L-valine at an optimal concentration of 0.5 
M of the former aldehyde, they discovered that the diastereoselectivity was moderate at 63:37. The 
structure of the amino acids presumably had no effect on the selectivity of the reaction. Using 4-
(dimethylamino)-3-pyridinecarboxaldehyde with L-valine afforded a superior d.r. of 84:16 under 
identical conditions. The best result of 93:7 d.r. was achieved with L-isoleucine, exhibiting a 
relationship of the α-amino acid structure and the latter aldehyde. Mandai et al. postulated that the 
preference of the formation of one diastereomer over the other was due to the prevention of steric 
hindrance from the bulky dimethylamino moiety from the aldehyde and the amino acid side chain 
during imine formation during the reaction. In addition, X-ray crystallography depicted an R-
configuration at the new stereogenic centre for the major Ugi diastereomer.65 
 
 
 
Figure 5: DMAP-based aldehydes. 
 
25 
 
Conventionally the carbonyl component in the Passerini reaction has only a minor influence on the 
stereoselectivity, yielding diastereomeric ratios varying between 1:1 and 4:1.66 On the contrary, 
Krishna and co-workers utilised p-toluenesulfonylmethyl isocyanide (TosMIC) in innovative 
asymmetric Passerini reactions with chiral glucose-derived aldehydes and attained average to notable 
d.e. values of 30 – 90% (Scheme 12).67 Although the diastereomers were not separately isolated by 
chromatographic purification, the d.e.’s were obtained using the integral ratios of the diastereomeric 
protons from 1H NMR data. In addition, the absolute configuration at the newly formed stereogenic 
centre of the major diastereomer was assigned as the ‘R- isomer’. This was also established via 
coupling constants from 1H NMR spectroscopy.67 
 
 
 
Scheme 12: Diastereomeric Passerini reaction with TosMIC. 
 
In the case of using chiral isocyanides in the Passerini reaction, Bock et al. achieved excellent 
diastereoselectivity using camphor-derived α,β-unsaturated isocyanides with aliphatic aldehydes 
(Scheme 13). However chiral isocyanides have a negligible effect on the diastereoselectvity of the U-
4CR. The Ugi reaction was carried out by the same research group with an additional benzylamine 
component and the d.r. was remarkably low at 10:6. 66, 68 
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Scheme 13: Diastereoselective MCRs using camphor-derived isocyanides. a) Passerini reaction b) U-
4CR. 
 
Banfi et al. studied the diastereoselectivity of peptidomimetic compounds as protease inhibitors via 
the PADAM (Passerini-amine deprotection-acyl migration) approach.69 This entailed the primary 
Passerini product spontaneously undergoing acyl migration once the amine group is deprotected by 
mediation of TFA. This gives rise to a product consisting of a hydroxyethylene amine entity, which is 
characteristic of most current PIs. They employed various chiral aldehydes based on amino acids in 
combination with an assortment of achiral isocyanides and chiral and achiral acids. The d.r. values 
obtained averaged at 2:1 with a greater value noted for the reaction in Scheme 14. The selectivity 
remained consistent regardless of the reagents involved. They did not however separate the mixture 
to ascertain the configuration of the major and minor diastereomers.69 
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Scheme 14: Reagents: a) CH2Cl2 b) TFA, CH2Cl2 c) Et3N. 
 
1.3 Enzymatic Kinetic Resolution/ Biocatalysis 
 
Enzymes are biological macromolecules which mediate most chemical transformations in living 
organisms. They are biocatalysts that decrease the activation energy required for processes, thereby 
speeding up reactions by up to 1021 times that of an uncatalysed reaction.70 Catalysis is achieved at a 
particular site on the enzyme called the active site, at which the enzyme interacts with the reactant 
or substrate by weak ionic, hydrogen or van der Waals forces. Enzymes are highly specific and only 
react with substrates that can bind in the active site. The major advantage of this is that all the 
substrate is converted to the desired product, eliminating the generation of by-products by side-
reactions, minimising waste and the negative impact on the environment.71  
 
Enzymes are proteins which require conditions close to those encountered in vivo to function. This 
generally includes low temperatures between 35 – 40 ˚C, pH of roughly 7.5 and dilute aqueous 
solvents. Extreme temperatures and pressures normally result in denaturation of the enzyme, 
inactivating it. The criteria for enzyme-function is mild, eco-friendly and requires less energy and high-
priced machinery, which is the key reason as to why even industries are attracted to biocatalysis for 
food and cosmetic production. Like all catalysts, enzymes are not altered or consumed during the 
reaction and can be used repeatedly after each catalytic cycle.72 
 
Biocatalysts exhibit chemo-, regio-, and stereo-selectivity - which makes them ideal in resolving 
racemic mixtures to obtain enantiomerically pure compounds, including those obtained from MCRs.71 
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This practice is referred to as enzymatic kinetic resolution (EKR), and occurs because enzymes react 
specifically or more rapidly with one enantiomer transforming it to the relevant product, and leaves 
the other unchanged, thereby allowing separation of the mixture. 61, 73, 74 
 
 
 
Figure 6: Outline of the combination of MCRs and biocatalysis to achieve stereochemically pure 
compounds. 
 
One illustration of biocatalysis in combination with the Ugi MCR (Figure 6) was reported by Klossowski 
et al.75 They set out to synthesise enantiomerically pure 1,3-diol peptidomimetic compounds which 
were previously used as kinase inhibitors, anticonvulsant agents and can act as intermediates in 
making effective anticancer treatments. Two EKR approaches were tested- one involved a 
diastereoselective method using lipase enzymes which acetylated compound 4 to compound 5 
(Scheme 15). The other route also employed lipases, and involved an enantioselective approach where 
the ester moiety of compound 4 was hydrolysed to a carboxylic acid in 6.75 
 
 
 
Scheme 15: Enzymatic resolution of 1,3-diol peptidomimetics using lipases. 
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In the first approach seven different lipases successfully catalysed the acylation reaction. They 
discovered that the solvent used is imperative in stereoselectivity of the lipase enzyme, and after 
investigating several organic solvents, diisopropyl ether was used.76 Maximum diastereoselectivity 
was exhibited with lipase Aspergillus oryzae with a disappointing d.e. of 48% being obtained.75 
 
Six different enzymes were found to hydrolyse the ester group in compound 4 in the second approach. 
This reaction yielded better results as compared to the acylation method. Exceptional 
enantioselectivity was observed with Candida antarctica and Rhizopus arrhizus lipase with e.e. of > 
99.9% and 82%, respectively. 
 
In conclusion Klossowski et al. effectively synthesised peptidomimetic compounds using the U-4CR, 
after which enantiomerically pure products were obtained by EKR with lipase enzymes.75 This 
combination of the U-4CR and biocatalysis proved to be a simple and versatile method in obtaining 
complex compounds with promising bioactivity.  
 
The same group also employed EKR in conjunction with the Passerini MCR to obtain enantiomerically 
pure compounds. For the synthesis of α-amino acids, Ostaszewski and colleagues applied the Passerini 
reaction using phenylacetaldehyde, acetic acid and p-methoxybenzyl isocyanide – of which the 
resultant product was selectively hydrolysed by Wheat Germ Lipase in 33% yield with an e.e. of 93% 
(Scheme 16).76, 77 They also ascertained that the hydrophobicity of the solvent greatly influenced the 
enantioselectivity of the reaction. Later they learnt that addition of a t-butyl ester group at the C-
terminus and using chloroacetic acid to provide a better leaving group for the hydrolysis, significantly 
enhanced the selectivity.76-78     
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Scheme 16: Preparation of α-amino acids using the Passerini reaction with EKR. Reagents: a) CH2Cl2, 
20 ˚C, 48 h b) Wheat Germ lipase, 8:2 phosphate buffer pH 7.0/ether, 20 ˚C, 48 h c) NaOH, 
MeOH/water, ultrasound, TosCl, Et3N,  CH2Cl2, 20 min. 
 
Scheme 17 shows the Passerini reaction implemented by Kourist et al. to prepare α,α-dialkyl-α-
hydroxylic acid esters, which are valuable intermediates in drug design.79 From more than 40 enzymes 
that were tested, an esterase of metagenomic origin afforded the best result.61, 79 
 
 
 
Scheme 17: Synthesis of enantiomerically pure tertiary alcohols employing the Passerini reaction in 
conjunction with enzymatic hydrolysis. Reagents: a) CH2Cl2 b) Esterase, phosphate buffer, DMF. 
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1.4 Proposed Synthesis 
 
The focus of this project is the synthesis of a library of peptidomimetic compounds using the Ugi and 
Passerini multicomponent reactions. The racemic mixtures generated from the reactions will be 
resolved by use of biocatalysts to obtain pure compounds with prospective bioactivity. 
 
First the U-4CR will be employed to prepare enantiomers as illustrated in Scheme 2. To afford Ugi 
products that are easily accessible to enzymes, we intend to use ammonia as the amine component 
in the reaction. This not only reduces steric hindrance due to the R3 group (Scheme 2), but also forms 
a secondary amide bond which is the basis of peptidomimetic compounds.47 Additionally we wish to 
compare the yields obtained when employing methanol and 2,2,2-trifluoroethanol as the solvents 
since significant byproduct formation occurs with the former as described earlier. To this point mainly 
lipases have been investigated for resolution of Ugi adducts, thus attention in this work will be on the 
application of EKR to U-4CR enantiomers using protease and penicillin G acylase enzymes.  
 
Secondly, EKR of the Passerini reaction starting from achiral starting materials will be investigated 
using lipases (Scheme 18). 
 
 
 
Scheme 18: Proposed enzymatic separation of Passerini enantiomers. 
 
Finally, the diastereoselectivity of the Passerini reaction will be investigated, starting from chiral 
aldehydes, acids and isocyanides. This is a continuation of work started in our laboratories by 
Zimuwandeyi.80 Zimuwandeyi made a library of compounds using a chiral aldehyde with achiral 
cyclohexyl-, xylyl- and adamantyl isocyanides and achiral acids. The diastereomeric ratios of the 
Passerini products were approximately 2:1 in each case (Scheme 19). On the other hand, using a chiral 
aldehyde with an isocyanide that also contains a stereogenic centre (phenylalanine isocyanide) 
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reduced the diastereomeric ratio to roughly 1.5:1.80 This preliminary data clearly indicated that the 
stereoselectivity of the Passerini reaction could be affected by the introduction of chiral starting 
material. Thus, our aim will be to fully investigate the reaction diastereoselectivity using chiral 
aldehydes, isocyanides and acids. 
 
 
 
Scheme 19: Diastereomeric Passerini reaction performed by Zimuwandeyi. 
 
The reagents will be synthesised from the commercially available amino acids, D- or L-phenylalanine. 
The Boc-protected version of phenylalanine will serve as the carboxylic acid component of the 
reaction. N-Boc-D- or L-phenylalaninal can be obtained from reduction of the Weinreb amide of N-
Boc-phenylalanine (Scheme 20). An extension of this synthetic route can be used to synthesise D- or 
L-phenylalanine isocyanide (Scheme 20). Adamantyl isocyanide, which does not possess a stereogenic 
centre will also be prepared via formylation of adamantyl amine, followed by dehydration to the 
desired product. 
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Scheme 20: Reagents: a) (Boc)2O, 1,4-dioxane, KOH b) CDI, CH2Cl2, NH(OMe)Me.HCl c) HCOOH, Ac2O, 
TFA d) PPh3, CCl4, DIPEA, CH2Cl2. 
 
1.5 Aims of the project 
 
Peptidomimetic compounds offer inventive solutions to the drawbacks posed by the use of natural 
peptides as drugs. MCRs present an efficient route to synthesising such compounds, which in 
combination with EKR provides the most eco-friendly approach to obtaining compounds with 
prospective biological activity. Hence the aims of this project are: 
 Synthesis of peptide mimics using the U-4CR with employment of ammonia to achieve 
enantiomers and resolution of the racemic mixtures by proteases and penicillin G acylase. 
 Synthesis of Passerini enantiomers alongside corresponding hydrolysis standards and 
resolution of the products using lipases. 
 Synthesis of chiral reagents for use in the Passerini reaction to generate diastereomers and 
analysis of reaction stereoselectivity followed by separation of the diastereomeric mixtures 
by preparative chromatography. 
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Chapter 2: Results and Discussion 
 
As per the aims discussed in Chapter 1, this project was divided into three main sections. The first part 
(2.1) details the attempt at using EKR for the resolution of enantiomers obtained from the Ugi 
reaction. Section 2.2 describes the synthesis of Passerini enantiomers and the biocatalytic resolution 
thereof. The enantioselectivity of the enzymatic reactions is also examined. The final section, 2.3, will 
centre on the diastereoselectivity of the Passerini reaction when a range of chiral starting materials 
are employed in this MCR. 
 
2.1 Attempted Enzymatic Kinetic Resolution of U-4CR Enantiomers 
 
2.1.1 Preparation of Ugi Enantiomers 
 
The objective of this section of the project was to prepare peptidomimetic compounds using the Ugi-
four component reaction. The racemic mixture resulting from this was intended to be separated by 
dint of EKR to produce enantiopure adducts that could potentially display biological activity. 
There have not been remarkable successes in the resolution of diastereomers from MCRs employing 
biocatalysts.80 Hence we opted first to synthesise Ugi enantiomers which perhaps could deliver more 
promising results.  
We envisaged synthesising a library of U-4CR analogues using readily available starting materials. 
Benzaldehyde, cyclohexyl isocyanide and ammonia (as the amine element) were chosen as the fixed 
reagents, with five different carboxylic acids as shown in Figure 7. The reaction was initially performed 
in methanol as the solvent, as is commonly done with the Ugi reaction. However this has a negative 
effect on the yields which will be discussed later. 
 
 
 
Figure 7: Commercially available carboxylic acids used in the U-4CR. 
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The U-4CR compounds, 7 - 11 (Scheme 21) were prepared by dissolving the aldehyde in a solution of 
ammonia in methanol. After 15 minutes of stirring, the acid was added followed by the isocyanide. 
This mixture was allowed to react overnight at room temperature. From thin layer chromatography 
(TLC) analysis, the reaction mixture did not show any distinct spots which could conceivably 
correspond to the desired compound, but rather a long streak that ran across the entire length of the 
TLC plate. This indicated that there were several products that resulted from the reaction, which were 
all similar in polarity and hence difficult to separate, even with a variety of solvents used as the mobile 
phase. Purification of the compounds by column chromatography proved to be challenging as 
approximately five different compounds were eluted, excluding starting material (cyclohexyl 
isocyanide which was viewed by use of an iodine stain, and benzaldehyde). The mobile phase which 
was a mixture of methanol and dichloromethane, had to be adjusted gradually and cautiously to allow 
compounds to elute from the column separately, especially since the Rf values of the anticipated 
products were not initially known. 
 
 
 
Scheme 21: General synthesis of the U-4CR compounds 7 - 11. 
 
The NMR spectra were obtained for all five eluted compounds to ascertain if the expected Ugi 
compound was successfully synthesised. Fortunately the products had been formed as a racemic 
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mixture, but predictably in low yields ranging from 3 – 18%. There have been numerous reports on 
the low yields experienced when using ammonia and methanol in the U-4CR, owing to extensive 
byproduct formation due to the involvement of the solvent in the reaction. In our hands, four different 
side products were obtained. Although 2 (Figure 4) was found to be the most common byproduct from 
these reactions as stated by Pick and co-workers,47 the NMR data from the unwanted compounds we 
obtained was indecipherable and could not be characterised as any noteworthy products. 
The 1H NMR spectra of the desired U-4CR compounds did however confirm their presence, although 
only small amounts were produced. The spectroscopic data for all the U-4CR compounds, 7- 11 were 
essentially similar except for the R groups (Scheme 21) which differ due to the carboxylic acid involved. 
Starting with 7 which was prepared using acetic acid (Scheme 22), the 1H NMR spectrum contained 8 
signals. Proton peaks were observed for the phenyl ring stemming from benzaldehyde at 7.47 – 7.15 
ppm which integrated for 5 protons as a multiplet. The cyclohexyl ring exhibited 2 peaks in the range 
of 1.97 – 0.88 ppm for the five CH2 groups both in the axial and equatorial position and a multiplet 
peak for H-7 at 3.84 – 3.50 ppm. The R-group, CH3 from acetic acid exhibited a singlet at 2.01 ppm 
which is in the expected region for protons of this moiety. The most valuable feature of the 1H NMR 
spectrum is the signal at 5.53 – 5.37 ppm which corresponds to H-2 of compound 7 at the new 
stereogenic centre generated from the reaction. The signal integrates for 1 proton split into a 
multiplet. Another important indication which proves the formation of the U-4CR 7 are the two NH 
signals which result from the two amide bonds characteristic of the α-acylaminocarboxamide product. 
The exact peaks corresponding to a particular NH could not be ascertained, but both signals appear as 
doublets at 6.97 and 5.86 ppm with J = 6.8 and 8.0 Hz, respectively. The multiplicity is most likely 
owing to coupling with H-2 and H-7 which are the nearest protons to the NH groups. 
 
 
Scheme 22: Synthesis of 7 with acetic acid. Reagents and conditions: MeOH, room temperature, 24 h.  
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Significant observations for 7 from the 13C NMR spectrum include two amide carbon atoms at 169.62- 
and 169.12 ppm, the newly formed stereogenic centre C-2 at 56.90 ppm and C-12 at 23.20 ppm for 
the R group. 
Compounds 8 – 11 display analogous peaks for the functional groups that are identical in both the 1H 
and 13C NMR spectra. Unfortunately the cyclohexyl CH2 proton signal at 1.89 – 0.81 ppm of 11 
integrates for more than the 10 expected protons, potentially due to impurities. The R groups from 
each of the acids used appear at the expected chemical shifts and verify that the Ugi compounds were 
successfully yielded.  In addition the 13C NMR spectrum of 8 contains doubled signals for C-12 at 29.72- 
and 29.52 ppm, indicating the presence of rotamers for this compound. 
Another indication of the presence of amide bonds was obtained by infrared spectroscopy. The NH 
stretch occurs at 3280 cm-1 and a strong C=O stretch appears at 1633 cm-1 for the U-4CR product 7. 
The other Ugi compounds display comparable results and are listed in Table 1. 
Table 1: Selected IR signals for Ugi compounds 8 – 11.  
Compound 8 9 10 11 
NH stretch (cm-1) 3283 3291 3295 3294 
C=O amide 
stretch (cm-1) 
1634 1633 1628 1632 
 
High resolution mass spectrometry was also carried out for all the compounds and support the other 
data to prove effective preparation of 7 – 11.  
In addition, the U-4CR was also performed using butyric, formic and benzoic acid, and no products 
were isolated, although a number of uncharacterisable byproducts were collected. 
Although five Ugi compounds were successfully obtained, the poor yields and problematic purification 
were still a concern which needed to be addressed. The apparent issue was the use of ammonia 
combined with methanol. From earlier reports, Thompson and Chen improved the yields of Ugi 
compounds by employing 2,2,2-trifluoroethanol as the solvent as it is less nucleophilic and less likely 
to participate in the reaction, causing side reactions.40 We decided to repeat the preparation of 7 and 
10, which were achieved with acetic and t-butylacetic acid, respectively, using 2,2,2-trifluoroethanol. 
The results were excellent as the yield for 7 improved from 12% to 40%, and from 18% to 70% for 
compound 10. This approximated to an increase of more than threefold, which is even greater than 
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that achieved by Thompson and Chen.40 Nevertheless, compound 11 was obtained in an unsatisfactory 
yield of 14% despite the fact that is was synthesised using 2,2,2-trifluoroethanol from the outset.  
2.1.2 Attempted EKR of 7 and 11 
 
After attaining the U-4CR enantiomers, we sought to subject the compounds to biocatalytic resolution. 
Although there have been past reports of EKR of Ugi compounds with lipase enzymes, no known work 
has been done using proteases. This presented an opportunity for our research into EKR of Ugi 
enantiomers via protease enzymes. 
Before subjecting the compounds to enzymatic reactions, the activity of the proteases had to be 
established. The assay was performed with N-acetylglycine ethyl ester dissolved in phosphate buffer 
of pH 7.5 at 40 ˚C. A control reaction was set up concurrently to affirm that the compound was not 
being hydrolysed without the enzyme. Five proteases (Alcalase, B. clausii protease, B. lentus protease, 
Bacillus. species protease and B. licheniformis protease) were tested and all proved active by 
hydrolysing the ester bond of the substrate to produce N-acetylglycine (Scheme 23). 
 
 
 
Scheme 23: a) Activity assay of proteases using N-acetylglycine ethyl ester b) Activity assay of penicillin 
G acylase with the substrate Penicillin G. 
 
In addition to proteases, we also investigated penicillin G acylase for EKR. This enzyme specialises in 
cleaving phenylacetylated compounds at the amide bond, making it more substrate-specific which is 
also the reason pharmaceutical industries are highly attracted to it for antibiotic production.81 On 
39 
 
account of this, the Ugi product 11 which incorporated phenylacetic acid (PAA) was prepared to allow 
hydrolysis by penicillin G acylase at the target bond. The activity of this enzyme was also determined 
by investigating the hydrolysis of the substrate Penicillin G to generate 6-aminopenicillanic acid (6-
APA) and PAA (Scheme 23). The assay was conducted under the same conditions as the proteases and 
also tested active. 
 
Scheme 24: Reagents and conditions: Protease enzyme, phosphate buffer pH 7.5, DMSO/ MBE, 40 ˚C. 
 
Henceforward we were able to perform the biocatalytic reactions on the Ugi compounds. We resolved 
to attempt EKR with the proteases on compound 7 first (Scheme 24) as it possessed the least bulky R-
group from acetic acid thus making it easier for enzymes to access, as compared to 8 – 11 which were 
synthesised using larger acids. We predicted that the enzymes would cleave the amide bond at the 
acetyl group of 7, but it was also possible for it to hydrolyse the cyclohexyl-containing amide bond as 
presented in Scheme 24. Compound 7 was insoluble in the aqueous buffer and needed to be dissolved 
in an aqueous-miscible organic solvent in order for the substrate and enzyme to be in the same phase, 
to increase the probability of a reaction taking place. This posed a problem since the substrate showed 
extremely poor solubility in roughly 40 different solvents (listed below). For a few of the solvents in 
which the compound proved marginally soluble when heated, the compound precipitated instantly 
out of solution when the buffer was added.  DMSO was the only water-miscible solvent in which 7 
dissolved, but it also precipitated out of solution in the buffer when large amounts of the compound 
were used. Hence the reaction was done with only 10 mg/ml in DMSO, and this was further diluted in 
a 0.2:1 volume ratio of solvent-substrate solution to aqueous buffer. A set of reactions was set up 
using each of the active proteases in generous quantities. TLC was the first choice of analysis method 
to monitor any transformation by the enzyme. A new spot was seen after 48 hours with enzyme FE202 
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(in a vanillin staining solution), but after obtaining the NMR and mass spectrometry results, none of 
the expected hydrolysed product was present and only starting material was isolated. Regardless of 
this, the reactions were repeated and left to stir for 30 days with no indication of hydrolysis and the 
experiments were then terminated.  
Organic solvents tested for solubility of compounds 7 and 11: 
1. 1,4-Dioxane                                          21. 2-Methyl-but-3-ene-2-ol (MBE) 
2. Acetone                                                22. Glycerine 
3. Ethyl acetate                                        23. Ethanol amine 
4. Diethyl ether                                       24. Iso-butyl alcohol 
5. Petroleum ether                                 25. Amyl alcohol 
6. Hexane                                                 26. 1,2-Dimethoxy ethane 
7. Methanol                                             27. Benzyl alcohol 
8. DMSO                                                   28. Methyl ethyl ketone 
9. Water                                                   29. Phenyl acetate 
10. Ethanol                                                 30. Diisopropyl ether 
11. n- Butyl ether                                      31. Chloroform 
12. Propan-2-ol                                         32. Dichloromethane 
13. DMF                                                      33. THF 
14. Xylene                                                  34. Di-n-butyl phthalate 
15. n- Heptane                                          35. Diphenyl ether 
16. Toluene                                               36. Octanol 
17. 2-Butanol                                             37. 3-Ethyl hexanol 
18. Cyclohexane                                       38. Ethylene glycol diethyl ether 
19. Acetic anhydride                                39. Acetonitrile 
20. 2-Methyl-propan-2-ol 
 
One other solvent that 7 was able to dissolve in was 2-methyl-but-3-ene-2-ol. This also had limitations 
as only small amounts of substrate could be added to the solvent for it to remain in solution, as well 
as MBE being immiscible with the phosphate buffer, hence the EKR reactions were performed as a 
two-phase reaction. After 14 days, this system also showed no positive outcome and all five of the 
proteases failed once more to hydrolyse any of the amide bonds of the Ugi compound 7. Because of 
the poor solubility of the product, we were unable to track the enzymatic reactions using HPLC to gain 
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a more accurate result. The two solvents, DMSO and MBE, which were used were not suitable to inject 
into HPLC chiral columns so we resorted to TLC, NMR and mass spectrometry for analysis. 
 
 
 
Scheme 25: Reagents and conditions: Penicillin G acylase, phosphate buffer pH 7.5, EtOH, 40 ˚C. 
 
Following the disappointing results with 7, our next endeavour was to resolve the U-4CR 11 with 
penicillin G acylase, in the hope that it would more likely hydrolyse the amide bond at the phenylacetic 
acid group, as it does for the natural substrate (Scheme 25). We began by assessing the solubility of 
the compound, and noticed that from the solvents listed above only ethanol dissolved the substrate, 
and only to a certain degree. Akin to substrate 7, the experiment was conducted using a mere 10 mg/ 
ml solution of 11 in ethanol in the aqueous buffer at 40 ˚ C. The reaction was monitored using the same 
techniques applied to the previous substrate, and likewise after 30 days, no reaction of any kind was 
observed. We postulated that even if a larger quantity of the compound was not completely soluble 
in the solvent at the beginning of the reaction, an enzymatic reaction could still occur as the mixture 
turns into a solution after some time of vigorous stirring. Consequently we ran a further experiment, 
this time using a larger quantity of compound. Within a number of days of agitation, the compound 
dissolved in the ethanol-buffer system, but still no enzymatic transformation had taken place. The 
reaction was again terminated after 30 days. 
With a great deal of time spent optimising the enzyme reactions, attempts at EKR on the Ugi 
enantiomers, particularly 7 and 11, yielded no favourable outcome. Failure of biocatalytic resolution 
could be due to several reasons, the most likely thought to be structural incompatibility between the 
U-4CR adducts and the enzymes concerned. Compound 7 could possibly be too bulky, causing steric 
hindrance, as seen in work completed by Zimuwandeyi on the Passerini reaction.80 Since penicillin G 
acylase is proficient in cleaving PAA chains, it is most likely other parts of the structure of 11 that are 
not suitable. It could be that the functional groups on the compound are not able to form non-covalent 
42 
 
bonds with the amino acid residues of the active site, leading to no reaction. Another cause of the lack 
of enzyme activity could also be the poor solubility of both the compounds, making it a greater 
challenge for the biocatalysts to come into close contact with the substrate. In brief, EKR of the 
enantiomers generated from the Ugi MCR was unsuccessful, thus investigation of resolution of Ugi 
diasteromers seemed futile at this point. Therefore we strove to separate peptidomimetic compounds 
from a similar MCR, the Passerini reaction, by means of enzymes which will be discussed in the 
following section. 
 
2.2 Separation of Passerini Enantiomers by EKR 
 
2.2.1 Synthesis of Passerini Enantiomers  
 
The Passerini reaction was performed with three different commercially available aldehydes as 
presented in Figure 8, using acetic acid and cyclohexyl isocyanide as the other reaction components. 
Cyclohexyl isocyanide was chosen as it is economical and more accessible in comparison to other 
isonitriles. The reaction was conducted using equimolar amounts of each of the reagents dissolved in 
CH2Cl2 with stirring for 3 days at room temperature. TLC indicated formation of a new product, as well 
as starting material. Purification by column chromatography was much less problematic than with the 
U-4CR products and led to the desired Passerini products 12, 13 and 14 (Scheme 26) as a racemate in 
average yields of 61-, 44- and 57%, respectively. 
 
 
 
Figure 8: Commercially available aldehydes used in the Passerini MCR. 
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Scheme 26: General synthesis of the Passerini compounds 12 - 14. 
 
The formation of 14, which was synthesised using benzaldehyde, was verified spectroscopically. The 
1H NMR spectrum showed a multiplet at 7.56 – 7.20 ppm integrating for 5 protons which corresponds 
to the aromatic protons of the aldehyde and a singlet was observed at 2.10 ppm for the acetyl CH3 
group. Another clear indication of the success of the reaction is emphasised by the signal at 6.02 ppm 
from the stereogenic centre for H-2, in addition to the NH peak which appears at 6.76 – 6.55 ppm 
attributed to the new amide bond created. Twelve distinct signals were observed in the 13C NMR 
spectrum as predicted. Downfield signals at 169.16 and 167.26 ppm were ascribed to the carbonyl 
groups from both the ester and amide bonds. The peak for the stereogenic carbon, C-2 was seen at 
75.54 ppm. The most shielded carbon atom, C-12, was characterised by the signal at 21.03 ppm. The 
characterisation data obtained for 14 corresponded to that reported in the literature for the same 
compound.82 
Compounds 12 and 13 were prepared using hydrocinnamaldehyde and trans-cinnamaldehyde, 
respectively, hence their structures are similar aside from the alkene bond of 13. For this reason the 
NMR data are also similar as shown in Table 2. The major disparities arise at the signals for H-3 and H-
4 as well as the proton at the stereogenic centre. H-3 and H-4 consist of two CH2 groups for 12, which 
are signalled in the 1H NMR spectrum as an atypical singlet at 2.10 ppm (expected to appear as a 
multiplet) and a triplet with J = 7.9 Hz at 2.67 ppm, respectively. However, compound 13 comprises of 
two CH groups at the double bond, with H-3 displaying a peak at 6.27 ppm and H-4 at 6.73 ppm, both 
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of which have the multiplicity of a doublet of doublets. The stereogenic centre proton, H-2, is located 
more downfield at 5.71 ppm for 13 owing to deshielding by the alkene group, as contrasted with H-2 
from 12 which occurs at an upfield shift of 5.13 ppm. The multiplicity of H-2 for 13 is likewise a doublet 
of doublets, indicating probable coupling of H-2 with both H-3 and H-4. 
The 13C NMR spectra support these differences showing a peak at 122.73 ppm for C-3 and another at 
135.72 ppm for C-4, representative of the C=C bond of product 13. More upfield signals for 12 are 
observed, with C-3 at 33.32 ppm and C-4 at 31.12 as anticipated. The position of the C-2 signals for 12 
and 13 were very similar as opposed to the significant difference in the chemical shifts of H-2 observed 
in the 1H NMR spectra of these compounds. Compound 13 exhibited a peak at 74.5 ppm and 12 a peak 
slightly upfield at 73.75 ppm for C-2.  
Table 2: Selected NMR shifts for identical groups of Passerini compounds 12 and 13.  
 Compound 12 Compound 13 
1H NMR 13C NMR 1H NMR 13C NMR 
Aromatic region δ 7.36 – 7.08 
(5H, m) 
δ 140.85 -
126.11 
δ 7.46 – 7.19 
(5H, m) 
δ 134.72 - 
126.83 
NH δ 5.86 (1H, d, 
J = 8.0 Hz) 
 
--- 
δ 5.89 (1H, d, 
J = 7.9 Hz) 
 
--- 
H-3 / C-3 δ 2.10 (2H, s) δ 33.32 δ 6.27 (1H, 
dd, J = 15.9, 
6.8 Hz) 
δ 122.73 
H-4 / C-4 δ 2.67 (2H, t, J 
= 7.9 Hz) 
δ 31.12 δ 6.73 (1H, 
dd, J = 16.0, 
0.9 Hz) 
δ 135.72 
H-9 / C-9 δ 3.87 – 3.69 
(1H, m) 
δ 48.02 δ 3.89 – 3.69 
(1H, m) 
δ 48.26 
H-14 / C-14 δ 2.17 (3H, s) δ 20.92 δ 2.20 (3H, s) δ 21.07 
Cyclohexyl CH2 δ 1.97 – 1.05 
(10H, 3xm) 
δ 30.91 - 
24.78 
δ 1.98 – 1.05 
(10H, 4xm) 
δ 33.02 - 
24.78 
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Analysis of the infrared spectra furthermore shows strong amide and ester stretches indicative of the 
new functional groups generated by the Passerini reaction to achieve compounds 12 – 14. The precise 
positions of the signals are contained in Table 3. Compound 12 is novel, however the literature data 
obtained for compound 13 matched the characterisation data that we obtained for 13.83 
 Table 3: Key IR signals that confirm the formation of Passerini products 12 – 14.  
Compound 12 13 14 
NH stretch (cm-1) 3284 3289 3318 
C=O ester  
stretch (cm-1) 
1740 1733 1738 
C=O amide  
stretch (cm-1) 
1650 1661 1660 
 
The melting points for compounds 13 and 14 were found to be equal at 123 – 125 ˚C, whereas 12 
displayed a lower value of 100 – 103 ˚C conceivably due to more aliphatic groups contained within the 
substrate. The melting point for 13 found in the literature was 132 – 133 ˚C which is notably similar to 
what we obtained.83 
2.2.2 Preparation of the Hydrolysis Standards for EKR 
 
With the Passerini enantiomers in hand, we could proceed with the synthesis of the hydrolysed 
compounds. Since we planned on resolving the Passerini compounds via lipase hydrolysis, it was 
necessary for us to prepare standards for the reaction as we set to pursue the EKR studies by way of 
HPLC, which will be expanded on later. 
Accordingly we chemically hydrolysed the ester functionality of the Passerini compounds 12 – 14 as 
illustrated in Scheme 27. 
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Scheme 27: Reagents and conditions: a) KOH, MeOH, 24 h b) 1.5 M H2SO4, EtOH, 90 min. 
 
Compounds 12 and 14 were hydrolysed under basic conditions. The starting material was treated with 
10 equivalents of KOH in a methanolic solution and the reaction continued for 24 hours. Following the 
work up and extraction with ethyl acetate, both 15 and 17 were furnished as cream-white solids, as 
racemic mixtures in yields of 51 and 75%, respectively. No further purification was required. The Rf 
values of the products were also lower than for the corresponding starting materials attributed to the 
more polar OH group formed at the stereogenic centre.  
The basic hydrolysis method was also initially performed on 13, but the desired compound was not 
produced. We postulated that another reaction, probably allylic substitution, was taking place at the 
double bond rather than the desired reaction at the ester moiety. Thus we adopted a hydrolysis 
method using acidic conditions. Compound 13 was reacted with 1.5 M H2SO4 in ethanol. After 90 
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minutes of slight heating and extraction using ethyl acetate, column chromatography was undertaken 
and 16 was successfully obtained in a good yield of 74% as a yellow solid. 
The 1H NMR spectra displayed significant changes for the hydrolysed products in comparison to the 
Passerini compounds. The proton peaks at ~2.1 ppm associated with CH3C=O at the ester functionality 
of 12 – 14 no longer appeared in the spectra of 15 – 17, validating effective hydrolysis of the ester 
bond. The signals for CH at the stereogenic centre shifted significantly upfield, with changes also seen 
for the NH peaks. For instance H-2 of 15 is observed at 4.08 ppm, whereas in the starting material it 
arises at 5.13 ppm. The NH peak shifted downfield from 5.86 ppm to 6.72 ppm in the product. This 
pattern also follows through in the 1H NMR spectra of compounds 16 and 17.  
The 13C NMR data is also convincing as there were two carbonyl peaks at ~168/ 169 ppm for the 
Passerini products, but the hydrolysed compounds only exhibited one C=O peak due to the amide 
bond, proving that hydrolysis of the ester group occured. Another clear confirmation is the absence 
of the CH3 signal which normally arose at ~21 ppm, from all three hydrolysed adducts. Moreover, a 
minor change in shift value for the stereogenic carbon atom to a more upfield position was noticed, 
for example 15 exhibited a C-2 peak at 71.38 ppm in comparison to 73.75 ppm for 12. 
The major peaks observed in the infrared spectra for 12 – 14 are shown in Table 4. Broad peaks 
correlating to the OH stretches are present (Table 4) which are not seen for the starting material. The 
ester C=O stretch at ~1740 cm-1 for 12 - 14 as shown in Table 3 is also non-existent in the products, 
once more substantiating successful hydrolysis of the Passerini compounds. 
Table 4: Major IR peaks of the Hydrolysis Standards.  
Compound 15 16 17 
NH stretch (cm-1) 3284 3395 3335 
OH stretch (cm-1) 3278 3272 3251 
C=O amide 
stretch (cm-1) 
1635 1636 1637 
 
The mass spectra of 15 – 17 were furthermore consistent with the expected masses of the standards. 
All the characterisation data obtained for compounds 15 – 17 corresponded to that obtained in the 
literature, proving that the synthesis of these compounds were successful.83-85  
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2.2.3 Enzymatic hydrolysis of the Passerini enantiomers 12 – 14 
 
Lipases have been shown to be useful biocatalysts in EKR of secondary alcohols and thus lipases were 
tested in the EKR of the Passerini enantiomers 12, 13 and 14. 
The lipases chosen to carry out the reactions were lipases 6Y (Cat # ESL-001-01, Lot # 6Y0240) and 6Z 
(Cat # ESL-001-01, Lot # 6Z0248), which were purchased from Recombinant BioCatalysis, as they were 
found in our laboratories to respond well to a range of organic molecules tested. These enzymes were 
identical except that they were prepared in different lots. An activity assay was also conducted with 
the enzymes before continuing with the Passerini substrates. Benzyl acetate was used as the test 
compound in acetonitrile and phosphate buffer. After 3 hours, the enzymes had hydrolysed the 
compound to produce benzyl alcohol and thus were sufficiently active to be tested on our products. 
A control reaction containing no lipase was performed simultaneously to establish that no reaction 
took place in the absence of an enzyme. Standard substrate tests were also performed to ensure that 
the enzymes responded to our compounds. 
 
 
 
Scheme 28: Proposed EKR of the Passerini enantiomers 12 – 14 by Lipases 6Y and 6Z. 
 
Having effectively synthesised the substrates and confirmed the lipase activity, we were now capable 
of investigating resolution of compounds 12 – 14 by use of both Lipases 6Y and 6Z as exemplified in 
Scheme 28. We planned on screening the enzymes with the substrates first to ascertain if a reaction 
was taking place. As acetonitrile was the solvent of choice for the activity assay, we used it as a starting 
point to test for compound solubility. Unlike the U-4CR adducts, the Passerini products dissolved in 
acetonitrile effortlessly, even in higher concentrations. Hence we performed the reaction with a 1:1 
ratio of phosphate buffer of pH 7.0 to acetonitrile, using a 1:2 ratio of substrate to enzyme (20 mg: 40 
mg). This was stirred at 40 ˚C for approximately 4 hours, with inspection by TLC throughout. The 
starting material and hydrolysed standards were spotted on a TLC plate, with the reaction mixture 
alongside. Roughly 20 minutes from the onset, we were elated to see that a new spot had already 
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formed with an Rf value that corresponded to the hydrolysed standards, in addition to starting 
material. This was observed for all three Passerini compounds 12, 13 and 14 from both lipases. This 
suggested that the enzymes were seemingly compatible with our substrates and were hydrolysing the 
ester bonds successfully. The reactions continued for nearly 4 hours and the biocatalysts transformed 
more of the substrate into the respective hydrolysed compounds. We then terminated the reactions 
and extracted the organic molecules using ethyl acetate. After concentration, we subjected the 
residue to HPLC, initially using the reversed phase C-18 column to confirm the positive outcome of the 
enzyme reaction that was observed from TLC. From this we could also determine the amount of 
substrate being converted to the product.  
This set of compounds dissolved without difficulty in acetonitrile, hence the samples for HPLC analysis 
were prepared at a concentration of 1 mg of substrate per ml of acetonitrile. Only a 25 µl portion of 
the solution was loaded onto the column for separation. Although compounds 13 – 17 were not novel, 
no information was available concerning a method to achieve baseline separation of these products 
by HPLC.  
We started with a mobile phase of a 50% mix of acetonitrile/water at a flow rate of 1 ml/minute. This 
did not result in the desired separation. We then varied the ratio of solvents until baseline separation 
was observed.  It was not extremely challenging to achieve separation of the substrate and product 
on the C-18 column. The optimum chromatograms were those showing elution times of less than 5 
minutes for the substrates and products of all three of the Passerini enzymatic reaction mixtures, 
making it simple to follow the EKR reactions.  
From the chromatograms of each of the reactions (Figures 9 -14), it is evident that the enzymes were 
indeed hydrolysing the Passerini products. Commencing with the enzyme reactions of 12, Figures 9 
and 10 show the appearance of both the substrate and the hydrolysed product. The hydrolysed 
compound 15 eluted at approximately 4 minutes with a mobile phase of an 80:20 acetonitrile/water 
mixture. The Passerini substrate 12 had an elution time of ~ 4.9 minutes. Using peak area percentage 
as a semi-quantitative measure, 58.4% of product 15 was produced, relative to the 41.6% of unreacted 
substrate, after 4 hours by Lipase 6Y. With Lipase 6Z (Figure 11), the results were virtually identical 
with 55.6% of product formed.  
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Figure 9: HPLC chromatogram of the enzymatic reaction of 12 with Lipase 6Y after 4 hours. 
 
 
 
Figure 10: HPLC chromatogram of the enzymatic reaction of 12 with Lipase 6Z after 4 hours. 
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Maintaining the mobile phase at a ratio of 80:20 acetonitrile/water afforded adequate separation of 
13 and 16. Figures 11 and 12 depict the EKR reactions of the Passerini product 13. The elution times 
of the compounds were very similar to those of 12 and 15 which is unsurprising since they are 
structurally related. Compound 16 was eluted at around 4 minutes and 13 at ~ 4.6 minutes. The rate 
of conversion of compound 13 was much more gradual in comparison to the previous product. Lipase 
6Y produced 18% of 16, and Lipase 6Z nearly 27% in a span of 4 hours. Although this is considered a 
positive outcome as the enzymes responded well to the Passerini compound, the rate of hydrolysis of 
12 to 15 is more than double that of 13 to 16 for both Lipases 6Y and 6Z. The only observable reason 
is the less-accessible alkene functionality contained in 13 that potentially causes the biocatalyst to 
react slower with the compound, and convert less of the substrate to the corresponding product.  
 
 
 
Figure 11: HPLC chromatogram of the enzymatic reaction of 13 with Lipase 6Y after 4 hours. 
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Figure 12: HPLC chromatogram of the enzymatic reaction of 13 with Lipase 6Z after 4 hours. 
 
Separation of 14 and 17 on the C-18 column using the same mobile phase as previously led to even 
shorter elution times than the preceding adducts. Figures 13 and 14 show that the substrate eluted 
the column at 4 minutes and the hydrolysed compound even earlier at 3.5 minutes. The enzymatic 
reactions of compound 14 were more rapid than for the other compounds. At 4 hours, Lipase 6Y had 
already produced 69% of 17 and Lipase 6Z was not far off with a production of 63%. The rate of these 
reactions were greater than both the EKR of 12 and 13. The only distinction between each of the three 
Passerini adducts are the aldehyde components with which they were synthesised. Compound 14 was 
prepared with benzaldehyde, which is a simpler, less bulky reagent as compared with 
hydrocinnamaldehyde and trans- cinnamaldehyde used to generate 12 and 13, respectively. Owing to 
this, 14 has a structure that is more easily accessible to enzymes, and perhaps fits better in the lipase 
active site. Hence the rate of hydrolysis is more rapid, affording excellent production of the hydrolysed 
product contrasted with the other Passerini analogues. Structural compatibility can also rationalise 
that 13, synthesised from trans- cinnamaldehyde, exhibited the lowest rate of hydrolysis by the lipases 
due to the complexity of the double bond it possesses. Overall Lipases 6Y and 6Z hydrolysed the set 
of Passerini compounds at an almost equal rate, aside from compound 13 for which Lipase 6Z had a 
greater degree of hydrolysis by 10%.  
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Figure 13: HPLC chromatogram of the enzymatic reaction of 14 with Lipase 6Y after 4 hours. 
 
 
Figure 14: HPLC chromatogram of the enzymatic reaction of 14 with Lipase 6Z after 4 hours. 
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Analysis by HPLC using the C-18 column provided adequate data to validate the occurrence of 
hydrolysis by lipases 6Y and 6Z. The conversions of each of the Passerini products were satisfactory. 
The outcomes of the enzymatic hydrolysis of substrates 12 – 14 were pleasing, and very different from 
the attempts at EKR on the Ugi compounds. Despite the confirmation of the enzyme reactions, we had 
yet to discover if the biocatalysts were reacting selectively with one of the two enantiomers, or if they 
were hydrolysing both enantiomers to the same extent. Hence we explored the enantioselectivity of 
the reactions by employment of chiral HPLC.  
2.2.4 EKR of the Passerini enantiomers 
 
Using the C-18 column we were only able to ascertain the compounds that were present in the 
enzymatic reaction mixture – specifically the Passerini substrate and the hydrolysed product being 
formed. However this route is not capable of separating enantiomers, and consequently indicating 
selectivity of the biocatalyst. Hence it was mandatory for us to subject the reactions to chiral HPLC. 
This would allow separation of both the substrate racemic mixture and enantiomers of the hydrolysed 
products, quantitatively. In this way, we could uncover the enantioselectivity of the lipases with regard 
to the Passerini compounds 12 - 14. 
We repeated the EKR reactions for all three Passerini compounds under the same conditions as 
mentioned earlier with both Lipases 6Y and 6Z. However, for the purpose of enantioselectivity studies, 
we removed a portion of the reaction mixture at 20 minute intervals for the duration of approximately 
3 hours. The organic layer was extracted with ethyl acetate and concentrated for injection onto the 
chiral column. This would not only reveal the selectivity of the enzymes but would also permit us to 
identify the optimal time for terminating the reactions with respect to conversion and selectivity. 
Finding a method that enabled separation of the compounds from the enzyme reactions on the C-18 
column by HPLC was straightforward. However, methods developed using C-18 columns are not 
transferable to chiral columns and new methods needed to be developed. We evaluated separation 
of our compounds with four different chiral columns, namely the Chiralcel OJ, Lux 5 µ Cellulose-1, 
Chiralpak AD-H and Lux 5 µm Amylose-2 columns. We proposed to find a method that would ideally 
separate both the substrate and hydrolysis standard enantiomers, thus displaying four distinct peaks 
in the chromatogram. Once the standard run provided sufficient separation, we could subject the 
samples from the enzymatic reactions for analysis. 
We began first by examining the OJ column. A standard sample containing both the Passerini product 
(12 – 14) with its corresponding hydrolysed compound (15 – 17) was dissolved in acetonitrile and 
injected onto the column. The mobile phase consisted of an IPA/ hexane solution as these are the 
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solvents permitted for use on this column. The first approach we used was an isocratic elution of IPA/ 
hexane mixtures, with ratios varying between 1:99 to 99:1. This afforded no separation for any of the 
compounds. The elution times for selected solvent ratios were over 60 minutes and only one large 
distorted peak would appear. We shifted to a gradient elution and still no baseline separation was 
seen. We concluded that the OJ column was not suitable for the compounds of interest and hence 
resorted to another option. 
The second column employed was the Cellulose-1 chiral column. For this the same approach was 
applied as for the previous column using various proportions of IPA/ hexane solutions. This too 
afforded no baseline separation for any of the three Passerini compounds and hydrolysis adducts. 
Subsequently we tested the AD-H column. A method was established that resulted in partial 
separation of 12/15 and 13/16. This column produced the best chromatogram for 14/17 and these 
results will be discussed in 2.2.4.1. 
2.2.4.1 Enantioselectivity of the EKR of 14 
 
 
 
Scheme 29: Proposed EKR of the Passerini compound 14. Reagents and conditions: Lipase 6Y/6Z, 50% 
MeCN in 50 mM phosphate buffer, pH 7.0, 40 ˚C, 3 h at 20 min intervals. 
 
The method that delivered optimal separation of 14/17 on the AD-H chiral column consisted of a 6:94 
IPA/ hexane mobile phase. Using an isocratic elution, the run persisted for ~35 minutes. Although this 
was time-consuming, it was the only method that afforded a pleasing result. Figure 15 shows the 
chromatogram obtained from the standard injection of 14 and 17. Four peaks were observed. The 
Passerini enantiomers eluted at ~17- and ~26 minutes. The hydrolysed standard 17 had elution times 
of ~14- and ~34 minutes. 
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Figure 15: Standard injection of 14 and 17 on the AD-H chiral column (6:94 IPA/ hexane). 
 
The relative peak areas reflect equal amounts for each of the set of enantiomers as expected for 
racemates - ~37% for both enantiomers of 14 and ~13% for 17 (Figure 15).  With separation of the 
standard sample having been achieved, we were now primed to subject the EKR reaction mixtures to 
the chiral column. The control reaction only displayed the substrate 14 at ~17- and ~26 minutes (in a 
50:50 ratio), establishing that no reaction occurred in the absence of the lipases. The first EKR injection 
was performed after 20 minutes. We began initially with assessing the reactions from Lipase 6Y (Figure 
16). At this time, the enzyme had hydrolysed some of the substrate to the product. The relative peak 
area of one substrate enantiomer decreased from 50% to 44.06% and the other decreased from 50% 
to 48.51% (Figure 16). The hydrolysed product enantiomers which were not present at the start of the 
reaction, were now increased to 5.82% for one and 1.60% for the other one. Thus one of the 
enantiomers of the hydrolysed product which eluted at 13.80 minutes was greater than the other at 
33.89 minutes. This shows that Lipase 6Y is somewhat selective as it reacted with one of the 
enantiomers at a faster rate than the other. 
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Figure 16: EKR of 14 with Lipase 6Y at 20 minutes.  
 
The reaction was followed after every 20 minutes for Lipase 6Y and at each time-period, both of the 
substrate 14 peaks showed a decrease in peak area. The product peaks also increased at each phase, 
with the product that elutes at ~14 minutes forming more rapidly. Figure 17 depicts the final injection 
of the Lipase 6Y reaction with 14. This was obtained 160 minutes after the onset of the reaction. The 
chromatogram reveals that the enzyme hydrolysed the one enantiomer at 16.88 minutes much faster 
to generate the corresponding hydrolysed product at 13.84 minutes. The lipase reacted almost 
completely with the said substrate, thus Figure 17 shows that only roughly a ratio of 1:13 of that 
enantiomer remained at this point. The other enantiomer at 26.03 minutes was not hydrolysed to the 
same extent as 13 times the amount of it still remained unreacted at 160 minutes as compared to the 
opposite enantiomer. It was apparent that Lipase 6Y preferred the one enantiomer above the other, 
but still hydrolysed a fraction of the other, making separation by EKR not as effective as desired.     
Following the same procedure with the reactions of Lipase 6Z, we noticed overall similar results, but 
the reaction occured at a swifter pace. From Figure 18, it is evident that the enzyme is hydrolysing one 
of the two enantiomers of the substrate quicker than the other. At merely 20 minutes, more than half 
the amount of substrate at 16.60 minutes was already hydrolysed to the product at 13.89 minutes. 
This contrasts with Lipase 6Y as approximately five times less the amount of the same hydrolysed 
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product was generated at 20 minutes (Figures 16 and 18). In comparison, a ratio of approximately 1:4 
of the other hydrolysed enantiomer was also formed and eluted at 33.67 minutes (Figure 18). 
 
 
 
Figure 17: EKR of 14 with Lipase 6Y at 160 minutes.  
 
 
 
Figure 18: EKR of 14 with Lipase 6Z at 20 minutes.  
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Akin to Lipase 6Y, Lipase 6Z reactions also showed escalating amounts of the hydrolysis products every 
20 minutes, more so with the enantiomer at ~14 minutes. The substrate peaks also reduced 
congruently. The last chromatogram acquired from the set of Lipase 6Z reactions was at 120 minutes 
(Figure 19). These results were consistent with those of Lipase 6Y. Only roughly a ratio of 1:11 of the 
preferred substrate remained and three times the amount of the complementary hydrolysed product 
was produced as compared to the other product enantiomer. Lipase 6Z produced three times less the 
amount of the hydrolysed product (at 33.86 minutes) in comparison to the other enantiomeric 
product, and hence approximately 11:1 of the less preferred substrate was still present after 2 hours.  
 
 
 
Figure 19: EKR of 14 with Lipase 6Z at 120 minutes.  
 
The outcomes of Lipase 6Y and 6Z were almost equivalent with the exception that Lipase 6Z initially 
reacted with the Passerini compounds quicker. However, both biocatalysts showed some selectivity 
as one enantiomer was hydrolysed quicker than the other from the commencement of the 
investigation. Using the relative peak areas achieved from the AD-H chiral column, we calculated the 
conversion and e.e. at each time interval to gain statistical insight into the EKR of 14. 
An example of the calculation of the e.e. of both the substrate (ees) and product (eep) of the EKR of 14 
is contained within the Appendix. The conversion (c) of the enzymatic reaction was determined using 
Equation 1. In 1982 C.J. Sih founded a dimensionless parameter to express the enantioselectivity (E) 
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of an EKR reaction.86 This value is meant to remain constant during the course of the reaction and is 
only dependent on the nature of the process. E is related to both the conversion and e.e. for 
irreversible ester hydrolysis such as the EKR studies of the Passerini compounds in this project, and 
can be computed using either Equation 2 or 3.86, 87 These parameters have been calculated using the 
aforementioned equations for the various time phases for the EKR of 14 with Lipases 6Y and 6Z and 
these are listed in Tables 5 and 6. 
  Conversion = ees / (ees + eep)                       …Equation 1 
E = Ln[1-c(1+eep)] / Ln[1-c(1-eep)]                  …Equation 2 
E = Ln[(1-c)(1-ees)] / Ln[(1-c)(1+ees)]             …Equation 3 
 
Table 5: Enantioselectivity parameters of 14 with Lipase 6Y.  
Time (min) ee P (%) ee S (%) conversion 
(%) 
E 
20 56.8 4.80 7.79 3.80 
40 56.3 9.64 14.7 3.93 
60 65.6 13.9 17.5 5.51 
80 68.9 17.9 20.6 6.46 
100 68.2 23.0 25.2 6.60 
120 62.9 45.4 41.9 6.79 
140 61.5 52.6 46.1 6.99 
160 47.9 85.3 64.0 7.24 
 
Table 6: Enantioselectivity parameters of 14 with Lipase 6Z.  
Time (min) ee P (%) ee S (%) conversion 
(%) 
E 
20 62.5 34.6 35.6 6.04 
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40 50.8 32.9 39.3 4.18 
60 62.8 47.3 43.0 6.90 
80 56.0 66.2 54.2 6.85 
100 53.8 78.5 59.4 7.60 
120 50.1 83.2 62.4 7.39 
 
From the numerical data, it is apparent that the enzymatic reactions were only somewhat 
enantioselective. The enantiomeric excess values (ees and eep) for Lipase 6Y and 6Z (Table 5 and 6) 
were not high enough to allow practical separation of the enantiomers. A general decrease for eep 
was observed as the reactions progressed for both enzymes, whereas ees displayed an increase over 
time as would be expected. Customarily an enantioselectivity or E value of 15 to 30 is considered as 
average to good selectivity. Any result below or exceeding this is interpreted as poor or exceptional 
correspondingly.88  The E- values obtained for the EKR of 14 are low, with no result greater than 8 for 
both lipases at any given time. What is noticeable from Table 5 is that E- values obtained at very low 
conversions are not reliable, and stabilise to a steady number once conversions are higher.88 This 
proves that whilst the enzymes successfully hydrolyse the Passerini enantiomer 14, they do so with 
only partial selectivity and are hence undesirable for functional purposes. The HPLC information 
reflects that the lipases are slightly discriminative towards the enantiomers, but the enantioselectivity 
ratios provide absolute values that give a good indication of how practically useful the EKR is likely to 
be. 
2.2.4.2 Enantioselectivity of the EKR of 12 
 
 
 
Scheme 30: Proposed EKR of the Passerini compound 12. Reagents and conditions: Lipase 6Y/6Z, 50% 
MeCN in 50 mM phosphate buffer, pH 7.0, 40 ˚C, 3 h at 20 min intervals. 
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We also attempted separation of 12/15 on the chiral AD-H column as it worked proficiently with 
14/17. A mobile phase of 9:91 IPA/ hexane was the only method that achieved 4 peaks corresponding 
to both sets of enantiomers. The elution time was quicker than with 14/17 and only lasted 16 minutes 
for the standard run. Unfortunately, a fifth peak was also observed which interfered with the baseline 
separation as it co-eluted with one of the substrate and hydrolysis product peaks. Hence accurate 
peak area quantities could not be obtained. We presumed that the additional peak was only present 
in the standard injection, thus we tested the enzymatic reactions using this same method on the AD-
H column. 
The EKR reactions were performed under the conditions stated in Scheme 30. As done previously, a 
portion of the reaction was extracted at 20 minute intervals, concentrated and injected onto the 
column. Unfortunately, with the enzymatic reactions, the additional peak still appeared in the 
chromatogram and interposed on the separation of the compounds of interest. We set to determine 
what the added peak was due to, but it was unidentifiable by any means.  
Owing to the constraints from the unknown contaminant spotted on the AD-H column, we shifted to 
an Amylose-2 chiral column. With this we managed to separate only the hydrolysed enantiomer 15, 
with one peak only seen for 12, totalling 3 peaks for the standard run (Figure 20). Although separation 
of both pairs of enantiomers is ideal, we could still acquire the enantioselectivity parameters from 3 
peaks. The solvent system used for this was 10:90 IPA/ hexane. Figure 20 depicts the Passerini 
compound at 29.39 minutes and the hydrolysis standards at 9.93- and 18.37 minutes, both roughly at 
equal peak area percentages as predicted. 
  
 
 
 Figure 20: Standard injection of 12 and 15 on the Amylose-2 chiral column (10:90 IPA/ hexane). 
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With a successful method in hand, we were now in a position to examine the EKR of the Lipase 6Y 
reactions. At 20 minutes, the enzyme had already hydrolysed both of the substrate enantiomers to 
some extent. A hydrolysis product peak was noted at 9.92 minutes in a relative quantity of 5.07%. 
Another peak for the other hydrolysed enantiomer at 18.54 minutes was seen at 36.05%. From this it 
was already evident that the lipase was fairly selective as one hydrolysed compound was formed more 
rapidly. This pattern continued over the course of the reaction until the 60-minute mark, where 
unusual results were obtained. Figure 21 shows the substrate peak at 28.04 minutes reduced to a 
relative amount of 36.66% and one hydrolysed enantiomer at 18.44 minutes increased to 58.65%. The 
disadvantage of the practice of EKR is that any of the two enantiomers can only be obtained at a 
maximum yield of 50%, given that the corresponding substrate enantiomer is completely consumed 
in the reaction. From Figure 21, we noticed that the hydrolysed enantiomer at ~18 minutes already 
exceeded 50% at 60 minutes.  
 
 
 
Figure 21: EKR of 12 with Lipase 6Y at 60 minutes.  
 
We resumed the reaction up till 180 minutes and injected the samples onto the chiral column. The 
hydrolysed product at 17.54 minutes increased even further to 84.93% (Figure 22). The substrate peak 
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at 28.96 minutes almost entirely disappeared with only 3.09% remaining. These results were 
unreasonable as even if the enzymes were not selective and hydrolysed both the substrate 
enantiomers at the same rate, 50% of each of the hydrolysed products would be seen. Figure 22 shows 
only 11.98% of the other enantiomer at 9.48 minutes. It is most obvious from Figure 22, with almost 
all of the starting material hydrolysed, there still seemed to be significant selectivity, which is not 
possible. The only justification was that another unknown side-reaction was perhaps occurring that 
would give rise to a product that elutes at the same position as the favoured hydrolysed product (~18 
minutes), causing the relative peak area to surpass the 50% maximum yield from EKR.  
 
 
 
Figure 22: EKR of 12 with Lipase 6Y at 180 minutes.  
 
We subjected the enzymatic reactions from Lipase 6Z at each time interval onto the column.  Likewise, 
the same irrational outcomes were observed from 100 minutes where the hydrolysed product was 
yielded over 50% and the starting material was almost completely reacted, even though the enzyme 
exhibited notable selectivity. At 180 minutes, only 21.6% of the substrate remained unreacted, and 
the favoured hydrolysed enantiomer was present at 71.26%. 
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The AD-H and Amylose-2 chiral columns yielded data that was inexplicable for the Passerini compound 
12. Although we could establish that the enzymes were hydrolysing the racemic mixture in a 
somewhat selective manner, we were unable to determine the enantioselectivity of the reactions with 
both Lipase 6Y and 6Z as the relative peak area values were inaccurate. This led us to a new solution 
to verify the degree of selectivity of the lipases during EKR of 12. 
In 1969, Mosher described an NMR-focussed technique termed the Mosher ester analysis, used to 
infer the absolute configuration of an otherwise unidentified chiral secondary alcohol centre.89 The 
mechanism involves transforming an enantiomeric mixture into a diastereomeric mixture (Mosher’s 
esters) by coupling it to a reagent that is itself chiral (Mosher’s acid of known chirality). The 1H NMR 
spectra of enantiomers are indistinguishable, but once the Mosher’s esters are formed, the 
diastereomeric protons will display different chemical shifts. By evaluating the variance in the 
chemical shifts of resonances of analogous protons of the two diastereomers, the absolute 
stereochemistry of the original enantiomers can be deduced.89 
Another function of the Mosher ester analysis, which is of interest in this project is the inference of 
the proportion, or e.e. of enantiomers present in a certain sample. This is accomplished in the same 
way used to determine absolute configuration. Mosher’s ester diastereomers must be prepared, and 
from either the 1H or 19F NMR spectra, the integration of corresponding protons or fluorine atoms 
from the two compounds are measured, offering a direct correlation to the concentration of each of 
the original enantiomers present in the mixture.89 
With the complications experienced from the chiral HPLC columns with 12, we used the Mosher ester 
method to measure the e.e. for the EKR of 12 with Lipases 6Y and 6Z.  
 
 
 
Scheme 31: Mosher ester analysis of the EKR of 12. Reagents and conditions: a) Lipase 6Y/6Z, 50% 
MeCN in 50 mM phosphate buffer, pH 7.0, 40 ˚C, 12 h b) (R)-MTPA, DCC, DMAP, CH2Cl2, 90 min. 
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The analysis was completed in two steps as demonstrated in Scheme 31. First a large-scale EKR 
reaction was performed (200 mg of 12) under the same conditions as stated previously. However the 
reaction proceeded for 12 hours and was not evaluated at 20 minute intervals as with those reactions 
subjected to chiral chromatography. The organic layer was then extracted with ethyl acetate and 
concentrated. Since Lipases 6Y and 6Z did not hydrolyse the substrate completely, the residues 
contained both the starting material 12, and the hydrolysed compound 15 as observed from TLC. 
Hence prior to carrying out the second step (b) of the analysis, the mixture was purified by column 
chromatography to obtain pure 15, as a scalemic mixture from both the enzyme reactions. A yield of 
22% of 15 was achieved from the Lipase 6Y reaction and 26% from Lipase 6Z, denoting that the 
enzymes hydrolysed the substrate at a very similar rate. Since a large amount of starting material was 
recovered from the column, it was expected that the yields would be notably low.  
In addition, the crude residues from the enzyme reactions were subjected to HPLC on the C-18 column 
to determine the conversion from EKR. The method used previously for separation of 12/15 on the C-
18 column was applied. With this, the hydrolysed enantiomeric products eluted at 4.02 minutes and 
the substrate mixture at 4.77 minutes. Figure 23 indicates that 45.7% of 15 was yielded in 12 hours by 
Lipase 6Y, whilst 31.2% was the yield by Lipase 6Z as displayed in Figure 24. The conversion values 
obtained from this reactions on the C-18 column are regarded as semi-quantitative data as they are 
based only on peak area and not standard curves. 
 
 
 
Figure 23: EKR of 12 with Lipase 6Y at 12 hours.  
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Figure 24: EKR of 12 with Lipase 6Z at 12 hours.  
 
With the scalemic mixtures of 15 from the lipase reactions in hand, we proceeded with the synthesis 
of 18 from the Mosher reaction as shown in Scheme 31 (step b). The scalemic mixture of compound 
15 was dissolved in CH2Cl2 and the Mosher’s acid (R)-MTPA, DCC and DMAP were added to the solution 
in stages. After 90 minutes of stirring, the product was extracted and isolated as a mixture of two 
diastereomers by column chromatography in a moderate yield of 67% from the Lipase 6Y reaction. 
The Lipase 6Z material yielded 18 at 78%. 
Successful preparation of 18 was substantiated spectroscopically. Infrared analysis exhibited two 
stretches for the amide and newly formed ester carbonyl groups of 18 at 1660- and 1753 cm-1, 
respectively. Significant stretches for the NH (3306 cm-1) and C-F (1017 cm-1) moieties were also noted. 
The 1H NMR spectra of 18 from Lipase 6Y and 6Z reactions are in essence identical, and confirm the 
effective synthesis of the Mosher’s esters. Two multiplet signals were apparent at 7.63 – 7.01 ppm 
which integrated for 10 protons from the two phenyl rings. A singlet was observed at 3.55 ppm 
corresponding to H-19 of the methoxy group. Another vital signal was that of H-2 at the more central 
stereogenic centre, which appeared as a multiplet at 5.41 – 5.26 ppm. Due to probable impurities, the 
cyclohexyl region at 1.87 – 0.95 ppm contains 17H instead of the anticipated 10 protons. 
Likewise the 13C NMR spectra provided further proof of the preparation of 18 as a mixture of two 
diastereomers, as doubling of some peaks were noticed. Two peaks appeared in the carbonyl region 
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consistent with the ester and amide functionalities. A characteristic CF3 peak was observed at 125.30 
ppm as anticipated. Duplicate peaks were seen at ~84 – 85 ppm for the stereogenic centre C-14, and 
a single peak for the second stereogenic centre C-2 at ~75.3 ppm. C-19 gave rise to a peak at ~55.4 
ppm. 
To reach the desired outcomes from the Mosher ester analysis, the data revealed by the 19F NMR was 
imperative. For both the Lipase 6Y and 6Z reactions separately, two singlet signals were seen at -70.66 
and -70.82 ppm for the CF3 groups of the two diastereomers. From the integration of the Lipase 6Y 
spectrum (Figure 25) the e.r. of the compounds was determined to be 1:9 which corresponds to an 
e.e. value of 80%. Lipase 6Z showed greater selectivity as the e.r. from the 19F NMR spectrum was 
1:10. Therefore, the e.e. of the product from the Lipase 6Z reaction was 90%. 
 
 
 
Figure 25: 19F NMR spectrum of 18 obtained from the Lipase 6Y reaction. 
 
Having obtained the semi-quantitative conversion of the Lipase 6Y and 6Z reactions of 12 from the C-
18 column, and the e.e. of the hydrolysed products from the 19 F NMR, we calculated the E value using 
Equation 2. The E-value of the EKR from Lipase 6Y was found to be 14.7, and 21.7 for Lipase 6Z. 
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The results reveal that Lipase 6Z exhibited a greater e.e. and hence enantioselectivity towards 12 as 
compared to Lipase 6Y, although the latter displayed greater conversion after 12 hours. As 
abovementioned, E-values in the range of 15 – 30 are beneficial for practical purposes.88 Therefore, 
the EKR of the Passerini compound 12 by both Lipases was successful as the E-values lie within a 
reasonable region. Separation of the enantiomers of 12 by Lipase 6Z would, however, be more feasible 
since the E-value is much greater. The enantioselectivity parameter of the EKR of 14 steadied at ~7 
(Tables 5 and 6). Hence this study suggests that Lipases 6Y and 6Z react more efficiently and selectively 
towards 12, making successful separation of this racemic mixture by means of enzymes more 
probable. 
2.2.4.3 Enantioselectivity of the EKR of 13 
 
 
 
Scheme 32: Mosher ester analysis of the EKR of 13. Reagents and conditions: a) Lipase 6Y/6Z, 50% 
MeCN in 50 mM phosphate buffer, pH 7.0, 40 ˚C, 20 h b) (R)-MTPA, DCC, DMAP, CH2Cl2, 90 min. 
 
As mentioned in 2.2.4, separation of the 13/16 mixture using the OJ, Cellulose-1 and AD-H columns 
were unproductive. We resorted to the Amylose-2 chiral column and with a mobile phase of 15.5:84.5 
IPA/ hexane, we managed to achieve separation of the hydrolysis products. With a standard 
chromatogram of 3 peaks (2 peaks for the product and one corresponding to the substrate 13), we 
could gain sufficient information to determine the enantioselectivity of the Lipase 6Y and 6Z reactions.  
We continued analysing the enzymatic reactions on the column at 20 minute intervals as done with 
the preceding compounds. Unfortunately, the substrate and one of the hydrolysed enantiomers co-
eluted at each of the injections, disturbing the baseline separation we had achieved in the standard 
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run. As we could not obtain the necessary data from the HPLC analysis, we opted to carry out the 
Mosher ester analysis of 13 as it produced successful results with 12. 
In the same way as for the Passerini compound 12, a large-scale enzymatic reaction of 13 was 
performed according to step a in Scheme 32. The reaction was left to stir for 20 hours, which was 
much longer in comparison to the EKR of 12. The lipases appear to react much slower with compound 
13 than with the other Passerini analogues. This was noted even in 2.2.3 (Figures 11 and 12) where 
the rate of hydrolysis of 13 by Lipases 6Y and 6Z was less than half that of the other Passerini 
enantiomers within the same time-period. 
The lipases did not hydrolyse the racemic mixture of the substrate entirely, hence column 
chromatography was carried out to separate the starting material from the scalemic mixture of 16. 
Pure 16 was recovered in an unsatisfactory yield of 14% from EKR of Lipase 6Y. A slightly improved 
yield of 48% was achieved by the Lipase 6Z reaction. To deduce the conversion, the method applied 
in 2.2.3 for the separation of 13/16 on the C-18 column was utilised, eluting the substrate at 4.51 
minutes and the hydrolysed adduct at 3.91 minutes. From HPLC, the yield of the product 16 was 21% 
due to Lipase 6Y (Figure 26). Figure 27 depicts a comparable yield by Lipase 6Z at 24%.   
 
 
 
Figure 26: EKR of 13 with Lipase 6Y at 20 hours.  
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Figure 27: EKR of 13 with Lipase 6Z at 20 hours.  
 
Although the conversion of the Passerini compound by the lipases afforded a minimal quantity of 16, 
we were still able to conduct the Mosher’s reaction (step b of Scheme 32). We undertook the synthesis 
in the same manner described for compound 12. After 90 minutes, TLC indicated a new spot and total 
consumption of the starting material. Following extraction and purification, the liquid product 
obtained was characterised. 
From assessment of the 1H and 13C NMR, we reached the conclusion that the expected Mosher’s ester 
products were not effectively prepared, either from the Lipase 6Y or the Lipase 6Z reaction. The 
spectra offered no indication of starting material or the Mosher’s acid reagent. We were not able to 
determine what compound had in fact been formed. The 19F NMR showed 2 peaks of roughly equal 
integration, which meant that the product formed contained fluorine atoms. However, we could not 
ascertain the enantioselectivity parameters from this result. We further analysed the compounds by 
mass spectroscopy, and no proof of the desired product was obtained. 
Evidently, the Passerini compound 13 was seemingly problematic from the onset. In 2.2.2 we 
attempted to chemically hydrolyse 13 under basic conditions as it yielded successful outcomes for 12 
and 14. However this was the first complication as it met with failure, and another route to preparing 
the hydrolysis standard 16 had to be taken. From the screening of the enzymatic reactions, 13 had the 
lowest conversion compared to its counterparts. Granted that the enzymes responded to this 
compound modestly, the enantioselectivity of the reactions could nonetheless not be elucidated by 
HPLC nor the Mosher ester analysis. 
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Having had no fruitful outcomes with the proteases on the Ugi compounds, we were pleased with the 
lipase response to the Passerini enantiomers. Although no inferences could be made regarding 
compound 13, we discovered that the lipases were not very selective towards 14. A positive result 
was obtained with the substrate 12, as not only does the enzymes hydrolyse the ester functionality, it 
also displays adequate enantioselectivity making separation of this racemic mixture rather promising. 
Due to time constraints, separation of this compound was not possible, but will be considered for 
future work. 
 
2.3 Diastereoselectivity Studies of the Passerini Reaction 
 
The following task we pursued involved diastereoselectivity studies of the Passerini reaction. This work 
is a progression based on that executed by Zimuwandeyi.80 Recent studies by Zimuwandeyi in our 
laboratories have shown that the use of chiral starting materials in the Passerini reaction can have a 
noteworthy impact on the reaction diastereoselectivity. Using N-Boc-phenylalaninal (which contains 
a fixed stereogenic centre) with achiral isocyanides and carboxylic acids resulted in a d.r. of 2:1 in most 
cases.  When employing a chiral isocyanide and aldehyde in the Passerini reaction, the d.r. reduced 
significantly.80 Henceforward we intended to further explore the diastereoselectivity of the reaction 
by introducing a combination of starting material with fixed chirality into the Passerini reaction. 
2.3.1 Preparation of N-Boc-D-phenylalanine 19 
 
The first step was the synthesis of the starting material. As most HIV PIs contain a phenylalanine 
moiety (including the potential HIV PI compounds synthesised by Zimuwandeyi)80, the majority of the 
reagents we prepared were based on N-Boc-phenylalanine. For the acid component in the Passerini 
reaction, we utilised both the natural and unnatural amino acid derivatives, N-Boc-L-phenylalanine 
and N-Boc-D-phenylalanine, respectively. The former was obtained commercially hence we were only 
required to prepare the unnatural analogue via Boc-protection of D-phenylalanine (Scheme 33). 
 
 
Scheme 33: Reagents and conditions: (Boc)2O, 1,4-dioxane, 1 M aq NaOH, 24 h. 
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The synthetic route applied was based on the work of Majumdar et al.90 D-phenylalanine was dissolved 
in 1,4-dioxane, followed by the addition of NaOH at 0 ˚C. After 20 minutes of stirring, Boc-anhydride 
was gradually added and the reaction continued overnight at room temperature. Following 
neutralisation of the mixture by KHSO4, the desired product 19 was extracted and purified resulting in 
a yield of 67%.   
The Boc-protection of D-phenylalanine was carried out successfully. The 1H NMR spectrum depicts a 
multiplet at 1.60 – 1.08 ppm integrating for 9 protons (H-10). The H-10 protons are expected to appear 
as a singlet as they do not couple to any other protons, hence the multiplet observed could be due to 
the presence of rotamers. Only one proton is present from NH at 6.66 ppm, indicative that the 
nitrogen was effectively Boc-protected. A singlet OH peak was also evident at 10.96 ppm. 13C NMR 
spectroscopy shows doubling of the majority of signals. Two signals at 156.76- and 155.47 ppm which 
both correspond to the newly formed Boc-group are observed. The tertiary carbon atom, C-9, is also 
represented by two peaks at 81.65- and 80.17 ppm. The characteristic C-10 signal appears as a pair of 
signals at 28.27- and 27.97 ppm. Both the 1H and 13C NMR data support the existence of rotamers of 
19 since doubling of the signals is seen. The presence of rotamers could be the result of H-bonding 
between the OH proton and nitrogen, or the double-bond nature of the C-N amide bonds. 
IR spectroscopy further verifies the presence of 19. Two C=O signals are noticed at 1709- and 1644 
cm-1 consistent with the carboxylic acid and carbamate functionalities. A broad OH signal also occurs 
at 3245 cm-1 and an NH peak at 3306 cm-1. 
2.3.2 Preparation of N-Boc-D- and L-phenylalaninal 
 
We planned to use N-Boc-D- and L-phenylalanine as the carboxylic acid constituents in the Passerini 
reaction. Moreover we also utilised these acids as a starting material to prepare the aldehyde 
components, N-Boc-D-phenylalaninal and N-Boc-L-phenylalaninal. According to Scheme 34, the 
aldehydes were prepared in two steps via the Weinreb amide of phenylalanine, employing the well-
known procedure established by Fehrentz et al.91 
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Scheme 34: Reagents: a) CDI, CH2Cl2, NH(OMe)Me.HCl b) LiAlH4, THF. 
 
We commenced with preparation of the Weinreb amide (Scheme 34, step a) of the unnatural amino 
acid derivative 20 from N-Boc-D-phenylalanine 19 (discussed in 2.3.1). CDI was added in small 
amounts to a solution of compound 19 in CH2Cl2. Effervescence was observed at each addition due to 
the evolution of CO2. After 60 minutes of stirring, N,O-dimethylhydroxylamine hydrochloride was 
added and the reaction resumed for 48 hours. Ensuing the work up procedure, TLC indicated a single 
product and no starting material. Hence no further purification was necessary and the expected 
compound was achieved in an excellent yield of 90%. 
A definite indication of the formation of 20 is two singlets at 3.65- and 3.16 ppm in the 1H NMR 
spectrum, due to H-12 and H-11, respectively, each integrating for 3 protons. The absence of an OH 
peak which was seen for 19 at 10.96 ppm also confirmed that the Weinreb amide had been formed. 
The Boc-group appeared as a singlet at 1.38 ppm, in contrast to the multiplet observed for 19 showing 
no sign of rotamers for this product. Correspondingly in the 13C NMR spectrum, C-11 and C-12 emerge 
at 32.06- and 61.54 ppm, respectively, signals which were not present in the starting material. In this 
spectrum only single peaks were present for each carbon environment, depicting only a single 
averaged conformation, unlike the rotamers obtained from 19. 
A key point from the infrared spectrum is the disappearance of the broad OH signal which was visible 
in the starting material at 3245 cm-1.   
The subsequent step involved reduction of the amide by LiAlH4 in THF at 0 ˚C (Scheme 34, step b) to 
produce the N-Boc-D-phenylalaninal enantiomer 21 in a pleasing yield of 86%. The optical rotation of 
21 was found to be [αD]20589 +40.6 (c 0.50, MeOH) which is similar to the literature value, justifying 
that the compound had not been racemised.80 
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Upon inspection of the 1H NMR data, a distinct aldehyde peak was depicted at 9.63 ppm as a singlet. 
The two singlet peaks due to H-11 and H-12 of compound 20 were no longer seen for 21. 13C NMR 
results also displayed no signals for C-11 and C-12 from the Weinreb amide. In addition, a signal at 
199.37 ppm was noted, representative of the C=O of the aldehyde.  
The melting point was determined to be 82 – 83 ˚C which is in accordance with the literature value 
(86 ˚C).91 
N-Boc-L-phenylalaninal 23 was prepared efficiently in a 78% yield using the same two-step procedure 
as applied with 21 (Scheme 34) starting from commercially obtained N-Boc-L-phenylalanine. The NMR 
and IR spectra were fundamentally identical to those seen for 21. The specific rotation was [αD]20589  
-41.4 (c 0.50, MeOH) which is similar to that of -44.4 reported in literature and also the negative 
equivalent of 21, which is predicted for enantiomers. Additionally the determined melting point of 81 
– 83 ˚C further supports the effective synthesis of 23.91 
With the chiral carboxylic acids and aldehydes in hand, we resumed synthesis of three different 
isocyanides to be used in the Passerini reaction, namely adamantyl-, D-phenylalanine- and L-
phenylalanine isocyanides. 
2.3.3 Preparation of adamantyl isocyanide 24 
 
 
 
Scheme 35: Reagents and conditions: a) HCOOH, Ac2O b) NEt3, POCl3, CH2Cl2, 24 h. 
 
Whilst adamantyl isocyanide is not chiral, Gravestock et al. had uncovered that branched isocyanides, 
like 24 led to enhanced inhibition of HIV protease.34 Hence as an advancement to the endeavours of 
Zimuwandeyi,80 we prepared 24 to be used in combination with chiral acids and aldehydes in the 
Passerini reaction to discover its effect on the reaction diastereoselectivity and compare it to that of 
chiral isocyanides.   
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As demonstrated in Scheme 35, adamantyl isocyanide was prepared via formylation (step a) and 
dehydration (step b) steps. Commercially purchased adamantylamine was treated with formic acid 
and acetic anhydride under a nitrogen atmosphere. The reaction was quenched after 24 hours to 
obtain crude adamantyl formamide. Without further purification, the compound underwent 
dehydration using triethylamine and POCl3 in CH2Cl2. The reaction was then quenched using Na2CO3. 
Due to the intensity of the resulting effervescence during the work-up, a great deal of the product was 
lost producing lower yields. Hence it was imperative to cool the mixture to 0 ˚C during this step. After 
extraction and purification, 24 was obtained in 81% yield, as a yellow solid having a distinctive 
repellent isocyanide odour. 
Two triplet peaks were observed in the 13C NMR spectrum at 151.81 ppm (C-2) and 54.21 ppm (C-1). 
This phenomenon, sometimes observed for isocyanides, was also encountered by Zimuwandeyi and 
is described further by Crews et al. as being attributable to the coupling of 13C to 14N as both are NMR-
active nuclei. 80, 92 Overall, NMR spectroscopy substantiated the synthesis of adamantyl isocyanide. 
2.3.4 Preparation of D- and L-phenylalanine isocyanide  
 
 
 
Scheme 36: Reagents: a) HCOOH, Ac2O, TFA b) PPh3, CCl4, DIPEA, CH2Cl2. 
 
Synthesis of the chiral D- and L-phenylalanine isocyanides was carried out in a similar fashion to 24. 
Starting from the Weinreb amide of D- or L- phenylalanine (described in 2.3.2), formylation and Boc-
deprotection were achieved in a single step using the reagents stated in Scheme 36, step a. Only the 
formamide of L-phenylalanine 27 was purified and isolated in a poor yield of 28%. Crude 25 was used 
in the subsequent step. Both compounds were highly polar and displayed an Rf value of 0.03 in a polar 
mobile phase of 5% MeOH/CH2Cl2.  
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NMR proved the formation of both 25 and 27 with the singlet formamide proton peaks at 8.13- and 
8.07 ppm, respectively. As expected, the Boc-group H-10 protons present in the starting material were 
not seen in the formamide products. Likewise, signals for C-8, C-9 and C-10 of 20 and 22 did not reflect 
in the desired products, but a C=O peak for the formyl group appeared at ~171 ppm for both the said 
compounds. 
The dehydration stage was attempted using NEt3 and POCl3 as performed with adamantyl formamide. 
However, this met with failure on numerous occasions. Thus we resorted to using a combination of 
triphenylphosphine, carbon tetrachloride and DIPEA in CH2Cl2 (Scheme 36, step b). This route not only 
resulted in the desired product (17% yield for 26 and 71% for 28), but also required no cooling and did 
not have problematic work-up procedures. Furthermore, no offensive smell was experienced from 
these chiral isocyanides. 
The 1H NMR spectra displayed no sign of the formamide proton as well as no NH peak, validating 
effective dehydration of 25 and 27. No formyl C=O peak was noted in the 13C NMR spectra of both the 
isocyanide products, however representative C≡N (C-8) signals were observed for both 26 and 28 at 
~159 ppm. As expected, the 1H and 13C NMR spectra for the two enantiomers were identical. 
The isocyanide C≡N triple bond was also reflected as a strong signal at ~2144 cm-1 in the IR spectra for 
both 26 and 28. No information on the optical rotation for these compounds was obtained from the 
literature, except the results previously obtained by Zimuwandeyi.80 The result determined for 26 was 
[αD]20589 -6.45 (c 2.00, CHCl3). The opposite enantiomer 28 had a specific rotation of [αD]20589 +3.55 (c 
2.00, CHCl3) which is roughly equivalent to +2.13 obtained by Zimuwandeyi for the same chiral 
compound under identical conditions.80 We expect these values to be identical but opposite in sign as 
they are enantiomers, but they are slightly higher as compared to that of Zimuwandeyi.80  
HRMS furthermore agreed with the previous data. The calculated mass of [M + H]+ for the isocyanides 
was 219.1134, and actual masses obtained, respectively for 26 and 28 were 219.1144 and 219.1132. 
Having effectually generated the chiral carboxylic acids, aldehydes and isocyanides (and the achiral 
adamantyl isocyanide), we were now at a stage to subject them to the Passerini reaction in various 
combinations to investigate their influence on the diastereoselectivity. 
2.3.5 Diastereoselectivity of the adamantyl isocyanide series 
 
We planned on synthesising three series of Passerini compounds, each employing one of the prepared 
isocyanides (adamantyl-, D-phenylalanine- and L-phenylalanine isocyanides) with the various chiral 
acids and aldehydes. The first sequence involved adamantyl isocyanide in combination with N-Boc-D- 
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or L-phenylalanine and N-Boc-D- or L-phenylalaninal (Figure 28). This gave rise to four different sets 
of diastereomeric mixtures from which the d.r. was determined. We then aimed to separate these 
mixtures by use of semi-preparative HPLC, which led to eight pure diastereomers for this set. 
 
 
Figure 28: Synthetic plan for Passerini diastereomers using adamantyl isocyanide.   
 
The reactions were completed using equimolar quantities of each of the starting materials in CH2Cl2. 
After 5 days of continuous stirring and purification by column chromatography, compounds 29 – 32 
were achieved as a mixture of two diastereomers, in respective yields of 92, 68, 56 and 92%. Preceding 
separation of the mixtures, we subjected the compounds to HPLC analysis on the C-18 column for 
obtaining the d.r. values. These compounds, like the Passerini enantiomers in 2.2, easily dissolved in 
a range of solvents. Acetonitrile was the solvent of choice for HPLC use. Baseline separation was 
accomplished without major challenges for all four compounds, using a gradient elution of 60:40 
acetonitrile/ water to a 90:10 ratio. As expected, the enantiomers 29 and 31 (having a D/D and an L/L 
combination of aldehyde and acid) had elution times for both diastereomers of <20 minutes, whereas 
30 and 32 (D/L and L/D mix of aldehyde and acid, respectively) which are also enantiomers eluted later 
at ~30 minutes. The d.r. values of this Passerini series are contained in Table 7. 
Table 7: Diastereomeric ratios of compounds 29 – 32.  
Compound 29 30 31 32 
d.r. 2.29 : 1.00 2.47 : 1.00 2.26 : 1.00 2.08 : 1.00 
 
Compounds 29 and 31 showed diastereomeric ratios which were virtually equal. Since adamantyl 
isocyanide is achiral, it might have no effect on the diastereoselectivity of the reaction, however it is 
a very bulky isocyanide. The D/D and L/L combination of the other starting material for 29 and 31 
would have an equal effect on the d.r., as although they are opposite enantiomers, they would have 
                                                                             N-Boc-D-phenylalaninal + N-Boc-D-phenylalanine                 29 
                                                                             N-Boc-D-phenylalaninal + N-Boc-L-phenylalanine                 30 
Adamantyl Isocyanide                                      N-Boc-L-phenylalaninal + N-Boc-L-phenylalanine                 31 
                                                                             N-Boc-L-phenylalaninal + N-Boc-D-phenylalanine                 32 
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the same impact on the reaction mechanism. We expected that this would also be true for 30 and 32, 
since they are also enantiomers. However 30 displays a significantly greater d.r., and 32 the lowest 
value of the series. 
Prior to characterising the products spectroscopically, we separated the compounds using preparative 
HPLC techniques. For this semi-preparative instrument, a large C-18 reverse phase column was used. 
The method utilised to achieve separation on the analytical HPLC was transferable to the semi-
preparative system, which was advantageous. Despite this, the separation procedure involved 
multiple runs of the sample until the desired amount of pure diastereomer was obtained. The flow 
rate required was 20 ml/ minute, which is 20 times faster than that of the conventional HPLC, implying 
that large quantities of HPLC-grade solvent had to be used which is uneconomical. In addition, only 
limited quantities of compound could be separated at each run as highly concentrated samples 
resulted in no baseline separation. Nonetheless, we succeeded in separating the diastereomeric 
mixtures 29 – 32, applying the gradient elution system mentioned previously. Eight pure 
diastereomers were isolated (Figure 29). To establish the stereochemistry of the major and minor 
diastereomers, we attempted to acquire crystals of the compounds. Unfortunately, this proved 
unsuccessful for any of the separated compounds. The findings by Zimuwandeyi concerning similar 
Passerini compounds (N-Boc-L-phenylalaninal, adamantyl isocyanide and propionic acid) to that of this 
project, show from crystal structures that the new stereogenic centre generated from the reaction for 
the major diastereomer was an R-centre when L-phenylalaninal was used.80 Hence for their library of 
Passerini compounds, they assigned the major diastereomer as R and the minor one as S configuration 
at the newly formed stereocentre. Since the diastereoselectivity of the Passerini reaction was found 
to be largely dictated by the chiral aldehyde, applying the unnatural D-phenylalaninal in the reaction 
would result in the opposite product being formed, with the major diastereomer having an S 
configuration at the newly formed stereogenic centre and R for the minor one. Thus for this project, 
in the absence of other data, we will infer the stereochemistry based on the work of Zimuwandeyi for 
the major and minor diastereomers for this series.80 
Infrared spectroscopy predicts significant NH and C=O signals for nearly all the compounds. The NH 
peak for 31A and 31B is not clear, but emerges at 3200 – 3400 cm-1 for the remainder of the products. 
The number of strong C=O stretches vary for each of the pure diastereomers. 30A, 30B and 32A display 
four well-defined carbonyl stretches in the 1750 – 1640 cm-1 range, which corresponds to the ester, 
amide and two Boc-entity C=O functionalities. The other Passerini adducts exhibit only three carbonyl 
group signals, whilst 29B shows only two, which means that certain signals are overlapping. 
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The 1H NMR spectra validated the synthesis and effective separation of all the Passerini compounds. 
Multiplet peaks for the aromatic protons for each of the compounds appeared at ~7.60 – 6.95 ppm. 
Unfortunately, the majority of the products integrated for slightly more than the 10 expected phenyl 
protons, possibly due to contaminants.  Proton peaks for the adamantyl group appeared as expected. 
H-15, however, appeared as a singlet at ~1.66 ppm for selected compounds, but emerged as a 
multiplet for 29B, 31A and 31B. From Table 8, it is evident that the NH and H-2 peaks appear differently 
for some of the separated products. Compounds 29A, 31A and 32B reflect individual peaks for each 
of the NH and H-2 protons, whereas these signals overlap for the other compounds. Additionally, the 
minor diastereomers (B) of 29, 31 and 32 show two singlet peaks for one of the NH protons found 
more upfield, as opposed to a single singlet for the rest of the products. A noteworthy observation 
was that C-2 appeared slightly more downfield in the 13C NMR spectra for the minor diastereomers of 
this series except for compound 30. This was also experienced by Zimuwandeyi for the newly formed 
stereogenic centre of separated Passerini diastereomers. This reinforces the notion that the 
configuration of the major and minor diastereomers established by Zimuwandeyi can also be 
attributed to our compounds.80 As 29 (A and B) and 31 (A and B), and 30 (A and B) and 32 (A and B) 
are pairs of enantiomers, we expect their characterisation data to be identical. Considering the C-2 
values (Table 8), the values for each of the enantiomers are virtually equal. However, the values of the 
enantiomers 29B and 31B and 30B and 32B differ somewhat. We noticed that there was a slight 
change in the shift values of C-2 (by roughly 0.2 ppm) from the 13C NMR data obtained from the 
mixture of diastereomers prior to separation by preparative HPLC and the separated diastereomers. 
This indicates that it is possible for the shift values to differ slightly under variable conditions which 
could be the result of the disparities observed with the C-2 values of the aforementioned compounds. 
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Figure 29: Adamantyl isocyanide series of pure Passerini diastereomers.   
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Table 8: NMR shifts of Passerini compounds from the adamantyl isocyanide series. 
 3 x NH and H-2 / C-2 H-3 and H-17 H-4 and H-18 / C-4 
and C-18 
1H NMR 13C 
NMR 
1H NMR 1H NMR 13C NMR 
29A δ 6.30 (1H, s, 
NH), 5.22 
(1H, d, J = 9.5 
Hz, NH), 5.14 
– 4.97 (1H, 
m, H-2), 4.96 
– 4.86 (1H, 
m, NH) 
δ 
74.32 
δ 4.35 – 4.25 and 4.24 
– 4.11 (2H, 2xm) 
δ 3.22 – 
2.90 and 
2.65 – 
2.44 (4H, 
2xm) 
δ 37.79 
and 37.33 
29B δ 6.32 and 
6.01 (1H, 2xs, 
NH), 5.37 – 
4.78 (3H, m, 
2xNH and H-
2) 
δ 
75.74 
δ 4.67 – 4.05 (2H, m) δ 3.37 – 
2.37 (4H, 
m) 
δ 37.77 
and 37.30 
30A δ 6.11 (1H, s, 
NH), 5.21 – 
4.98 (2H, m, 
NH and H-2), 
4.90 – 4.74 
(1H, m, NH) 
δ 
74.76 
δ 4.61 – 4.42 and 4.40 
– 4.20 (2H, 2xm) 
δ 3.27 – 
2.94 and 
2.86 – 
2.51 (4H, 
2xm) 
δ 38.07 
and 37.40 
30B δ 6.30 (1H, s, 
NH), 5.40 – 
5.22 and 
5.17 – 4.96 
(2H, 2xm, NH 
and H-2), 
4.50 – 4.07 
δ 
74.73 
δ 4.50 – 4.07 (2H, 3xm) δ 3.21 – 
2.96 and 
2.82 – 
2.60 (4H, 
2xm) 
δ 38.03 
and 37.33 
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(1H, 3xm, 
NH) 
31A δ 6.30 (1H, s, 
NH), 5.23 
(1H, d, J = 9.0 
Hz, NH), 5.16 
– 5.01 (1H, 
m, H-2), 5.01 
– 4.85 (1H, 
m, NH) 
δ 
74.26 
δ 4.38 – 4.23 and 4.29 
– 4.09 (2H, 2xm) 
δ 3.14 – 
2.92 and 
2.66 – 
2.47 (4H, 
2xm) 
δ 37.74 
and 37.28 
31B δ 6.29 and 
6.00 (1H, 2xs, 
NH), 5.31 – 
5.00 (2H, m, 
NH and H-2), 
4.99 – 4.76 
(1H, m, NH), 
δ 
74.27 
δ 4.61 – 4.10 (2H, m) δ 3.24 – 
2.72 and 
2.63 – 
2.49 (4H, 
2xm) 
δ 37.75 
and 37.29 
32A δ 6.10 (1H, s, 
NH), 5.21 – 
4.96 (2H, m, 
NH and  H-2), 
4.89 – 4.74 
(1H, m, NH), 
δ 
74.73 
δ 4.60 – 4.43 and 4.39 
– 4.21  (2H, 2xm) 
δ 3.27 – 
2.94 and 
2.87 – 
2.57 (4H, 
2xm) 
δ 38.02 
and 37.35 
32B δ 6.34 and 
6.10 (1H, 2xs, 
NH), 5.40 – 
5.23 (1H, m, 
H-2), 5.16 – 
5.01 (1H, m, 
NH) 4.57 – 
4.06 (1H, 
3xm, NH) 
δ 
75.22 
δ 4.57 – 4.06 (2H, 3xm) δ 3.22 – 
2.94 and 
2.83 – 
2.58 (4H, 
2xm) 
δ 38.01 
and 37.76 
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The melting points for this series show an interesting pattern. From Table 9, each of the pairs of 
diastereomers have a melting point that is markedly similar. However, 32A and 32B are the only 
exception as their melting points differ substantially. Compounds 29A and 29B and 31A and 31B have 
similar melting points as expected as they are pairs of enantiomers. Compounds 30 (A and B) and 32 
(A and B) show considerably greater values however, 30B and 32B have significantly different melting 
points. 
Table 9: Melting points of compounds 29 – 32.  
Compound 29A 29B 30A 30B 31A 31B 32A 32B 
m.p. (˚C) 92 - 94 86 - 88 181 - 
183 
185 - 
187 
79 - 80 80 - 82 192 - 
195 
102 - 
104 
 
2.3.6 Diastereoselectivity of the D-phenylalanine isocyanide series 
 
 
 
Figure 30: Synthetic plan for Passerini diastereomers using D-phenylalanine isocyanide.   
 
With success in the preparation and separation of the adamantyl isocyanide sequence, we progressed 
to applying the chiral D-phenylalanine isocyanide in the reaction and monitored the influence on the 
d.r. The reactions were conducted in the same manner stated previously using 0.46 mmol of each of 
the starting materials. Again, four reactions were carried out as shown in Figure 30. After purification, 
compounds 33 – 36 (Figure 31) were obtained as a mixture of two diastereomers in yields ranging 
between 42 – 80%.  Developing a separation method on the C-18 column for this collection of 
compounds was less straightforward than that described in 2.3.5. Using a gradient elution of 60:40 to 
65:35 acetonitrile/ water ultimately allowed determination of the d.r. for these compounds with 
lengthy elution times just below 60 minutes. 
                                                                                 N-Boc-D-phenylalaninal + N-Boc-D-phenylalanine              33  
                                                                                 N-Boc-L-phenylalaninal + N-Boc-L-phenylalanine               34 
D –Phenylalanine Isocyanide                             N-Boc-D-phenylalaninal + N-Boc-L-phenylalanine               35 
                                                                                N-Boc-L-phenylalaninal + N-Boc-D-phenylalanine                 36 
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Table 10: Diastereomeric ratios of compounds 33 – 36.  
Compound 33 34 35 36 
d.r. 1.97 : 1.00 2.46 : 1.00 1.80 : 1.00 1.94 : 1.00 
 
Table 10 indicates a d.r. of approximately 2:1 for 33 and 36, whilst 34 and 35 are outliers. With a result 
of 2.46 : 1.00, 34 displays the highest d.r. indicating preference of one diastereomer over the other. 
Hence this would be “matched” because it leads to greater diastereoselectivity. On the other hand, 
compound 35 is a “mismatch” as it led to a decrease in diastereoselectivity. This denotes that the use 
of chiral isocyanides does indeed play a role in the diastereoselectivity of the reaction, in addition to 
the combination of chiral acids and aldehydes involved. 
We moved on to separate the diastereomers using semi-preparative HPLC with the same method 
applied on the C-18 column. Since these runs persisted for nearly an hour, liberal amounts of HPLC 
solvent were expended and only minute quantities of the compounds were collected for further 
characterisation. Unfortunately, we were unable to obtain crystals for this series, and so the 
stereochemistry of this set of compounds was also extrapolated as per Zimuwandeyi’s results, with 
the major diastereomer being R and the minor one being S at the new stereogenic centre for 
compounds prepared with L-phenylalaninal.80 On the other hand, the opposite product was obtained 
when D-phenylalaninal was employed. 
Upon analysis of the 1H NMR spectra, synthesis of all eight compounds was confirmed. For the major 
diastereomer of 33 (A), the aromatic rings appeared as a multiplet at 7.38 – 7.09 ppm integrating for 
17 protons (greater than the expected 15H due to probable contamination). The H-12 signal 
overlapped with the peak consistent with H-2 as a multiplet at 5.35 – 5.11 ppm. The three NH signals 
were reflected further upfield as three separate multiplets. The very similar, H-22 and H-3 occurred 
as two multiplets between 4.52 - and 4.10 ppm with an integration of 2H. However, H-12 which is also 
similar to H-22 and H-3 appeared more downfield overlapped with H-2 as noted from 2D NMR data 
as well as from the NMR data of Zimuwandeyi for compounds containing similar starting material to 
that of our products.80 The Boc-groups appeared as a multiplet at the predicted position, with H-20 
arising as a singlet at 3.62 ppm.  
All seven 1H NMR spectra of the other pure diastereomers resembled that of 33A, apart from the two 
NH, H-12 and H-2 signals which did not appear as separate peaks for selected products. Additionally 
H-20 appeared as a multiplet for 33B, 34A, 35B and 36 (A and B) instead of the predicted singlet. 
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The 13C NMR spectra further validated the formation of the above compounds. Since only single peaks 
for each carbon environment were observed (in contrast to doubling of peaks for a mixture of 
compounds), the separation of the diastereomers also proved successful. Five carbonyl peaks were 
seen due to the ester, two amide and two Boc-carbamate functionalities for each of the adducts. C-
22, C-12 and C-3 appear between 56- and 50.00 ppm. Similarly C-23, C-13 and C-4 all appear in a close 
range of 38 – 37.00 ppm. As with the adamantyl isocyanide series, C-2 is observed more downfield for 
the minor diastereomers (33B – 36B) (Table 11). Compound 36B was the only exception in this case. 
Table 11: 13C NMR shifts for C-2 of compounds 33 – 36. 
Compound 33A 33B 34A 34B 35A 35B 36A 36B 
δ C-2 73.97 74.19 74.04 74.19 74.46 75.03 75.09 75.05 
 
The NH and C=O stretches were key from the infrared data. Three carbonyl peaks were noted for each 
of the separated diastereomers as presented in Table 12, conforming to the carbamate, amide and 
ester functional groups. 
Table 12: Major IR peaks of compounds 33 – 36. 
Compound 33A 33B 34A 34B 35A 35B 36A 36B 
NH stretch 
(cm-1) 
3358 3352 3349 3358 3309 3322 3313 3312 
C=O  
stretches 
(cm-1) 
1756, 
1691, 
1660 
1756, 
1689, 
1659 
1755, 
1689, 
1656 
1755, 
1691, 
1656 
1746, 
1693, 
1658 
1756, 
1689, 
1660 
1753, 
1695, 
1656 
1753, 
1692, 
1656 
 
Mass spectroscopy also verified preparation of 33 – 36. 
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Figure 31: D-phenylalanine isocyanide series of pure Passerini diastereomers.   
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2.3.7 Diastereoselectivity of the L-phenylalanine isocyanide series 
 
 
Figure 32: Synthetic plan for Passerini diastereomers using D-phenylalanine isocyanide.   
 
The final collection of diastereomers were prepared with the chiral L-phenylalanine isocyanide (Figure 
32). Compounds 37 – 40 (Figure 33) were achieved in an excellent average yield of 88%. An identical 
method for both the C-18 and semi-preparative separation was employed for this set as for the D-
phenylalanine isocyanide group. The d.r. values for these compounds are approximately 2:1 (Table 
13). Nonetheless no significant pattern is displayed with the diastereoselectivity, even for the 
compounds prepared with D/D, L/L and D/L, L/D acids and aldehydes. Hence for this series, no 
conclusion can be made on whether the various combination of chiral starting material in the Passerini 
reaction largely impacts the d.r. Once more, the configuration of the major and minor diastereomers 
were assigned according to that of Zimuwandeyi as acquisition of crystals for these separated 
compounds were problematic.80 
Table 13: Diastereomeric ratios of compounds 37 – 40.  
Compound 37 38 39 40 
d.r. 1.90 : 1.00 1.78 : 1.00 1.85 : 1.00 2.03 : 1.00 
 
The 1H NMR data for this separated series is virtually identical to the aforementioned series. The 
phenyl ring protons for all 8 diastereomers appear at ~7.50 – 6.95 ppm as a multiplet with an 
integration of greater than 15H. All three Passerini series reflect a larger number of aromatic protons 
than predicted, the most likely reason being contamination. For some compounds the NH, H-12 and 
H-2 signals appeared as individual peaks, whereas in others they overlapped. Just as for the series in 
2.3.6, H-22 and H-3 appear alongside each other but H-12, although it is remarkably similar appeared 
slightly more downfield. The signals for H-4, H-13, H-19 and H-23 appear together as a multiplet for 
                                                                                 N-Boc-D-phenylalaninal + N-Boc-D-phenylalanine                 37  
                                                                                N-Boc-L-phenylalaninal + N-Boc-L-phenylalanine                  38 
L –Phenylalanine Isocyanide                             N-Boc-D-phenylalaninal + N-Boc-L-phenylalanine                 39 
                                                                               N-Boc-L-phenylalaninal + N-Boc-D-phenylalanine                 40 
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most of the compounds at ~3.30 – 2.40 ppm. The Boc-protons H-11 and H-30 are observed as a 
multiplet ~1.60 – 1.15 ppm and integrate for 18 expected protons. 13C NMR spectroscopy displayed 
each of the peaks for all the compounds as anticipated. Table 14 shows C-2 for both the major and 
minor diastereomers. As predicted from the work of Zimuwandeyi and the results obtained from the 
previous series, the major diastereomers (A) reflect further upfield as compared to the minor 
counterpart -  indicating that the stereochemistry of both diastereomers are correctly assumed.80 
Compound 39A however does not fit the predicted result. 
Table 14: 13C NMR shifts for C-2 of compounds 37 – 40. 
Compound 37A 37B 38A 38B 39A 39B 40A 40B 
δ C-2 74.13 74.19 73.97 75.05 75.09 75.03 74.46 75.05 
 
Infrared spectroscopy for each of the separated diastereomers of this series display an NH and three 
strong C=O stretches, analogous to the D-phenylalanine isocyanide group. The melting points of 37 
and 38 (A and B) prepared using a mix of D/D and L/L aldehyde and acid, respectively, were 
considerably higher (98 – 139 ˚C) to that of compounds 39 and 40 (A and B) at 65 – 74 ˚C, which were 
synthesised with a mixture of D/L and L/D aldehydes and acids, respectively. 
Table 15: 13C NMR shifts for C-2 for the sets of enantiomers of compounds 33 – 40. 
Compound δ C-2 Compound δ C-2 
33A 73.97 38A 73.97 
33B 74.19 38B 75.05 
34A 74.04 37A 74.13 
34B 74.19 37B 74.19 
35A 74.46 40A 74.46 
35B 75.03 40B 75.05 
36A 75.09 39A 75.09 
36B 75.05 39B 75.03 
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Figure 33: L-phenylalanine isocyanide series of pure Passerini diastereomers.   
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From the D-phenylalanine isocyanide and L-phenylalanine isocyanide series of the Passerini 
diastereomers, it is evident that sets of enantiomers exist between the two groups. For instance, 
compound 33 (A and B) is an enantiomer of 38 (A and B) as they were synthesised using a combination 
of D/D/D and L/L/L isocyanide/aldehyde/acid reagents, respectively. Likewise, 34 and 37, 35 and 40 
and 36 and 39 are also sets of enantiomers. Hence we expect the characterisation data of these pairs 
of compounds to be identical. From 13C NMR spectroscopy, the C-2 values of the major (A) and the 
minor (B) diastereomers of these four sets of enantiomers are virtually equal as predicted (Table 15). 
The only exception is 33B and 38B, for which the C-2 values differ substantially (74.19 and 75.05 ppm). 
As seen with the adamantyl isocyanide series, the shift values differed slightly when the samples were 
run as a diastereomeric mixture in comparison to the separated diastereomers, making it possible for 
the C-2 values to be slightly different. As noted previously with our results and with that noticed by 
Zimuwandeyi, the C-2 values of the minor diastereomers appeared more downfield in comparison to 
the major diastereomer.80 What is interesting is that the outlier from the D-phenylalanine isocyanide 
series was compound 36, and that from the L-phenylalanine isocyanide collection was 39, and these 
compounds are found to be a set of enantiomers. Hence, this indicates a definite relationship between 
compounds prepared with certain combinations of chiral starting materials in the Passerini reaction.  
2.3.8 Proposed model for the configuration and diastereoselectivity of the Passerini 
reaction 
From the results obtained it is evident that the d.r. values of the diastereomeric compounds in each 
of the three series are close to 2:1. However, the D and L-phenylalanine isocyanide series reflect values 
slightly lower than the average, whilst the adamantyl isocyanide series display values greater than 2:1 
for all four pairs of diastereomers (29 – 32). Zimuwandeyi found that the chiral aldehyde 
(phenylalaninal) largely dictates the diastereoselectivity of the Passerini reaction, but from our results 
it is apparent that the type of isocyanide also plays a role in the d.r. values of the compounds.80 
To rationalise the configuration of the newly generated stereocentre in the Passerini reaction, 
Zimuwandeyi proposed that the reaction followed a chelation controlled pathway instead of the 
Felkin-Anh model.80 Section 1.2.2 outlines the Passerini reaction mechanism in aprotic solvents which 
involves H-bonding between the acid and aldehyde, followed by addition of the nucleophilic 
isocyanide. Since the aldehyde is chiral in this case, the nucleophile can approach it by either the Re 
or Si face. According to the Felkin-Anh mechanism, the isocyanide would attack the Re face to 
minimise steric hindrance due to the large mono-substituted amino aldehyde, giving rise to an S 
configuration at the newly formed stereocentre of the major diastereomer when the natural L-
phenylalaninal is used (Scheme 37). The opposite configuration would be achieved when D-
phenylalaninal is employed. However, Zimuwandeyi realised from crystal structures that the 
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compounds exhibited the stereochemistry opposite to that suggested by the Felkin-Anh model.80 This 
led to the conception that intramolecular H-bonding that occurs between the carbonyl oxygen and 
the NH of the aldehyde, allowed the reaction to adhere to the chelation model which is further 
described by Hili.94 This arranges the aldehyde in a fixed position in which the large phenyl group lies 
perpendicular to the carbonyl moiety, making the Si face the most favourable for the nucleophile to 
attack in cases when L-phenylalaninal is used (Scheme 37). The result would be an R configuration for 
the major diastereomer at the new stereocentre, which substantiates the data obtained by 
Zimuwandeyi.80 Once more, the opposite configuration is achieved when D-phenylalaninal is applied, 
resulting in an S-centre for the major product. The stereochemistry of the diastereomers obtained in 
our project was based on the findings by Zimuwandeyi, as our compounds were non-crystalline hence 
obtaining crystal structures was not possible.80 
 
 
Scheme 37: Mechanism of the Passerini reaction with L-phenylalaninal, indicating formation of the 
major diastereomer: a) Felkin-Anh model b) chelation controlled model. 
 
Generally, the size of the nucleophile significantly influences the stereoselectivity of the reaction, with 
larger nucleophiles resulting in superior diastereoselectivity. Since H-bonding occurs between two 
moeities of the aldehyde, fixing the arrangement of the transition state, the nucleophile (isocyanide) 
attacks the face which results in the least steric hindrance. Adamantyl isocyanide is especially bulky as 
93 
 
compared to the D and L-phenylalanine isocyanides, hence causing a slightly greater discrimination 
with the diastereoselectivity. As a result, the d.r. values for the branched adamantyl isocyanide series 
exceeded the average 2:1 ratio. The results obtained in this project are consistent with those found 
by Zimuwandeyi, where larger isocyanides somewhat enhanced the diastereoselectivity of the 
Passerini reaction as opposed to smaller isocyanides.80 
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Chapter 3: Conclusions and Future work 
 
3.1 Conclusions 
 
We endeavoured to synthesise peptidomimetic compounds using MCRs. The racemic mixtures 
obtained from these reactions were suitable for separation by means of EKR to generate pure products 
with prospective bioactivity. 
A library of enantiomeric adducts were prepared via the isocyanide-based U-4CR MCR employing a 
variety of carboxylic acids. As methanol and ammonia were utilised in the reaction, extremely low 
yields of all the compounds were obtained as predicted. Altering the solvent to the less nucleophilic 
2,2,2-trifluoroethanol increased the yields by nearly threefold. Proteases and penicillin G acylase were 
then applied to the racemates in order to resolve them by hydrolysis of the amide bonds. Regrettably, 
the enzymes failed to hydrolyse the Ugi-compounds and showed no chemical transformation under 
various reaction conditions. Also these compounds exhibited poor solubility in organic solvents which 
could also contribute to the failure of EKR. 
Using a range of aldehydes, enantiomeric compounds were produced by the Passerini MCR reaction. 
This time we opted to resolve the mixtures using lipases 6Y and 6Z. These compounds displayed 
greater solubility than the previous set in most organic solvents. Enzymatic reactions were performed 
on these compounds and both lipases effectively hydrolysed the products in a short period of time. 
With the success experienced using the biocatalysts, we aimed to determine the enantioselectivity of 
the EKR reactions using chiral HPLC. The Passerini benzaldehyde-derivative portrayed moderate 
conversion and selectivity by both lipases as ascertained by the AD-H chiral column. Failure to obtain 
the necessary information to investigate the selectivity of the other Passerini enantiomers by chiral 
HPLC, led us to conduct the Mosher ester analysis. From 19F NMR, we established that EKR of the 
racemic hydrocinnamaldehyde-derivative exhibited good enantioselectivity and that they could 
effectively be separated through biocatalysts. On the other hand, no data regarding selectivity of the 
Passerini compound formed by trans-cinnamaldehyde could be deduced either by chiral columns or 
by reaction with Mosher’s acid. In essence, we have successfully demonstrated that EKR is an effective 
technique for the separation of racemic mixtures. Greater enantioselectivity can be achieved in future 
by modification of reaction conditions, enzyme (via enzyme engineering) and the substrate involved. 
In addition to EKR of peptide mimics, we also set out to investigate the diastereoselectivity of the 
Passerini reaction. Previous studies have shown that the involvement of starting material in this MCR 
which contains a fixed stereogenic centre, plays a significant role in the d.r of the reaction. We 
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prepared three series of Passerini diastereomers using three different isocyanides, namely adamantyl, 
D-phenylalanine- and L-phenylalanine isocyanides, in combination with chiral Boc-D- or L-
phenylalanine and Boc-D- or L-phenylalaninal. Four diasteromeric mixtures were obtained in each 
group and the d.r. was close to 2:1 for most products.  
Prior to characterisation of these mixtures, separation by semi-preparative HPLC was undertaken to 
generate eight pure diastereomers in each Passerini series. The stereochemistry of the diastereomers 
could not be established by X-ray crystallography as the compounds were not crystalline hence, by 
analogy to previous work by Zimuwandeyi we concluded the configuration of the newly formed 
stereogenic centre of the major diastereomer to be R and S for that of the minor diastereomer when 
L-phenylalaninal was employed as the aldehyde component. Since the diastereoselectivity of the 
Passerini reaction is significantly affected by the aldehyde, the opposite product was obtained when 
D-phenylalaninal was used, with the major diastereomer having an S configuration for the newly 
formed stereocentre and R for the minor one. 13C NMR spectroscopy of the separated compounds 
showed distinct patterns for particular environments which reinforced the proposed configurations. 
The peaks from the 13C NMR spectra of only two compounds from the D- and L-phenylalanine series 
did not conform to this. 
The d.r. values obtained from this study indicated that the use of chiral starting material does in fact 
impact the diastereoselectivity of the Passerini reaction. The use of a D/D, L/L or D/L, L/D combination 
of reagents seem to influence the d.r. in most cases, probably due to the effect of steric hindrance.  
The Felkin-Anh chelation controlled mechanism rationalises the stereochemistry of the major and 
minor diastereomers. The size of the isocyanide evidently affects the diastereoselectivity of the 
Passerini reaction, with the bulky adamantyl isocyanide series displaying the greatest d.r. values in 
comparison to the other two series. However further studies must be carried out to resolve the 
inconsistencies as not all the data suggest a clear significant trend with the various combinations of 
starting materials. 
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3.2 Future work 
 
Given that no positive result was gained by EKR of the Ugi-enantiomers, it would be interesting to 
investigate the diastereoselectivity of this reaction by the introduction of chiral starting material. The 
Mosher ester analysis of the trans-cinnamaldehyde Passerini derivative 13 would have to be 
reconsidered in order to ascertain the enantioselectivity of the EKR of this compound. If not, a 
different method could be tested to gain insight into the selectivity of this reaction. The absolute 
configuration of the Passerini enantiomers (12 – 14) could also be discovered in order to distinguish 
which enantiomer is preferably being hydrolysed by Lipases 6Y and 6Z. Since no definite conclusions 
could be drawn from the trend using certain combinations of chiral starting materials on the 
diastereoselectivity of the Passerini reaction, different chiral isocyanides (eg. glucose isocyanide) can 
be synthesised and the effect on the d.r. can be determined. In this way we can deduce how different 
chiral starting materials participate in the reaction and hence predict which combinations would lead 
to preference of one diastereomer over the other. Additionally the pure Passerini diastereomers 
isolated can be subjected to biological testing to establish if they display any promise of bioactivity. 
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Chapter 4: Experimental Procedures 
 
4.1 General Experimental Procedures 
 
4.1.1 Purification of Reagents and Solvents 
 
All reagents and HPLC solvents were purchased from commercial suppliers and used without further 
purification. Solvents used for preparative chromatography were distilled before use. For reaction 
purposes, solvents were stored over activated molecular sieves (4 Å) and then distilled over the 
appropriate drying agent under a nitrogen atmosphere. THF was distilled from sodium wire with 
benzophenone as an indicator. CH2Cl2 was distilled from calcium hydride. 
4.1.2 Chromatography  
 
Thin layer chromatography was performed on aluminium-backed Macherey-Nagel UV254 plates pre-
coated with silica gel 60, and was visualised under UV light or by using iodine, ninhydrin or vanillin 
staining solutions. Column chromatography was carried out using Fluka silica gel 60 (particle size 0.063 
– 0.200 mm). Analytical HPLC was performed on a Dionex Ultimate 3000 pump using a Luna 5u C18 
(2) reverse phase column with gradient elution of MeCN/H2O for diastereomers and a Chiralpak AD-H 
or Lux 5 µm Amylose-2 chiral column with isocratic elution of IPA/Hexane for enantiomers (flow rate 
of 1 ml/min at 217 nm). Preparative HPLC was carried out using an Agilent 3000 instrument with an 
Agilent prep C18 reverse phase column (21.2 x 20.0 mm) with gradient elution of MeCN/H2O (flow 
rate of 20 ml/min at 217 nm). All calculations were based on peak area. 
4.1.3 Spectroscopic and Physical Data 
 
Optical rotations were measured on a Jasco P-2000 Polarimeter at 20 ˚ C at the sodium D line (589 nm). 
Melting points were determined using a Stuart SMP10 apparatus and are uncorrected. 
Infrared spectra were obtained using a Bruker Tensor 27 Fourier Transform spectrometer fitted with 
a diamond ATR device.  
1H NMR and 13C NMR spectra were recorded on a Bruker AVANCE 300 spectrometer at 300 MHz and 
75 MHz, respectively unless stated otherwise. Chemical shifts are reported in parts per million (ppm) 
relative to the internal standard, tetramethylsilane for 1H and CDCl3 (77.00 ppm) for 13C. 
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HRMS data was obtained using a Waters Synapt G2 spectrometer. 
4.2 Enzymatic Kinetic Resolution of U-4CR Enantiomers 
 
4.2.1 Synthesis of U-4CR Enantiomers 
 
4.2.1.1 Synthesis of 2-acetamido-N-cyclohexyl-2-phenylacetamide 7 
 
Benzaldehyde (305 µl, 3.00 mmol) was added to a solution of ammonia (224 µl of a 25% solution, 3.00 
mmol) in MeOH (3 ml) and the mixture was stirred for 15 min. Acetic acid (172 µl, 3.00 mmol) was 
then added and the reaction stirred for a further 5 min after which cyclohexyl isocyanide (373 µl, 3.00 
mmol) was added. The mixture was left to stir overnight at room temperature. Excess solvent was 
removed in vacuo and the residue was purified by column chromatography (CH2Cl2/MeOH 1:0 to 9:1) 
to afford 7 (0.10 g, 12%) as a white solid. 
The synthesis of compound 7 was repeated as described above except using 2,2,2-trifluoro-ethanol as 
the solvent (0.33 g, 40%). 
 
Rf = 0.35 (5% MeOH/CH2Cl2); m.p. 243 – 245 ˚C; IR (vmax/cm-1): 3280 (NH), 2935, 2855 (C-H), 1633 
(C=O), 1540 (C=C), 1058 (C-N); 1H NMR (300 MHz, CDCl3) δ 7.47 – 7.15 (5H, m, Ar-H), 6.97 (1H, d, J = 
6.8 Hz,  NH), 5.86 (1H, d, J = 8.0 Hz, NH), 5.53 – 5.37 (1H, m, H-2), 3.84 – 3.50 (1H, m, H-7), 2.01 (3H, s, 
H-12), 1.97 – 1.45 (5H, m, CH2eq), 1.44 – 0.88 (5H, m, CH2ax); 13C NMR (75 MHz, CDCl3) δ 169.62 and 
169.12 (C-11 and C-1), 138.45 (C-3), 128.89 (C-5, C-5’), 128.17 (C-6), 127.17 (C-4, C-4’), 56.90 (C-2), 
48.71 (C-7), 32.73 and 32.55 (C-8, C-8’), 25.42 (C-10), 24.69 and  24.57 (C-9, C-9’), 23.20 (C-12); HRMS 
m/z: calculated for C16H23N2O2: 275.1760, found [M + H]+: 275.1764. 
 
4.2.1.2 Synthesis of N-(2-(cyclohexylamino)-2-oxo-1-phenylethyl)propionamide 8 
 
Benzaldehyde (305 µl, 3.00 mmol) was added to a solution of ammonia (224 µl of a 25% solution, 3.00 
mmol) in MeOH (3 ml) and the mixture was stirred for 15 min. Propionic acid (225 µl, 3.00 mmol) was 
then added and the reaction stirred for a further 5 min after which cyclohexyl isocyanide (373 µl, 3.00 
99 
 
mmol) was added. The preparation was completed using the same procedure as described in 4.2.1.1 
to afford 8 (0.03 g, 3%) as a white solid. 
 
Rf = 0.43 (5% MeOH/CH2Cl2); m.p. 217 – 218 ˚C; IR (vmax/cm-1): 3283 (NH), 2935, 2854 (C-H), 1634 
(C=O), 1533 (C=C); 1H NMR (300 MHz, CDCl3) δ 7.83 (0.2H, d,  J = 8.0 Hz, NH), 7.47 – 7.32 and 7.29 – 
7.21 (6H, 2xm, Ar-H and NH), 7.04 (0.8H, d, J = 8.0 Hz, NH), 5.78 (1H, d, J = 7.8 Hz, H-2), 3.76 – 3.58 
(1H, m, H-7), 2.28 (2H, q,  J = 7.6 Hz, H-12), 1.90 – 1.47 (5H, m, CH2eq), 1.36 – 0.97 (8H, 2xm overlapped 
with t, J = 7.5 Hz, CH2ax and H-13); 13C NMR (75 MHz, CDCl3) δ 173.21 and 169.15 (C-11 and C-1), 138.62 
(C-3), 128.86 (C-5, C-5’), 128.11 (C-6), 127.14 (C-4, C-4’), 56.77 (C-2), 48.71 (C-7), 32.76 and 32.59 (C-
8, C-8’), 29.72 and 29.52 (C-12), 25.43 (C-10), 24.73 and 24.62 (C-9, C-9’), 9.62 (C-13); HRMS m/z: 
calculated for C17H25N2O2: 289.1916, found [M + H]+: 289.1917. 
4.2.1.3 Synthesis of 2-(2-chloroacetamido)-N-cyclohexyl-2-phenylacetamide 9 
 
Benzaldehyde (305 µl, 3.00 mmol) was added to a solution of ammonia (224 µl of a 25% solution, 3.00 
mmol) in MeOH (3 ml) and the mixture was stirred for 15 min. Chloroacetic acid (283 mg, 3.00 mmol) 
was then added and the reaction stirred for a further 5 min after which cyclohexyl isocyanide (373 µl, 
3.00 mmol) was added. The preparation was completed using the same procedure as described in 
4.2.1.1 to afford 9 (0.14 g, 15%) as a white solid. 
 
Rf = 0.56 (5% MeOH/CH2Cl2); m.p. 211 – 213 ˚C; IR (vmax/cm-1): 3291 (NH), 2931, 2855 (C-H), 1633 
(C=O), 1538 (C=C); 1H NMR (300 MHz, CDCl3) δ 7.99 (1H, d, J = 6.4 Hz, NH), 7.48 – 7.26 (5H, m, Ar-H), 
5.80 (1H, d, J = 7.8 Hz, NH), 5.44 (1H, d, J = 7.0 Hz, H-2), 4.02 (2H, s, H-12), 3.84 – 3.64 (1H, m, H-7), 
1.96 – 1.47 (5H, m, CH2eq), 1.40 – 0.86 (5H, m, CH2ax); 13C NMR (75 MHz, CDCl3) δ 168.23 and 165.53 
(C-11 and C-1), 137.71 (C-3), 129.10 (C-5, C-5’), 128.58 (C-6), 127.30 (C-4, C-4’), 57.26 (C-2), 48.92 (C-
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7), 42.48 (C-12), 32.77 and 32.56 (C-8, C-8’), 25.38 (C-10), 24.69 and 24.56 (C-9, C-9’); HRMS m/z: 
calculated for C16H22ClN2O2: 309.1370, found [M + H]+: 309.1358. 
4.2.1.4 Synthesis of N-(2-(cyclohexylamino)-2-oxo-1-phenylethyl)-3,3-dimethylbutanamide 
10 
 
Benzaldehyde (305 µl, 3.00 mmol) was added to a solution of ammonia (224 µl of a 25% solution, 3.00 
mmol) in MeOH (3 ml) and the mixture was stirred for 15 min. t-Butylacetic acid (383 µl, 3.00 mmol) 
was then added and the reaction stirred for a further 5 min after which cyclohexyl isocyanide (373 µl, 
3.00 mmol) was added. The preparation was completed using the same procedure as described in 
4.2.1.1 to afford 10 (0.18 g, 18%) as a white solid. 
The synthesis of compound 10 was repeated as described above except using 2,2,2-trifluoro-ethanol 
as the solvent (0.69 g, 70%). 
 
Rf = 0.44 (5% MeOH/CH2Cl2); m.p. 231 – 233 ˚C; IR (vmax/cm-1): 3295 (NH), 2936, 2859 (C-H), 1628 
(C=O), 1520 (C=C), 1059 (C-N); 1H NMR (300 MHz, CDCl3) δ 7.45 – 7.29 (5H, m, Ar-H), 6.81 (1H, d, J = 
6.9 Hz, NH), 5.79 (1H, d, J = 8.0 Hz, NH), 5.46 (1H, d, J = 7.0 Hz, H-2), 3.86 – 3.62 (1H, m, H-7), 2.10 (2H, 
s, H-12), 2.04 – 1.82 and 1.79 – 1.48 (5H, 2xm, CH2eq), 1.46 – 1.18 and 1.16 – 0.96 (5H, 2xm, CH2ax), 
0.99 (9H, s, H-14); 13C NMR (75 MHz, CDCl3) δ 171.09 and 169.03 (C-11 and C-1), 138.65 (C-3), 128.74 
(C-5, C-5’), 128.14 (C-6), 127.31 (C-4, C-4’), 56.93 (C-2), 50.38 (C-12), 48.72 (C-7), 32.78 and 32.61 (C-
8, C-8’), 31.04 (C-13), 29.84 (C-14), 25.42 (C-10), 24.73 and 24.61 (C-9, C-9’); HRMS m/z: calculated for 
C20H31N2O2: 331.2386, found [M + H]+: 331.2381. 
 
4.2.1.5 Synthesis of N-cyclohexyl-2-phenyl-2-(2-phenylacetamido)acetamide 11 
 
Benzaldehyde (305 µl, 3.00 mmol) was added to a solution of ammonia (224 µl of a 25% solution, 3.00 
mmol) in 2,2,2-trifluoro-ethanol (3 ml) and the mixture was stirred for 15 min. Phenylacetic acid (408 
mg, 3.00 mmol) was then added and the reaction stirred for a further 5 min after which cyclohexyl 
isocyanide (373 µl, 3.00 mmol) was added. The preparation was completed using the same procedure 
as described in 4.2.1.1 to afford 11 (0.15 g, 14%) as a white solid. 
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Rf = 0.59 (5% MeOH/CH2Cl2); m.p. 245 – 247 ˚C; IR (vmax/cm-1): 3294 (NH), 2937, 2864 (C-H), 1632 
(C=O), 1529 (C=C), 1053 (C-N); 1H NMR (300 MHz, CDCl3) δ 7.46 – 7.24 (10H, m, Ar-H), 6.88 (1H, d, J = 
6.8 Hz, NH), 5.48 (1H, d, J = 8.2 Hz, NH), 5.36 (1H, d, J = 6.8 Hz, H-2), 3.80 – 3.61 (1H, m, H-7), 3.58 (2H, 
s, H-12), 1.89 – 1.51 (9H, m, CH2eq), 1.39 – 0.81 (13H, m, CH2ax); 13C NMR (75 MHz, CDCl3) δ 170.30 and 
168.63 (C-11 and C-1), 138.27 (Ar-C), 134.56 (Ar-C), 129.34 (Ar-C), 128.98 (Ar-C), 128.94 (Ar-C), 128.31 
(Ar-C), 127.33 (Ar-C), 127.22 (Ar-C), 57.16 (C-2), 48.73 (C-7), 43.62 (C-12), 32.77 and 32.58 (C-8, C-8’), 
25.35 (C-10), 24.68 and 24.54 (C-9, C-9’); HRMS m/z: calculated for C22H27N2O2: 351.2073, found [M + 
H]+: 351.2076. 
 
4.2.2 U-4CR Enzyme Reactions 
 
4.2.2.1 Activity test reaction of Proteases 
 
N-acetylglycine ethyl ester (20 mg, 0.14 mmol) was dissolved in 25 mM phosphate buffer of pH 7.5 (2 
ml) and the solution was stirred at 40 ˚C. Protease enzyme (350 mg) was added and the mixture was 
left to stir for 24 hours. TLC was used to monitor the reaction and ascertain if the enzyme was active 
and had effectively hydrolysed the substrate. A control reaction containing no enzyme was performed 
to establish that hydrolysis failed to occur in the absence of enzyme. 
4.2.2.2 Activity test reaction of Penicillin G Acylase 
 
Penicillin G sodium salt (10 mg, 0.03 mmol) was dissolved in 25 mM phosphate buffer of pH 7.5 (1 ml) 
and the solution was stirred at 40 ˚C. Penicillin G acylase enzyme (30 µl) was added and the mixture 
was left to stir for 24 hours. TLC was used to monitor the reaction and ascertain if the enzyme was 
active and had effectively hydrolysed the substrate. A control reaction containing no enzyme was 
performed to establish that hydrolysis failed to occur in the absence of enzyme. 
From the six enzymes tested, all exhibited activity against the respective test substrates. 
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List of active enzymes: 
1. Alcalase (FE201) 
2. B. clausii protease (FE202) 
3. B. lentus protease (FE203) 
4. Bacillus. species protease (FE212) 
5. B. licheniformis protease (FE213) 
6. Penicillin G acylase 
4.2.2.3 Attempted EKR of compound 7  
 
Compound 7 (10 mg, 0.04 mmol) was dissolved in DMSO (1 ml). A portion of this solution (0.2 ml) was 
then added to 25 mM phosphate buffer of pH 7.5 (1 ml) and the mixture was stirred at 40 ˚C. Protease 
enzyme (1200 mg) was added and the reaction was left to stir for 30 d. No reaction was observed from 
TLC analysis for all active proteases and the experiment was discontinued. A control reaction 
containing no enzyme was performed to establish that hydrolysis failed to occur in the absence of 
enzyme. 
4.2.2.4 Attempted EKR of compound 7 in a two-phased system  
 
Compound 7 (10 mg, 0.04 mmol) was dissolved in MBE (0.5 ml). The solution was added to 25 mM 
phosphate buffer of pH 7.5 (1 ml) and the two-phased mixture was stirred at 40 ˚C. Protease enzyme 
(1200 mg) was then added and the reaction was left to stir for 14 d. No reaction was observed from 
TLC analysis for all active proteases and the experiment was discontinued. A control reaction 
containing no enzyme was performed to establish that hydrolysis failed to occur in the absence of 
enzyme. 
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4.2.2.5 Attempted EKR of compound of 11  
 
 
Compound 11 (10 mg, 0.03 mmol) was dissolved in EtOH (1 ml). The solution was then added to 25 
mM phosphate buffer of pH 7.5 (9 ml) and the mixture was stirred at 40 ˚ C. Penicillin G acylase enzyme 
(30 µl) was added and the reaction was left to stir for 30 d. No reaction was observed from TLC analysis 
and the experiment was discontinued. A control reaction containing no enzyme was performed to 
establish that hydrolysis failed to occur in the absence of enzyme. 
4.3 Enzymatic Kinetic Resolution of Passerini Enantiomers 
 
4.3.1 Synthesis of Passerini Enantiomers and Hydrolysis Standards 
  
4.3.1.1 Synthesis of 1-(cyclohexylamino)-1-oxo-4-phenylbutan-2-yl acetate 12 
 
Hydrocinnamaldehyde (658 µl, 5.00 mmol), acetic acid (286 µl, 5.00 mmol) and cyclohexyl isocyanide 
(622 µl, 5.00 mmol) were stirred in CH2Cl2 (10 ml) at room temperature for 3 d. Excess solvent was 
removed in vacuo and the residue was purified by column chromatography (EtOAc/Hexane 0:1 to 3:7) 
to yield 12 (0.92 g, 61%) as a white solid, as a racemate. 
 
Rf = 0.66 (50% EtOAc/Hexane); m.p. 100 – 103 ˚C; IR (vmax/cm-1): 3284 (NH), 2936, 2855 (C-H), 1740, 
1650 (C=O), 1556 (C=C), 1232 (C-O);  1H NMR (300 MHz, CDCl3) δ 7.36 – 7.08 (5H, m, Ar-H), 5.86 (1H, 
d, J = 8.0 Hz, NH), 5.13 (1H, t, J = 5.9 Hz, H-2), 3.87 – 3.69 (1H, m, H-9), 2.67 (2H, t, J = 7.9 Hz, H-4), 2.17 
(3H, s, H-14), 2.10 (2H, s, H-3), 1.97 – 1.84 and 1.75 – 1.55 (5H, 2xm, CH2eq), 1.47 – 1.05 (5H, m, CH2ax); 
13C NMR (75 MHz, CDCl3) δ 169.64 and 168.46 (C-13 and C-1), 140.85 (C-5), 128.48 and 128.38 (C-7, 
C-7’ and C-6, C-6’), 126.11 (C-8), 73.75 (C-2), 48.02 (C-9), 33.32 (C-3), 31.12 (C-4), 30.91 (C-10, C-10’), 
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25.49 (C-12), 24.78 (C-11, C-11’), 20.92 (C-14); HRMS m/z: calculated for C18H26NO3: 304.1913, found 
[M + H]+: 304.1908. 
4.3.1.2 Synthesis of (E)-1-(cyclohexylamino)-1-oxo-4-phenylbut-3-en-2-yl acetate 13  
 
trans-Cinnamaldehyde (630 µl, 5.00 mmol), acetic acid (286 µl, 5.00 mmol) and cyclohexyl isocyanide 
(622 µl, 5.00 mmol) were stirred in CH2Cl2 (10 ml) at room temperature for 3 d. The preparation was 
completed using the same procedure as described in 4.3.1.1 to yield 13 (0.66 g, 44%) as a white solid, 
as a racemate. 
 
Rf = 0.64 (50% EtOAc/Hexane), m.p. 123 – 125 ˚C (lit m.p. 132 – 133 ˚C)83 ; IR (vmax/cm-1): 3289 (NH), 
2934, 2853 (C-H), 1733, 1661 (C=O), 1547 (C=C), 1229 (C-O), 1056 (C-N), 964 (trans CH=CH); 1H NMR 
(300 MHz, CDCl3) δ 7.46 – 7.19 (5H, m, Ar-H), 6.73 (1H, dd, J = 16.0, 0.9 Hz, H-4), 6.27 (1H, dd, J = 15.9, 
6.8 Hz, H-3), 5.89 (1H, d, J = 7.9 Hz, NH), 5.71 (1H, dd, J = 6.9, 1.2 Hz, H-2), 3.89 – 3.69 (1H, m, H-9), 
2.20 (3H, s, H-14), 1.98 – 1.87 and 1.76 – 1.53 (5H, 2xm, CH2eq), 1.47 – 1.28 and 1.27 – 1.05 (5H, 2xm, 
CH2ax). 13C NMR (75 MHz, CDCl3) δ 169.18 and 167.04 (C-13 and C-1), 135.72 (C-4), 134.72 (C-5), 128.61 
(C-7, C-7’), 128.40 (C-8), 126.83 (C-6, C-6’), 122.73 (C-3), 74.50 (C-2), 48.26 (C-9), 33.02 (C-10, C-10’), 
25.48 (C-12), 24.78 (C-11, C-11’), 21.07 (C-14); HRMS m/z: calculated for C18H24NO3: 302.1756, found 
[M + H]+: 302.1759. 
4.3.1.3 Synthesis of 2-(cyclohexylamino)-2-oxo-1-phenylethyl acetate 14 
 
Benzaldehyde (508 µl, 5.00 mmol), acetic acid (286 µl, 5.00 mmol) and cyclohexyl isocyanide (622 µl, 
5.00 mmol) were stirred in CH2Cl2 (10 ml) at room temperature for 3 d. The preparation was completed 
using the same procedure as described in 4.3.1.1 to yield 14 (0.79 g, 57%) as a white solid, as a 
racemate. 
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Rf = 0.64 (50% EtOAc/Hexane); m.p. 123 – 125 ˚C; IR (vmax/cm-1): 3318 (NH), 2934, 2855 (C-H), 1738, 
1660 (C=O), 1543 (C=C), 1235 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.56 – 7.20 (5H, m, Ar-H), 6.76 – 6.55 
(1H, m, NH), 6.02 (1H, s, H-2), 3.88 – 3.60 (1H, m, H-3), 2.10 (3H, s, H-12), 1.94 – 1.47 (5H, m, CH2eq), 
1.40 – 1.00 (5H, m, CH2ax). 13C NMR (75 MHz, CDCl3) δ 169.16 and 167.26 (C-11 and C-1), 135.86 (C-7), 
128.89 (Ar-C), 128.70 (Ar-C), 127.43 (Ar-C), 75.54 (C-2), 48.23 (C-3), 32.94 (C-4, C-4’), 25.47 (C-6), 24.75 
(C-5, C-5’), 21.03 (C-12); HRMS m/z: calculated for C16H22NO3: 276.1600, found [M + H]+: 276.1600.82 
4.3.1.4 Synthesis of N-cyclohexyl-2-hydroxy-4-phenylbutanamide 15 
 
KOH (10 eq., 460 mg, 8.20 mmol) was added to a solution of 12 (250 mg, 0.82 mmol) in MeOH (4 ml). 
The reaction was left to stir in air at room temperature overnight. H2O (10 ml) and 6 M HCl (5 ml) were 
added and the product was extracted with EtOAc (3 x 15 ml). The combined organic layers were dried 
over MgSO4 and concentrated in vacuo to obtain 15 (0.11 g, 51%) as a cream white solid.  
 
Rf = 0.38 (50% EtOAc/Hexane); m.p. 86 - 87 ˚C; IR (vmax/cm-1): 3284 (NH), 3278 (OH), 2926, 2853 (C-H), 
1635 (C=O), 1536 (C=C), 1103 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.41 – 7.03 (5H, m, Ar-H), 6.72 (1H, 
d, J = 8.2 Hz, NH), 4.08 (1H, dd, J = 7.8, 3.5 Hz, H-2), 3.82 – 3.62 (1H, m, H-9), 2.73 (2H, t, J = 7.8 Hz, H-
4), 2.18 – 1.51 (7H, m, H-3 and CH2eq), 1.44 – 1.02 (5H, m, CH2ax). 13C NMR (75 MHz, CDCl3) δ 173.37 
(C-1), 141.45 (C-5), 128.47 and 128.43 (C-7, C-7’ and C-6, C-6’), 125.96 (C-8), 71.38 (C-2), 47.96 (C-9), 
36.55 (C-3), 32.92 (C-10, C-10’), 31.21 (C-4), 25.46 (C-12), 24.77 (C-11, C-11’); HRMS m/z: calculated 
for C16H24NO2: 262.1807, found [M + H]+: 262.1809.84 
4.3.1.5 Synthesis of (E)-N-cyclohexyl-2-hydroxy-4-phenylbut-3-enamide 16 
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1.5 M H2SO4 (3 ml) was added to a suspension of 13 (250 mg, 0.83 mmol) in EtOH (9 ml). The reaction 
was heated mildly under reflux for 90 min. Excess solvent was removed in vacuo and the product 
extracted with EtOAc (3 x 20 ml). The combined organic layers were washed with H2O (4 x 20 ml) 
followed by brine (20 ml) and dried over MgSO4. Excess solvent was removed in vacuo and the residue 
was purified by column chromatography (EtOAc/Hexane 0:1 to 1:1) to yield 16 (0.16 g, 74%) as a yellow 
solid. 
 
Rf = 0.30 (50% EtOAc/Hexane); m.p. 90 – 93 ˚C (lit m.p. 79 - 79.5 ˚C)83 ; IR (vmax/cm-1): 3395 (NH), 3272 
(OH), 2928, 2855 (C-H), 1636 (C=O), 1541 (C=C), 966 (trans CH=CH); 1H NMR (300 MHz, CDCl3) δ 7.48 
– 7.14 (5H, m, Ar-H), 6.74 (1H, d, J = 15.8 Hz, H-4), 6.43 – 6.20 (1H, m, H-3), 6.25 (1H, d, J = 7.0 Hz, NH), 
4.78 (1H, d, J = 7.0 Hz, H-2), 3.85 – 3.68 (1H, m, H-9), 1.96 – 1.50 (5H, m, CH2eq), 1.42 – 1.01 (5H, m, 
CH2ax); 13C NMR (75 MHz, CDCl3) δ 171.66 (C-1), 135.97 (C-4), 133.47 (C-5), 128.61 (C-7, C-7’), 128.15 
(C-8), 126.76 (C-6, C-6’), 126.65 (C-3), 72.75 (C-2), 48.69 (C-9), 32.81 (C-10, C-10’), 25.39 (C-12), 24.72 
(C-11, C-11’); HRMS m/z: calculated for C16H22NO2: 260.1651, found [M + H]+: 260.1657. 
4.3.1.6 Synthesis of N-cyclohexyl-2-hydroxy-2-phenylacetamide 17 
 
KOH (10 eq., 511 mg, 9.10 mmol) was added to a solution of 14 (250 mg, 0.91 mmol) in MeOH (4 ml). 
The preparation was completed using the same procedure as described in 4.3.1.4 to obtain 17 (0.16 
g, 75%) as a cream white solid. 
 
Rf = 0.34 (50% EtOAc/Hexane); m.p. 94 – 96 ˚C; IR (vmax/cm-1): 3335 (NH), 3251 (OH), 2931, 2852 (C-
H), 1637 (C=O), 1539 (C=C), 1195 (C-O), 1058 (C-N); 1H NMR (300 MHz, CDCl3) δ 7.43 - 7.21 (5H, m, Ar-
H), 5.96 (1H, s, NH), 4.97 (1H, s, H-2), 3.81 – 3.57 (1H, m, H-7), 1.93 – 1.52 (5H, m, CH2eq), 1.43 – 0.96 
(5H, m, CH2ax); 13C NMR (75 MHz, CDCl3) δ 171.37 (C-1), 139.84 (C-3), 128.69 (C-5, C-5’), 128.40 (C-6), 
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126.81 (C-4, C-4’), 74.06 (C-2), 48.28 (C-7), 32.87 (C-8, C-8’), 25.44 (C-10), 24.68 (C-9, C-9’); HRMS m/z: 
calculated for C14H20NO2: 234.1494, found [M + H]+: 234.1505.85 
4.3.2 Passerini Enzyme Reactions 
 
4.3.2.1 Activity test reaction of Lipases 
 
Benzyl acetate (20 mg, 0.13 mmol) was dissolved in MeCN (100 µl). The solution was added to a 
mixture of 50 mM phosphate buffer of pH 7.0 (100 µl) and Lipase 6Y/ 6Z (40 mg). The reaction was 
then stirred at 40 ˚C for 3 h. TLC was used to monitor the reaction and ascertain if the enzyme was 
active and had effectively hydrolysed the substrate. A control reaction containing no enzyme was 
performed to establish that hydrolysis failed to occur in the absence of enzyme. Both Lipase 6Y and 
6Z exhibited activity against the test substrate. 
4.3.2.2 EKR of compound of 14 with Lipases 6Y and 6Z  
 
 
Compound 14 (20 mg, 0.07 mmol) was dissolved in MeCN (100 µl). The solution was added to a 
mixture of 50 mM phosphate buffer of pH 7.0 (100 µl) and Lipase 6Y/ 6Z (40 mg). The reaction was 
then stirred at 40 ˚C for 3 h. A portion of the reaction mixture was removed at 20 min intervals and 
the organic layer extracted with EtOAc. The residue was then subjected to chiral HPLC and both 
enzymes was found to hydrolyse 14 to 17. The conversion, e.e. and enantioselectivity at each time 
period of the reaction was determined using HPLC peak area. A control reaction containing no enzyme 
was performed to establish that hydrolysis failed to occur in the absence of enzyme. 
4.3.2.3 EKR of compound of 12 with Lipase 6Y  
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Compound 12 (200 mg, 0.66 mmol) was dissolved in MeCN (5 ml). The solution was added to a mixture 
of 50 mM phosphate buffer of pH 7.0 (5 ml) and Lipase 6Y (400 mg). The reaction was then stirred at 
40 ˚C for 12 h. The organic layer was extracted with EtOAc. Excess solvent was removed in vacuo and 
the sample was subjected to chiral HPLC with the conversion determined to be 45.7% using HPLC peak 
area. The residue was purified by column chromatography (EtOAc/Hexane) to yield both starting 
material and compound 15 (38.0 mg, 22%) as a scalemic mixture. A control reaction containing no 
enzyme was performed to establish that hydrolysis failed to occur in the absence of enzyme. 
4.3.2.4 EKR of compound of 12 with Lipase 6Z  
 
Compound 12 (200 mg, 0.66 mmol) was dissolved in MeCN (5 ml). The solution was added to a mixture 
of 50 mM phosphate buffer of pH 7.0 (5 ml) and Lipase 6Z (400 mg). The reaction was then stirred at 
40 ˚C for 12 h. The organic layer was extracted with EtOAc. Excess solvent was removed in vacuo and 
the sample was subjected to chiral HPLC with the conversion determined to be 31.2% using HPLC peak 
area. The residue was purified by column chromatography (EtOAc/Hexane) to yield both starting 
material and compound 15 (45.3 mg, 26%) as a scalemic mixture. A control reaction containing no 
enzyme was performed to establish that hydrolysis failed to occur in the absence of enzyme. 
4.3.2.5 Synthesis of (2R)-1-(cyclohexylamino)-1-oxo-4-phenylbutan-2-yl 3,3,3-trifluoro-2-
methoxy-2-phenylpropanoate 18 from EKR with Lipase 6Y 
 
Compound 15 (38.0 mg, 0.15 mmol) as a scalemic mixture obtained from the enzyme reaction, was 
dissolved in anhydrous CH2Cl2 (4 ml) and the solution was stirred for 10 min. (R)-MTPA (3.2 eq., 111 
mg, 0.48 mmol) and DCC (2.4 eq., 74.2 mg, 0.36 mmol) were added to CH2Cl2 (6 ml) and the mixture 
was added to the stirring solution. DMAP (0.4 eq., 7.50 mg, 0.06 mmol) was then added and the 
reaction was left to stir for 90 min. The product was then extracted with CH2Cl2 (3 x 20 ml) and the 
combined organic layers dried over Na2SO4. Solvent was removed in vacuo and the residue was 
purified by column chromatography (EtOAc/Hexane 0:1 to 1:1) to yield 18 (47.7 mg, 67%), a thick clear 
liquid, as a mixture of diastereomers. The e.e. of the reaction was determined from the relative 
integration of 19F NMR.  
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Rf = 0.92 (50% EtOAc/Hexane); e.e.: 79.4%; E: 14.7; IR (vmax/cm-1): 3306 (NH), 2932, 2855 (C-H), 1753, 
1660 (C=O), 1167 (C-O), 1017 (C-F); 1H NMR (300 MHz, CDCl3) δ 7.63 – 7.35 (5H, m, Ar-H), 7.33 – 7.01 
(5H, m, Ar-H), 5.80 (1H, d, J = 8.1 Hz, NH), 5.41 – 5.26 (1H, m, H-2), 3.84 – 3.66 (1H, m, H-9), 3.55 (3H, 
s, H-19), 2.64 – 2.49 (2H, m, H-4), 2.31 – 2.11 (2H, m, H-3), 1.87 – 1.44 and 1.42 – 0.95 (17H, 2xm, 
cyclohexyl CH2); 13C NMR (75 MHz, CDCl3) δ 167.31 and 165.29 (C-13 and C-1), 140.36 (Ar-C), 131.54 
(Ar-C), 130.05 (Ar-C), 128.83 (Ar-C), 128.54 (Ar-C), 128.37 (Ar-C), 127.25 (Ar-C), 126.26 (Ar-C), 125.30 
(C-20), 85.00 and 84.63 (C-14), 75.34 (C-2), 55.40 (C-19), 48.03 (C-9), 33.67, 32.85, 32.77 and 30.50 (C-
10, C-10’, C-4 and C-3) , 25.40 (C-12), 24.57 (C-11, C-11’); 19F NMR (471 MHz, CDCl3) δ -70.66 (1F, s, 
CF3), -70.82 (9F, s, CF3). 
4.3.2.6 Synthesis of (2R)-1-(cyclohexylamino)-1-oxo-4-phenylbutan-2-yl 3,3,3-trifluoro-2-
methoxy-2-phenylpropanoate 18 from EKR with Lipase 6Z 
 
Compound 15 (45.3 mg, 0.17 mmol) as a scalemic mixture obtained from the enzyme reaction, was 
dissolved in anhydrous CH2Cl2 (4 ml) and the solution was stirred for 10 min. (R)-MTPA (3.2 eq., 126 
mg, 0.54 mmol) and DCC (2.4 eq., 84.1 mg, 0.41 mmol) were added to CH2Cl2 (6 ml) and the mixture 
was added to the stirring solution. DMAP (0.4 eq., 8.50 mg, 0.07 mmol) was then added and the 
reaction was left to stir for 90 min. The preparation was completed using the same procedure as 
described in 4.3.2.4 to yield 18 (63.7 mg, 78%), a thick clear liquid, as a mixture of diastereomers. The 
e.e. of the reaction was determined from the relative integration of 19F NMR. 
 
e.e.: 92.7%; E: 40.6; 19F NMR (471 MHz, CDCl3) δ -70.66 (1F, s, CF3), -70.82 (10F, s, CF3). 
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4.3.2.7 EKR of compound of 13 with Lipase 6Y  
 
 
Compound 13 (200 mg, 0.66 mmol) was dissolved in MeCN (5 ml). The solution was added to a mixture 
of 50 mM phosphate buffer of pH 7.0 (5 ml) and Lipase 6Y (400 mg). The reaction was then stirred at 
40 ˚C for 20 h. The organic layer was extracted with EtOAc. Excess solvent was removed in vacuo and 
the sample was subjected to chiral HPLC with the conversion determined to be 21.5% using HPLC peak 
area. The residue was purified by column chromatography (EtOAc/Hexane) to yield both starting 
material and compound 16 (23.9 mg, 14%) as a scalemic mixture. A control reaction containing no 
enzyme was performed to establish that hydrolysis failed to occur in the absence of enzyme. 
4.3.2.8 EKR of compound of 13 with Lipase 6Z  
 
Compound 13 (200 mg, 0.66 mmol) was dissolved in MeCN (5 ml). The solution was added to a mixture 
of 50 mM phosphate buffer of pH 7.0 (5 ml) and Lipase 6Z (400 mg). The reaction was then stirred at 
40 ˚C for 20 h. The organic layer was extracted with EtOAc. Excess solvent was removed in vacuo and 
the sample was subjected to chiral HPLC with the conversion determined to be 24.4% using HPLC peak 
area. The residue was purified by column chromatography (EtOAc/Hexane) to yield both starting 
material and compound 16 (82.1 mg, 48%) as a scalemic mixture. A control reaction containing no 
enzyme was performed to establish that hydrolysis failed to occur in the absence of enzyme. 
4.4 Diastereoselectivity of the Passerini reaction 
 
4.4.1 Synthesis of N-Boc-D-phenylalanine 19  
 
D-phenylalanine (5.00 g, 30.3 mmol) was added to 1,4-dioxane (44 ml) and the mixture was vigorously 
stirred for 20 min. 1 M NaOH (26 ml) was added and the reaction was stirred for a further 20 min at 0 
˚C. Boc anhydride (1.75 eq., 12.2 ml, 53.0 mmol) was then added in small amounts and the mixture 
was left to stir overnight at room temperature. The reaction was acidified to a pH of 2 by dropwise 
addition of 1 M KHSO4. The solvent was removed in vacuo and H2O (100 ml) was added.  The product 
was then extracted with EtOAc (3 x 100 ml) and the combined organic layers washed with brine (200 
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ml) and dried over MgSO4. Solvent was removed in vacuo and the residue was purified by column 
chromatography (2% MeOH/CHCl3) to yield N-Boc-D-phenylalanine 19 (5.37 g, 67%) as a clear 
glutinous oil. 
 
Rf = 0.29 (5% MeOH/CHCl3); IR (vmax/cm-1): 3306 (NH), 3245 (OH), 2978, 2937 (C-H), 1709, 1644 (C=O), 
1155 (C-O); 1H NMR (300 MHz, CDCl3) δ 10.96 (1H, s, OH), 7.43 – 7.10 (5H, m, Ar-H), 6.66 (0.35H, d, J 
= 7.7 Hz, NH), 5.20 (0.49H, d, J = 8.1 Hz, NH), 4.71 – 4.52 (0.51H, m, H-2), 4.48 – 4.24 (0.37H, m, H-2), 
3.36 – 2.69 (2H, m, H-3), 1.60 - 1.08 (9H, m, H-10); 13C NMR (75 MHz, CDCl3) δ 175.72 (C-1), 156.76 
and 155.47 (C-8), 136.50 and 136.06 (C-4), 129.43 (C-6, C-6’), 128.48 (C-5, C-5’), 126.91 (C-7), 81.65 
and 80.17 (C-9), 56.25 and 54.31 (C-2), 38.84 and 37.84 (C-3), 28.27 and 27.97 (C-10). 
 
4.4.2 Synthesis of (R)-tert-butyl (1-(methoxy(methyl)amino)-1-oxo-3-phenylpropan-2-
yl)carbamate 20 
 
N-Boc-D-phenylalanine 19 (4.00 g, 15.1 mmol) was dissolved in CH2Cl2 (40 ml). CDI (1.2 eq., 2.93 g, 
18.1 mmol) was added to the solution in small portions, observing effervescence at each addition. The 
mixture was stirred for 45 min after which N,O-dimethylhydroxylamine hydrochloride (1.2 eq., 1.77 g, 
18.1 mmol) was added. The reaction was left to stir in air at room temperature for 48 h. CH2Cl2 (90 ml) 
was added and the reaction mixture was washed with H2O (90 ml) followed by 2 M NaOH (90 ml) and 
1 M HCl (90 ml). The organic layer was dried over MgSO4 and the solvent removed in vacuo to afford 
the amide 20 (4.19 g, 90%) as a thick colourless oil that was used without further purification. 
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Rf = 0.57 (50% EtOAc/Hexane); IR (vmax/cm-1): 3316 (NH), 2976, 2934 (C-H), 1700, 1656 (C=O), 1163 (C-
O); 1H NMR (300 MHz, CDCl3) δ 7.34 – 7.10 (5H, m, Ar-H), 5.16 (1H, d, J = 9.2 Hz, NH), 4.95 (1H, d, J = 
5.8 Hz, H-2), 3.65 (3H, s, H-12), 3.16 (3H, s, H-11), 3.05 (1H, dd, J = 13.6, 6.1 Hz, H-3), 2.96 – 2.70 (1H, 
m, H-3), 1.38 (9H, s, H-10); 13C NMR (75 MHz, CDCl3) δ 172.30 (C-1), 155.16 (C-8), 136.59 (C-4), 129.45 
(C-6, C-6’), 128.33 (C-5, C-5’), 126.74 (C-7), 79.57 (C-9), 61.54 (C-12), 51.52 (C-2), 38.88 (C-3), 32.06 (C-
11), 28.31 (C-10). 
4.4.3 Synthesis of (R)-tert-butyl (1-oxo-3-phenylpropan-2-yl)carbamate 21 
 
The Weinreb amide 20 (1.45 g, 4.70 mmol) was added to dry THF (80 ml) in a two-necked round-
bottomed flask. The solution was cooled to 0 ˚C and LiAlH4 (1.5 eq., 0.27 g, 7.05 mmol) was added in 
one portion to the stirring solution under N2. The reaction was left to stir for  90 min. KHSO4 (1.5 eq., 
0.96 g, 7.05 mmol) was then added slowly with vigorous stirring for 30 min. EtOAc (90 ml) was added 
and the reaction mixture was washed with 1 M HCl (90 ml) followed by a saturated solution of NaHCO3 
(90 ml) and brine (90 ml). The organic layer was dried over MgSO4 and concentrated in vacuo to obtain 
21 (1.01 g, 86%) as a white solid. 
 
Rf = 0.78 (50% EtOAc/Hexane); [αD]20589 +40.6 (c 0.50, MeOH); m.p. 82 – 83 ˚C; IR (vmax/cm-1): 3367 
(NH), 2980, 2845 (C-H), 1729, 1687 (C=O), 1519 (C=C), 1165 (C-O), 1054 (C-N); 1H NMR (300 MHz, 
CDCl3) δ 9.63 (1H, s, H-1), 7.36 – 7.13 (5H, m, Ar-H), 5.14 – 4.92 (1H, m, NH), 4.52 – 4.33 (1H, m, H-2), 
3.12 (2H, d, J = 6.4 Hz, H-3), 1.44 (9H, s, H-10); 13C NMR (75 MHz, CDCl3) δ 199.37 (C-1), 155.35 (C-8), 
135.77 (C-4), 129.33 (C-6, C-6’), 128.76 (C-5, C-5’), 127.08 (C-7), 80.21 (C-9), 60.79 (C-2), 35.51 (C-3), 
28.28 (C-10). 
4.4.4 Synthesis of (S)-tert-butyl (1-(methoxy(methyl)amino)-1-oxo-3-phenylpropan-2-
yl)carbamate 22 
 
N-Boc-L-phenylalanine (4.00 g, 15.1 mmol) was dissolved in CH2Cl2 (40 ml). CDI (1.2 eq., 2.93 g, 18.1 
mmol) was added to the solution in small portions, observing effervescence at each addition. The 
mixture was stirred for 45 min after which N,O-dimethylhydroxylamine hydrochloride (1.2 eq., 1.77 g, 
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18.1 mmol) was added. The preparation was completed using the same procedure as described in 
4.4.2 to afford the amide 22 (4.31 g, 93%) as a thick colourless oil that was used without further 
purification. 
 
Rf = 0.56 (50% EtOAc/Hexane); IR (vmax/cm-1): 3321 (NH), 2976, 2936 (C-H), 1708, 1654 (C=O), 1164 (C-
O); 1H NMR (300 MHz, CDCl3) δ 7.34 – 7.10 (5H, m, Ar-H), 5.16 (1H, d, J = 7.8 Hz, NH), 4.95 (1H, d, J = 
6.5 Hz, H-2), 3.65 (3H, s, H-12), 3.16 (3H, s, H-11), 3.05 (1H, dd, J = 13.5, 6.0 Hz, H-3), 2.96 – 2.69 (1H, 
m, H-3), 1.38 (9H, s, H-10); 13C NMR (75 MHz, CDCl3) δ 172.32 (C-1), 155.17 (C-8), 136.59 (C-4), 129.45 
(C-6, C-6’), 128.33 (C-5, C-5’), 126.75 (C-7), 79.58 (C-9), 61.55 (C-12), 51.53 (C-2), 38.86 (C-3), 32.07 (C-
11), 28.31 (C-10). 
4.4.5 Synthesis of (S)-tert-butyl (1-oxo-3-phenylpropan-2-yl)carbamate 23 
 
The Weinreb amide 22 (4.00 g, 13.0 mmol) was added to dry THF (80 ml) in a two-necked round-
bottomed flask. The solution was cooled to 0 ˚C and LiAlH4 (1.5 eq., 0.74 g, 19.5 mmol) was added in 
one portion to the stirring solution under N2. The reaction was left to stir for  90 min. KHSO4 (1.5 eq., 
2.66 g, 19.5 mmol) was then added slowly with vigorous stirring for 30 min The preparation was 
completed using the same procedure as described in 4.4.3 to obtain 23 (2.52 g, 78%) as a white solid. 
 
Rf = 0.78 (50% EtOAc/Hexane); [αD]20589 -41.4 (c 0.50, MeOH); m.p. 81 – 83 ˚C (lit m.p. 86 ˚C)91 ; IR 
(vmax/cm-1): 3366 (NH), 2982, 2846 (C-H), 1730, 1687 (C=O), 1519 (C=C), 1164 (C-O), 1054 (C-N); 1H 
NMR (300 MHz, CDCl3) δ 9.54 (1H, s, H-1), 7.38 – 7.12 (5H, m, Ar-H), 5.49 – 5.38 (1H, m, NH), 4.39 – 
4.22 (1H, m, H-2), 3.21 – 3.04 (1H, m, H-3), 3.02 – 2.92 (1H, m, H-3), 1.40 (9H, s, H-10); 13C NMR (75 
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MHz, CDCl3) δ 199.62 (C-1), 155.48 (C-8), 136.27 (C-4), 129.29 (C-6, C-6’), 128.58 (C-5, C-5’), 126.84 (C-
7), 79.85 (C-9), 60.78 (C-2), 35.06 (C-3), 28.22 (C-10). 
4.4.6 Synthesis of 1-isocyanoadamantane 24 
 
4.4.6.1 Formylation of adamantylamine 
 
Adamantylamine (0.50 g, 3.31 mmol) was added to acetic anhydride (10 ml), followed by formic acid 
(10 eq., 1.25 ml, 33.1 mmol). The mixture was stirred under N2 at room temperature overnight. The 
reaction was then cooled in ice and quenched using small successive amounts of solid Na2CO3. After 
effervescence had subsided, brine (100 ml) was added and the product extracted with EtOAc (2 x 100 
ml). The combined organic layers were dried over MgSO4 and concentrated in vacuo to obtain 
adamantyl formamide (0.55 g crude) as a white solid. 
4.4.6.2 Dehydration of adamantyl formamide 
 
Anhydrous CH2Cl2 (50 ml) was added under N2 to crude adamantyl formamide (0.55 g, ≈ 3.07 mmol). 
Et3N (18 eq., 7.71 ml, 55.3 mmol) was then added gradually and the solution was cooled to 0 ˚C. POCl3 
(3 eq., 0.86 ml, 9.21 mmol) was added dropwise and the reaction was stirred for 30 min. The mixture 
was then warmed to room temperature and left to stir overnight under N2. The reaction was cooled 
in ice and quenched using small portions of solid Na2CO3. After effervescence had ceased, brine (100 
ml) was added and the product extracted with CH2Cl2 (100 ml). The organic layer was dried over MgSO4 
and concentrated in vacuo. Purification by column chromatography (20% EtOAc/Hexane) yielded 24 
(0.43 g, 81%) as a pale yellow solid with a pungent odour.  
 
Rf = 0.87 (50% EtOAc/Hexane) visulaised with iodine; m.p. 184 – 187 ˚C (lit m.p. 188 - 193 ˚C)93 ; 1H 
NMR (300 MHz, CDCl3) δ 2.15 – 2.06 (3H, m, H-4, H-4’, H-4’’), 2.03 – 2.02 (6H, m, H-3, H-3’, H-3’’), 1.68 
– 1.66 (6H, m, H-5, H-5’, H-5’’); 13C NMR (75 MHz, CDCl3) δ 151.81 (t, JC-N = 5.12 Hz, C-2), 54.21 (t, JC-N 
= 6.9 Hz, C-1), 43.60 (C-3, C-3’, C-3’’), 35.50 (C-5, C-5’, C-5’’), 28.74 (C-4, C-4’, C-4’’). 
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4.4.7 Synthesis of (R)-2-isocyano-N-methoxy-N-methyl-3-phenylpropanamide 26 
 
4.4.7.1 Synthesis of (R)-2-formamido-N-methoxy-N-methyl-3-phenylpropanamide 25 
 
Compound 20 (4.29 g, 13.9 mmol) was added to acetic anhydride (10 ml), followed by formic acid (35 
ml). The mixture was stirred under N2 at room temperature for 10 min. TFA (5 eq., 5.32 ml, 69.5 mmol) 
was then added dropwise and the reaction was left to stir overnight. The mixture was cooled in ice 
and quenched using small successive amounts of solid Na2CO3. After effervescence had subsided, brine 
(200 ml) was added and the product extracted with EtOAc (2 x 100 ml). The combined organic layers 
were dried over MgSO4 and concentrated in vacuo to obtain 25 (3.38 g crude) as a thick yellowish oil 
that was used without further purification. 
 
Rf = 0.03 (5% MeOH/CH2Cl2); IR (vmax/cm-1): 3290 (NH), 2972, 2865 (C-H), 1642 (C=O); 1H NMR (300 
MHz, CDCl3) δ 8.13 (1H, s, H-8), 7.38 – 7.12 (5H, m, Ar-H), 6.46 (1H, d, J = 7.2 Hz, NH), 5.35 (1H, dd, J = 
14.4, 7.6 Hz, H-2), 3.69 (3H, s, H-10), 3.19 and 3.12 (4H, s overlapped with dd, J = 13.8, 6.0 Hz, H-3 and 
H-9), 2.97 (1H, dd, J = 13.6, 7.0 Hz, H-3); 13C NMR (75 MHz, CDCl3) δ 171.26 (C-8), 160.52 (C-1), 135.99 
(C-4), 129.45 (C-6, C-6’), 128.44 (C-5, C-5’), 127.02 (C-7), 61.66 (C-10), 48.91 (C-2), 38.21 (C-3), 32.14 
(C-9); HRMS m/z: calculated for C12H17N2O3: 237.1239, found [M + H]+: 237.1242. 
 
4.4.7.2 Dehydration of (R)-2-formamido-N-methoxy-N-methyl-3-phenylpropanamide 
 
Compound 25 (3.38 g, ≈ 14.3 mmol) was dissolved in CH2Cl2 (60 ml) followed by the addition of PPh3 
(1.5 eq., 5.64 g, 21.5 mmol), CCl4 (1.5 eq., 2.08 ml, 21.5 mmol), and DIPEA (1.5 eq., 3.75 ml, 21.5 mmol). 
The mixture was stirred under N2 at room temperature overnight. Excess solvent was removed in 
vacuo and the residue was purified by column chromatography (EtOAc/Hexane 1:9 to 3:7) to yield 26 
(0.53 g, 17%) as a light brown oil. 
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Rf = 0.56 (50% EtOAc/Hexane); [αD]20589 -6.45 (c 2.00, CHCl3); IR (vmax/cm-1): 2967, 2844 (C-H), 2145 
(C≡N), 1653 (C=O); 1H NMR (300 MHz, CDCl3) δ 7.41 – 7.23 (5H, m, Ar-H), 4.85 – 4.74 (1H, m, H-2), 
3.66 (3H, s, H-10), 3.30 – 3.23 and 3.21 (4H, m overlapped with s, H-3 and H-9), 3.19 – 3.05 (1H, m, H-
3). 13C NMR (75 MHz, CDCl3) δ 165.83 (C-1), 159.24 (C-8), 135.24 (C-4), 129.31 (C-6, C-6’), 128.63 (C-
7), 127.55 (C-5, C-5’), 61.66 (C-10), 55.51 (C-2), 38.70 (C-3), 32.50 (C-9); HRMS m/z: calculated for 
C12H15N2O2: 219.1134, found [M + H]+: 219.1144. 
4.4.8 Synthesis of (S)-2-isocyano-N-methoxy-N-methyl-3-phenylpropanamide 28 
 
4.4.8.1 Synthesis of (S)-2-formamido-N-methoxy-N-methyl-3-phenylpropanamide 27 
 
Compound 22 (5.33 g, 17.3 mmol) was added to acetic anhydride (10 ml), followed by formic acid (35 
ml). The mixture was stirred under N2 at room temperature for 10 min. TFA (5 eq., 6.62 ml, 86.5 mmol) 
was then added dropwise and the reaction was left to stir overnight. The preparation was completed 
using the same procedure as described in 4.4.7.1 to yield 27 (1.13 g, 28%) as a thick yellow oil. 
 
Rf = 0.03 (5% MeOH/CH2Cl2); IR (vmax/cm-1): 3298 (NH), 2940 (C-H), 1643 (C=O); 1H NMR (300 MHz, 
CDCl3) δ 8.07 (1H, s, H-8), 7.50 (1H, d, J = 8.0 Hz, NH), 7.31 – 7.12 (5H, m, Ar-H), 5.42 – 5.24 (1H, m, H-
2), 3.66 (3H, s, H-10), 3.14 and 3.10 – 3.02 (4H, s overlapped with m, H-9 and H-3), 2.98 – 2.85 (1H, m, 
H-3); 13C NMR (75 MHz, CDCl3) δ 171.57 (C-8), 161.13 (C-1), 136.36 (C-4), 129.38 (C-6, C-6’), 128.33 (C-
5, C-5’), 126.85 (C-7), 61.55 (C-10), 48.99 (C-2), 38.04 (C-3), 32.01 (C-9); HRMS m/z: calculated for 
C12H17N2O3: 237.1239, found [M + H]+: 237.1246. 
 
4.4.8.2 Dehydration of (S)-2-formamido-N-methoxy-N-methyl-3-phenylpropanamide 
 
Compound 27 (1.13 g, 4.78 mmol) was dissolved in CH2Cl2 (60 ml) followed by the addition of PPh3 (1.5 
eq., 1.88 g, 7.17 mmol), CCl4 (1.5 eq., 694 µl, 7.17 mmol), and DIPEA (1.5 eq., 1.25 ml, 7.17 mmol). The 
preparation was completed using the same procedure as described in 4.4.7.2 to yield 28 (0.74 g, 71%) 
as a light brown oil. 
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Rf = 0.56 (50% EtOAc/Hexane); [αD]20589 +3.55 (c 2.00, CHCl3); IR (vmax/cm-1): 2973, 2844 (C-H), 2144 
(C≡N), 1676 (C=O); 1H NMR (300 MHz, CDCl3) δ 7.43 – 7.13 (5H, m, Ar-H), 4.88 – 4.71 (1H, m, H-2), 
3.62 (3H, s, H-10), 3.29 – 3.19 and 3.17 (4H, m overlapped with s, H-3 and H-9), 3.13 – 3.00 (1H, m, H-
3); 13C NMR (75 MHz, CDCl3) δ 165.78 (C-1), 159.23 (C-8), 135.23 (C-4), 129.30 (C-6, C-6’), 128.69 (C-5, 
C-5’), 127.51 (C-7), 61.67 (C-10), 55.52 (C-2), 38.67 (C-3), 32.48 (C-9); HRMS m/z: calculated for 
C12H15N2O2: 219.1134, found [M + H]+: 219.1132. 
4.4.9 Synthesis of (2R)-(3R)-1-(adamantan-1-ylamino)-3-((tert-butoxycarbonyl)amino)-1-
oxo-4-phenylbutan-2-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 29 
 
Adamantyl isocyanide (161 mg, 1.00 mmol), N-Boc-D-phenylalaninal (249 mg, 1.00 mmol) and N-Boc-
D-phenylalanine (265 mg, 1.00 mmol) were stirred in CH2Cl2 (3 ml) at room temperature for 5 d. Excess 
solvent was removed in vacuo and the residue was purified by column chromatography 
(EtOAc/Hexane ) to yield 29 (0.62 g, 92%) as a (2.29 : 1.00) mixture of diastereomers. The mixture was 
then separated by preparative HPLC to obtain two pure diastereomers, the major being 29A and the 
minor 29B.  
(2R)-(2S,3R)-1-(adamantan-1-ylamino)-3-((tert-butoxycarbonyl)amino)-1-oxo-4-
phenylbutan-2-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 29A 
 
Rf = 0.86 (50% EtOAc/Hexane); m.p. 92 – 94 ˚C; IR (vmax/cm-1): 3394, 3354 (NH), 2974, 2911 (C-H), 
1749, 1713, 1669 (C=O), 1542, 1497 (C=C), 1160 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.42 – 7.03 (13H, 
m, Ar-H), 6.30 (1H, s, NH), 5.22 (1H, d, J = 9.5 Hz, NH), 5.14 – 4.97 (1H, m, H-2), 4.96 – 4.86 (1H, m, 
NH), 4.35 – 4.25 and 4.24 – 4.11 (2H, 2xm, H-3 and H-17), 3.22 – 2.90 and 2.65 – 2.41 (4H, 2xm, H-4 
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and H-18), 2.14 – 1.94 (9H, m, H-13 and H-14), 1.66 (6H, s, H-15), 1.54 – 1.24 (18H, m, H-11 and H-25); 
13C NMR (75 MHz, CDCl3) δ 171.09 and 166.91 (C-16 and C-1), 155.53 and 154.78 (C-23 and C-9), 
137.53 (Ar-C), 135.62 (Ar-C), 129.42 (Ar-C), 129.13 (Ar-C), 128.98 (Ar-C), 128.29 (Ar-C), 127.52 (Ar-C), 
126.40 (Ar-C), 80.53 and 79.19 (C-24 and C-10), 74.32 (C-2), 55.55, 52.84 and 52.53 (C-17, C-12 and C-
3), 41.19 (C-13), 37.79 and 37.33 (C-18 and C-4), 36.40 (C-15), 30.91 (C-14), 29.48 and 28.27 (C-25 and 
C-11); HRMS m/z: calculated for C39H54N3O7: 676.3962, found [M + H]+: 676.3967. 
 
(2R)-(2R,3R)-1-(adamantan-1-ylamino)-3-((tert-butoxycarbonyl)amino)-1-oxo-4-
phenylbutan-2-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 29B 
 
Rf = 0.86 (50% EtOAc/Hexane); m.p. 86 – 88 ˚ C; IR (vmax/cm-1): 3326 (NH), 2975, 2910 (C-H), 1752, 1694 
(C=O), 1497 (C=C), 1164 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.41 – 7.08 (11H, m, Ar-H), 6.32 and 6.01 
(1H, 2xs, NH), 5.37 – 4.78 (3H, m, 2xNH and H-2), 4.67 – 4.05 (2H, m, H-3 and H-17), 3.37 – 2.37 (4H, 
m, H-4 and H-18), 2.09 – 1.98 (9H, m, H-13 and H-14), 1.71 – 1.62 (6H, m, H-15), 1.45 – 1.26 (18H, m, 
H-11 and H-25); 13C NMR (75 MHz, CDCl3) δ 170.74 and 166.09 (C-16 and C-1), 155.51 and 154.76 (C-
23 and C-9), 137.13 (Ar-C), 135.93 (Ar-C), 129.40 (Ar-C), 129.11 (Ar-C), 128.97 (Ar-C), 128.27 (Ar-C), 
127.21 (Ar-C), 126.55 (Ar-C), 80.55 and 79.51 (C-24 and C-10), 75.74 (C-2), 54.75, 52.82 and 52.52 (C-
17, C-12 and C-3), 41.18 (C-13), 37.77 and 37.30 (C-18 and C-4), 36.32 (C-15), 30.90 (C-14), 29.46 and 
28.26 (C-25 and C-11); HRMS m/z: calculated for C39H54N3O7: 676.3962, found [M + H]+: 676.3967. 
 
4.4.10 Synthesis of (2S)-(3R)-1-(adamantan-1-ylamino)-3-((tert-butoxycarbonyl)amino)-1-
oxo-4-phenylbutan-2-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 30 
 
Adamantyl isocyanide (242 mg, 1.50 mmol), N-Boc-D-phenylalaninal (374 mg, 1.50 mmol) and N-Boc-
L-phenylalanine (398 mg, 1.50 mmol) were stirred in CH2Cl2 (3 ml) at room temperature for 5 d. The 
preparation was completed using the same procedure as described in 4.4.9 to yield 30 (0.69 g, 68%) 
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as a (2.47 : 1.00) mixture of diastereomers. The mixture was then separated by preparative HPLC to 
obtain two pure diastereomers, the major being 30A and the minor 30B. 
(2S)-(2S,3R)-1-(adamantan-1-ylamino)-3-((tert-butoxycarbonyl)amino)-1-oxo-4-
phenylbutan-2-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 30A 
 
Rf = 0.86 (50% EtOAc/Hexane); m.p. 181 – 183 ˚C; IR (vmax/cm-1): 3273 (NH), 2977, 2912 (C-H), 1747, 
1720, 1689, 1643 (C=O), 1547, 1492 (C=C), 1164 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.47 – 7.05 (10H, 
m, Ar-H), 6.11 (1H, s, NH), 5.21 – 4.98 (2H, m, NH and H-2), 4.90 – 4.74 (1H, m, NH), 4.61 – 4.42 and 
4.40 – 4.20 (2H, 2xm, H-3 and H-17), 3.27 – 2.94 and 2.86 – 2.51 (4H, 2xm, H-4 and H-18), 2.13 – 1.92 
(9H, m, H-13 and H-14), 1.66 (6H, s, H-15), 1.51 – 1.19 (18H, m, H-11 and H-25); 13C NMR (75 MHz, 
CDCl3) δ 170.28 and 166.62 (C-16 and C-1), 155.70 and 154.87 (C-23 and C-9), 137.42 (Ar-C), 135.85 
(Ar-C), 129.34 (Ar-C), 129.18 (Ar-C), 128.96 (Ar-C), 128.45 (Ar-C), 127.40 (Ar-C), 126.54 (Ar-C), 80.51 
and 79.43 (C-24 and C-10), 74.76 (C-2), 54.77, 52.85 and 52.55 (C-17, C-12 and C-3), 41.25 (C-13), 38.07 
and 37.40 (C-18 and C-4), 36.35 (C-15), 30.90 (C-14), 29.46 and 28.36 (C-25 and C-11); HRMS m/z: 
calculated for C39H54N3O7: 676.3962, found [M + H]+: 676.3968. 
 
(2S)-(2R,3R)-1-(adamantan-1-ylamino)-3-((tert-butoxycarbonyl)amino)-1-oxo-4-
phenylbutan-2-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 30B 
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Rf = 0.86 (50% EtOAc/Hexane); m.p. 185 – 187 ˚C; IR (vmax/cm-1): 3271 (NH), 2973, 2921 (C-H), 1748, 
1720, 1689, 1644 (C=O), 1541, 1493 (C=C), 1163, 1057 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.54 – 6.98 
(10H, m, Ar-H), 6.30 (1H, s, NH), 5.40 – 5.22 and 5.17 – 4.96 (2H, 2xm, NH and H-2), 4.50 – 4.37, 4.36 
– 4.20 and 4.20 – 4.07 (3H, 3xm, NH, H-3 and H-17), 3.21 – 2.96 and 2.82 – 2.60 (4H, 2xm, H-4 and H-
18), 2.10 – 1.94 (9H, m, H-13 and H-14), 1.67 (6H, s, H-15), 1.50 - 1.30 (18H, m, H-11 and H-25); 13C 
NMR (126 MHz, CDCl3) δ 170.28 and 166.60 (C-16 and C-1), 155.67 and 154.87 (C-23 and C-9), 137.39 
(Ar-C), 135.80 (Ar-C), 129.33 (Ar-C), 129.17 (Ar-C), 128.95 (Ar-C), 128.45 (Ar-C), 127.38 (Ar-C), 126.54 
(Ar-C), 80.49 and 79.39 (C-24 and C-10), 74.73 (C-2), 54.71, 52.83 and 52.55 (C-17, C-12 and C-3), 41.23 
(C-13), 38.03 and 37.33 (C-18 and C-4), 36.34 (C-15), 30.92 (C-14), 29.44 and 28.35 (C-25 and C-11); 
HRMS m/z: calculated for C39H54N3O7: 676.3962, found [M + H]+: 676.3968. 
 
4.4.11 Synthesis of (2S)-(3S)-1-(adamantan-1-ylamino)-3-((tert-butoxycarbonyl)amino)-1-
oxo-4-phenylbutan-2-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 31 
 
Adamantyl isocyanide (81 mg, 0.50 mmol), N-Boc-L-phenylalaninal (125 mg, 0.50 mmol) and N-Boc-L-
phenylalanine (133 mg, 0.50 mmol) were stirred in CH2Cl2 (3 ml) at room temperature for 5 d. The 
preparation was completed using the same procedure as described in 4.4.9 to yield 31 (0.19 g, 56%) 
as a (2.26 : 1.00) mixture of diastereomers. The mixture was then separated by preparative HPLC to 
obtain two pure diastereomers, the major being 31A and the minor 31B. 
(2S)-(2R,3S)-1-(adamantan-1-ylamino)-3-((tert-butoxycarbonyl)amino)-1-oxo-4-
phenylbutan-2-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 31A 
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Rf = 0.86 (50% EtOAc/Hexane); m.p. 79 – 80 ˚C; IR (vmax/cm-1): 2973, 2922 (C-H), 1751, 1695, 1655 
(C=O), 1535, 1497 (C=C), 1165, 1054 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.40 – 7.10 (19H, m, Ar-H), 
6.30 (1H, s, NH), 5.23 (1H, d, J = 9.0 Hz, NH), 5.16 – 5.01 (1H, m, H-2), 5.01 – 4.85 (1H, m, NH), 4.38 – 
4.23 and 4.24 – 4.09 (2H, 2xm, H-3 and H-17), 3.14 – 2.92 and 2.66 – 2.47 (4H, 2xm, H-4 and H-18), 
2.07 – 2.01 (9H, m, H-13 and H-14), 1.66 – 1.59 (6H, m, H-15), 1.44 - 1.34 (18H, m, H-11 and H-25); 13C 
NMR (126 MHz, CDCl3) δ 171.06 and 166.83 (C-16 and C-1), 155.48 and 154.71 (C-23 and C-9), 137.51 
(Ar-C), 135.46 (Ar-C), 129.40 (Ar-C), 129.09 (Ar-C), 128.99 (Ar-C), 128.28 (Ar-C), 127.54 (Ar-C), 126.39 
(Ar-C), 80.60 and 79.18 (C-24 and C-10), 74.26 (C-2), 55.47, 52.81 and 52.55 (C-17, C-12 and C-3), 41.18 
(C-13), 37.74 and 37.28 (C-18 and C-4), 36.38 (C-15), 30.93 (C-14), 29.45 and 28.25 (C-25 and C-11); 
HRMS m/z: calculated for C39H54N3O7: 676.3962, found [M + H]+: 676.3955. 
 
(2S)-(2S,3S)-1-(adamantan-1-ylamino)-3-((tert-butoxycarbonyl)amino)-1-oxo-4-
phenylbutan-2-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 31B 
 
Rf = 0.86 (50% EtOAc/Hexane); m.p. 80 – 82 ˚C; IR (vmax/cm-1): 2981, 2922 (C-H), 1751, 1690, 1651 
(C=O), 1531, 1498 (C=C), 1163, 1055 (C-O);  1H NMR (300 MHz, CDCl3) δ 7.39 – 7.09 (13H, m, Ar-H), 
6.29 and 6.00 (1H, 2xs, NH), 5.31 – 5.00 (2H, m, NH and H-2), 4.98 – 4.76 (1H, m, NH), 4.61 – 4.10 (2H, 
m, H-3 and H-17), 3.24 – 2.72 and 2.63 – 2.49 (4H, 2xm, H-4 and H-18), 2.09 – 1.98 (9H, m, H-13 and 
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H-14), 1.69 – 1.65 (6H, m, H-15), 1.46 – 1.32 (18H, m, H-11 and H-25); 13C NMR (126 MHz, CDCl3) δ 
170.73 and 166.06 (C-16 and C-1), 155.49 and 154.76 (C-23 and C-9), 137.85 (Ar-C), 135.90 (Ar-C), 
129.40 (Ar-C), 129.10 (Ar-C), 128.98 (Ar-C), 128.28 (Ar-C), 127.20 (Ar-C), 126.57 (Ar-C), 80.57 and 79.18 
(C-24 and C-10), 74.27 (C-2), 55.46, 52.81 and 52.42 (C-17, C-12 and C-3), 41.30 (C-13), 37.75 and 37.29 
(C-18 and C-4), 36.31 (C-15), 30.93 (C-14), 29.45 and 28.26 (C-25 and C-11); HRMS m/z: calculated for 
C39H54N3O7: 676.3962, found [M + H]+: 676.3955. 
 
4.4.12 Synthesis of (2R)-(3S)-1-(adamantan-1-ylamino)-3-((tert-butoxycarbonyl)amino)-1-
oxo-4-phenylbutan-2-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 32 
 
Adamantyl isocyanide (161 mg, 1.00 mmol), N-Boc-L-phenylalaninal (249 mg, 1.00 mmol) and N-Boc-
D-phenylalanine (265 mg, 1.00 mmol) were stirred in CH2Cl2 (3 ml) at room temperature for 5 d. The 
preparation was completed using the same procedure as described in 4.4.9 to yield 32 to yield   (0.62 
g, 92%) as a (2.08 : 1.00) mixture of diastereomers. The mixture was then separated by preparative 
HPLC to obtain two pure diastereomers, the major being 32A and the minor 32B. 
(2R)-(2R,3S)-1-(adamantan-1-ylamino)-3-((tert-butoxycarbonyl)amino)-1-oxo-4-
phenylbutan-2-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 32A 
 
Rf = 0.86 (50% EtOAc/Hexane); m.p. 192 – 195 ˚C; IR (vmax/cm-1): 3275 (NH), 2967, 2922 (C-H), 1747, 
1721, 1689, 1644 (C=O), 1538, 1491 (C=C), 1163, 1056 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.43 – 7.09 
(10H, m, Ar-H), 6.10 (1H, s, NH), 5.21 – 4.96 (2H, m, NH and  H-2), 4.89 – 4.74 (1H, m, NH), 4.60 – 4.43 
and 4.39 – 4.21  (2H, 2xm, H-3 and H-17), 3.27 – 2.94 and 2.87 – 2.57 (4H, 2xm, H-4 and H-18), 2.10 – 
1.95 (9H, m, H-13 and H-14), 1.66 (6H, s, H-15), 1.53 - 1.22 (18H, m, H-11 and H-25); 13C NMR (75 MHz, 
CDCl3) δ 170.26 and 166.59 (C-16 and C-1), 155.65 and 154.84 (C-23 and C-9), 137.41 (Ar-C), 135.79 
(Ar-C), 129.33 (Ar-C), 129.16 (Ar-C), 128.95 (Ar-C), 128.44 (Ar-C), 127.40 (Ar-C), 126.53 (Ar-C), 80.51 
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and 79.42 (C-24 and C-10), 74.73 (C-2), 54.73, 52.82 and 52.54 (C-17, C-12 and C-3), 41.23 (C-13), 38.02 
and 37.35 (C-18 and C-4), 36.33 (C-15), 30.91 (C-14), 29.44 and 28.35 (C-25 and C-11); HRMS m/z: 
calculated for C39H54N3O7: 676.3962, found [M + H]+: 676.3973. 
 
(2R)-(2S,3S)-1-(adamantan-1-ylamino)-3-((tert-butoxycarbonyl)amino)-1-oxo-4-
phenylbutan-2-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 32B 
 
Rf = 0.86 (50% EtOAc/Hexane); m.p. 102 – 104 ˚C; IR (vmax/cm-1): 3342 (NH), 2973, 2921 (C-H), 1760, 
1692, 1654 (C=O), 1540, 1497 (C=C), 1163, 1056 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.42 – 7.03 (12H, 
m, Ar-H), 6.34 and 6.10 (1H, 2xs, NH), 5.40 – 5.23 and 5.16 – 5.01 (2H, 2xm, H-2 and NH), 4.57 – 4.36, 
4.36 – 4.24 and 4.22 – 4.06 (3H, 3xm, H-3, H-17 and NH), 3.22 – 2.94 and 2.83 – 2.58 (4H, 2xm, H-4 
and H-18), 2.04 – 2.00 (9H, m, H-13 and H-14), 1.67 (6H, s, H-15), 1.49 – 1.29 (18H, m, H-11 and H-25); 
13C NMR (75 MHz, CDCl3) δ 171.51 and 166.11 (C-16 and C-1), 155.77 and 154.99 (C-23 and C-9), 
137.60 (Ar-C), 135.79 (Ar-C), 129.39 (Ar-C), 129.14 (Ar-C), 128.96 (Ar-C), 128.44 (Ar-C), 127.48 (Ar-C), 
126.44 (Ar-C), 80.53 and 79.40 (C-24 and C-10), 75.22 (C-2), 55.86, 53.01 and 52.41 (C-17, C-12 and C-
3), 41.22 (C-13), 38.01 and 37.76 (C-18 and C-4), 36.38 (C-15), 30.91 (C-14), 29.46 and 28.26 (C-25 and 
C-11); HRMS m/z: calculated for C39H54N3O7: 676.3962, found [M + H]+: 676.3973. 
 
4.4.13 Synthesis of (2R)-(5R,9R)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-dioxa-
3,6,10-triazatetradecan-8-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 33 
 
D-phenylalanine isocyanide (100 mg, 0.46 mmol), N-Boc-D-phenylalaninal (115 mg, 0.46 mmol) and 
N-Boc-D-phenylalanine (122 mg, 0.46 mmol) were stirred in CH2Cl2 (4 ml) at room temperature for 5 
d. The preparation was completed using the same procedure as described in 4.4.9 to yield 33 (0.14 g, 
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42%) as a (1.97 : 1.00) mixture of diastereomers. The mixture was then separated by preparative HPLC 
to obtain two pure diastereomers, the major being 33A and the minor 33B. 
(2R)-(5R,8S,9R)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-dioxa-3,6,10-
triazatetradecan-8-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 33A 
 
Rf = 0.62 (50% EtOAc/Hexane); m.p. 136 – 139 ˚C; IR (vmax/cm-1): 3358 (NH), 2981, 2936 (C-H), 1756, 
1691, 1660 (C=O), 1528 (C=C), 1166 (C-O). 1H NMR (300 MHz, CDCl3) δ 7.38 – 7.09 (17H, m, Ar-H), 5.35 
– 5.11 (2H, m, H-2 and H-12), 5.10 – 4.99 (1H, m, NH), 4.99 – 4.87 (1H, m, NH), 4.52 – 4.32 and 4.30 – 
4.10 (2H, 2xm, H-22 and H-3), 3.62 (3H, s, H-20), 3.25 – 2.83 and 2.64 – 2.43 (10H, 2xm, NH, H-4, H-13, 
H-19 and H-23), 1.52 – 1.25 (18H, m, H-11 and H-30); 13C NMR (75 MHz, CDCl3) δ 171.20, 170.81 and 
167.43 (C-21, C-18 and C-1), 155.45 and 154.78 (C-28 and C-9), 137.39 (Ar-C), 136.48 (Ar-C), 135.61 
(Ar-C), 129.44 (Ar-C), 129.39 (Ar-C), 129.14 (Ar-C), 128.91 (Ar-C), 128.39 (Ar-C), 128.34 (Ar-C), 127.41 
(Ar-C), 126.83 (Ar-C), 126.43 (Ar-C), 80.63 and 79.27 (C-29 and C-10), 73.97 (C-2), 61.56 (C-20), 55.22, 
52.90 and 50.23 (C-22, C-12 and C-3), 37.99, 37.71 and 37.40 (C-23, C-13 and C-4), 32.08 (C-19), 28.32 
(C-30 and C-11); HRMS m/z: calculated for C40H53N4O9: 733.3813, found [M + H]+: 733.3810. 
 
(2R)-(5R,8R,9R)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-dioxa-3,6,10-
triazatetradecan-8-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 33B 
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Rf = 0.62 (50% EtOAc/Hexane); m.p. 83 – 84 ˚C; IR (vmax/cm-1): 3352 (NH), 2981, 2940 (C-H), 1756, 
1689, 1659 (C=O), 1516, 1497 (C=C), 1164 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.46 – 6.99 (18H, m, Ar-
H), 5.38 – 4.89 and 4.72 – 4.15  (6H, 2xm, 2xNH,  H-2, H-3, H-12  and H-22), 3.76 – 3.56 (3H, m, H-20), 
3.29 – 2.83 and 2.75 – 2.45 (10H, 2xm, NH, H-4, H-13, H-19  and H-23), 1.47 – 1.26 (18H, m, H-11 and 
H-30); 13C NMR (75 MHz, CDCl3) δ 171.16, 170.66 and 167.37 (C-21, C-18 and C-1), 155.57 and 154.83 
(C-28 and C-9), 137.40 (Ar-C), 136.42 (Ar-C), 135.69 (Ar-C), 129.46 (Ar-C), 129.39 (Ar-C), 129.18 (Ar-C), 
128.86 (Ar-C), 128.46 (Ar-C), 128.33 (Ar-C), 127.30 (Ar-C), 126.93 (Ar-C), 126.41 (Ar-C), 80.56 and 79.39 
(C-29 and C-10), 74.19 (C-2), 61.56 (C-20), 55.14, 52.91 and 50.60 (C-22, C-12 and C-3), 37.93, 37.81 
and 37.52 (C-23, C-13 and C-4), 32.09 (C-19), 28.35 (C-30 and C-11); HRMS m/z: calculated for 
C40H53N4O9: 733.3813, found [M + H]+: 733.3810. 
 
4.4.14 Synthesis of (2S)-(5R,9S)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-dioxa-
3,6,10-triazatetradecan-8-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 34 
 
D-phenylalanine isocyanide (100 mg, 0.46 mmol), N-Boc-L-phenylalaninal (115 mg, 0.46 mmol) and N-
Boc-L-phenylalanine (122 mg, 0.46 mmol) were stirred in CH2Cl2 (4 ml) at room temperature for 5 d. 
The preparation was completed using the same procedure as described in 4.4.9 to yield 34 (0.17 g, 
50%) as a (2.46 : 1.00) mixture of diastereomers. The mixture was then separated by preparative HPLC 
to obtain two pure diastereomers, the major being 34A and the minor 34B. 
(2S)-(5R,8R,9S)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-dioxa-3,6,10-
triazatetradecan-8-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 34A 
 
Rf = 0.62 (50% EtOAc/Hexane); m.p. 89 – 90 ˚C; IR (vmax/cm-1): 3349 (NH), 2972, 2940 (C-H), 1755, 
1689, 1656 (C=O), 1527, 1497 (C=C), 1164 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.46 – 6.99 (17H, m, Ar-
H), 5.48 – 4.89 and 4.69 – 4.15  (6H, 2xm, 2xNH,  H-2, H-3, H-12 and H-22), 3.76 – 3.56 (3H, m, H-20), 
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3.29 – 2.83 and 2.75 – 2.45 (10H, 2xm, NH, H-4, H-13, H-19  and H-23), 1.47 – 1.26 (18H, m, H-11 and 
H-30); 13C NMR (75 MHz, CDCl3) δ 171.15, 170.70 and 167.00 (C-21, C-18 and C-1), 155.43 and 154.74 
(C-28 and C-9), 137.30 (Ar-C), 136.41 (Ar-C), 135.82 (Ar-C), 129.46 (Ar-C), 129.40 (Ar-C), 129.18 (Ar-C), 
128.86 (Ar-C), 128.46 (Ar-C), 128.33 (Ar-C), 127.21 (Ar-C), 126.89 (Ar-C), 126.38 (Ar-C), 80.57 and 79.38 
(C-29 and C-10), 74.04 (C-2), 61.58 (C-20), 55.15, 52.81 and 50.58 (C-22, C-12 and C-3), 38.03, 37.68 
and 37.36 (C-23, C-13 and C-4), 32.10 (C-19), 28.35 (C-30 and C-11); HRMS m/z: calculated for 
C40H53N4O9: 733.3813, found [M + H]+: 733.3814. 
(2S)-(5R,8S,9S)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-dioxa-3,6,10-
triazatetradecan-8-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 34B 
 
Rf = 0.62 (50% EtOAc/Hexane); m.p. 108 – 109 ˚C; IR (vmax/cm-1): 3358 (NH), 2968, 2937 (C-H), 1755, 
1691, 1656 (C=O), 1526, 1497 (C=C), 1166 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.38 – 7.09 (17H, m, Ar-
H), 5.35 – 5.11 (2H, m, H-2 and H-12), 5.11 – 5.00 (1H, m, NH), 4.99 – 4.87 (1H, m, NH), 4.52 – 4.32 and 
4.30 – 4.10 (2H, 2xm, H-22 and H-3), 3.62 (3H, s, H-20), 3.25 – 2.83 and 2.64 – 2.43 (10H, 2xm, NH, H-
4, H-13, H-19 and H-23), 1.52 – 1.25 (18H, m, H-11 and H-30); 13C NMR (75 MHz, CDCl3) δ 171.16, 
170.66 and 167.37 (C-21, C-18 and C-1), 155.57 and 154.83 (C-28 and C-9), 137.40 (Ar-C), 136.42 (Ar-
C), 135.69 (Ar-C), 129.46 (Ar-C), 129.39 (Ar-C), 129.18 (Ar-C), 128.86 (Ar-C), 128.46 (Ar-C), 128.33 (Ar-
C), 127.30 (Ar-C), 126.93 (Ar-C), 126.41 (Ar-C), 80.56 and 79.39 (C-29 and C-10), 74.19 (C-2), 61.56 (C-
20), 55.14, 52.91 and 50.60 (C-22, C-12 and C-3), 37.93, 37.81 and 37.52 (C-23, C-13 and C-4), 32.09 
(C-19), 28.35 (C-30 and C-11); HRMS m/z: calculated for C40H53N4O9: 733.3813, found [M + H]+: 
733.3814. 
4.4.15 Synthesis of (2S)-(5R,9R)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-dioxa-
3,6,10-triazatetradecan-8-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 35 
 
127 
 
D-phenylalanine isocyanide (100 mg, 0.46 mmol), N-Boc-D-phenylalaninal (115 mg, 0.46 mmol) and 
N-Boc-L-phenylalanine (122 mg, 0.46 mmol) were stirred in CH2Cl2 (4 ml) at room temperature for 5 
d. The preparation was completed using the same procedure as described in 4.4.9 to yield 35 (0.17 g, 
50%) as a (1.80 : 1.00) mixture of diastereomers. The mixture was then separated by preparative HPLC 
to obtain two pure diastereomers, the major being 35A and the minor 35B. 
(2S)-(5R,8S,9R)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-dioxa-3,6,10-
triazatetradecan-8-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 35A 
 
Rf = 0.62 (50% EtOAc/Hexane); m.p. 73 – 76 ˚C; IR (vmax/cm-1): 3309 (NH), 2980, 2937 (C-H), 1746, 
1693, 1658 (C=O), 1497, 1455 (C=C), 1161 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.43 – 7.05 (17H, m, Ar-
H), 5.31 – 5.03 (2H, m, H-2 and H-12), 4.98 – 4.77 (2H, m, 2xNH), 4.56 – 4.40  and 4.40 – 4.21 (2H, 2xm, 
H-22  and H-3), 3.66 (3H, s, H-20), 3.21 – 2.84 and 2.79 – 2.59 (10H, 2xm, NH, H-4, H-13, H-19  and H-
23), 1.53 – 1.19 (18H, m, H-11 and H-30); 13C NMR (75 MHz, CDCl3) δ 171.04, 170.42 and 167.50 (C-
21, C-18 and C-1), 155.62 and 154.90 (C-28 and C-9), 137.34 (Ar-C), 136.41 (Ar-C), 135.96 (Ar-C), 129.47 
(Ar-C), 129.35 (Ar-C), 129.19 (Ar-C), 128.89 (Ar-C), 128.46 (Ar-C), 128.41 (Ar-C), 127.26 (Ar-C), 126.89 
(Ar-C), 126.52 (Ar-C), 80.66 and 79.43 (C-29 and C-10), 74.46 (C-2), 61.54 (C-20), 54.62, 52.89 and 50.69 
(C-22, C-12 and C-3), 37.85, 37.69 and 37.40 (C-23, C-13 and C-4), 32.16 (C-19), 28.36 and 28.28 (C-30 
and C-11); HRMS m/z: calculated for C40H53N4O9: 733.3813, found [M + H]+: 733.3807. 
(2S)-(5R,8R,9R)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-dioxa-3,6,10-
triazatetradecan-8-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 35B 
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Rf = 0.62 (50% EtOAc/Hexane); m.p. 67 – 70 ˚C; IR (vmax/cm-1): 3322 (NH), 2979, 2937 (C-H), 1756, 
1689, 1660 (C=O), 1497, 1455 (C=C), 1161 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.45 – 7.02 (18H, m, Ar-
H), 5.47 – 4.77 and 4.61 – 4.12  (6H, 2xm, 2xNH,  H-2, H-3, H-12  and H-22), 3.77 – 3.58 (3H, m, H-20), 
3.23 – 2.83, 2.82 – 2.59 and 2.58 – 2.42 (10H, 3xm, NH, H-4, H-13, H-19  and H-23), 1.54 – 1.19 (18H, 
m, H-11 and H-30); 13C NMR (75 MHz, CDCl3) δ 171.09, 170.94 and 167.39 (C-21, C-18 and C-1), 155.18 
and 154.39 (C-28 and C-9), 137.36 (Ar-C), 136.66 (Ar-C), 136.07 (Ar-C), 129.47 (Ar-C), 129.37 (Ar-C), 
129.17 (Ar-C), 128.88 (Ar-C), 128.46 (Ar-C), 128.27 (Ar-C), 127.26 (Ar-C), 126.95 (Ar-C), 126.41 (Ar-C), 
80.47 and 79.44 (C-29 and C-10), 75.03 (C-2), 61.57 (C-20), 54.67, 52.61 and 50.28 (C-22, C-12 and C-
3), 38.04, 37.85 and 37.38 (C-23, C-13 and C-4), 32.13 (C-19), 28.33 (C-30 and C-11); HRMS m/z: 
calculated for C40H53N4O9: 733.3813, found [M + H]+: 733.3807. 
4.4.16 Synthesis of (2R)-(5R,9S)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-dioxa-
3,6,10-triazatetradecan-8-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 36 
 
D-phenylalanine isocyanide (100 mg, 0.46 mmol), N-Boc-L-phenylalaninal (115 mg, 0.46 mmol) and N-
Boc-D-phenylalanine (122 mg, 0.46 mmol) were stirred in CH2Cl2 (4 ml) at room temperature for 5 d. 
The preparation was completed using the same procedure as described in 4.4.9 to yield 36 (0.27 g, 
80%) as a (1.94 : 1.00) mixture of diastereomers. The mixture was then separated by preparative HPLC 
to obtain two pure diastereomers, the major being 36A and the minor 36B. 
(2R)-(5R,8R,9S)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-dioxa-3,6,10-
triazatetradecan-8-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 36A 
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Rf = 0.62 (50% EtOAc/Hexane); m.p. 83 – 85 ˚C; IR (vmax/cm-1): 3313 (NH), 2974, 2938 (C-H), 1753, 
1695, 1656 (C=O), 1497, 1455 (C=C), 1163 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.45 – 6.99 (17H, m, Ar-
H), 5.39 – 4.86 and 4.70 – 4.12  (6H, 2xm, 2xNH,  H-2, H-3, H-12  and H-22), 3.81 – 3.55 (3H, m, H-20), 
3.31 – 2.76 and 2.75 – 2.46 (10H, 2xm, NH, H-4, H-13, H-19  and H-23), 1.50 – 1.21 (18H, m, H-11 and 
H-30); 13C NMR (75 MHz, CDCl3) δ 171.09, 170.89 and 167.37 (C-21, C-18 and C-1), 155.18 and 154.38 
(C-28 and C-9), 137.34 (Ar-C), 136.04 (Ar-C), 135.97 (Ar-C), 129.47 (Ar-C), 129.37 (Ar-C), 129.17 (Ar-C), 
128.88 (Ar-C), 128.41 (Ar-C), 128.27 (Ar-C), 127.24 (Ar-C), 126.95 (Ar-C), 126.41 (Ar-C), 80.50 and 79.40 
(C-29 and C-10), 75.09 (C-2), 61.51 (C-20), 54.73, 52.56 and 50.25 (C-22, C-12 and C-3), 37.86, 37.72 
and 37.35 (C-23, C-13 and C-4), 32.13 (C-19), 28.33 (C-30 and C-11); HRMS m/z: calculated for 
C40H53N4O9: 733.3813, found [M + H]+: 733.3824.  
(2R)-(5R,8S,9S)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-dioxa-3,6,10-
triazatetradecan-8-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 36B 
 
Rf = 0.62 (50% EtOAc/Hexane); m.p. 72 – 75 ˚C; IR (vmax/cm-1): 3312 (NH), 2973, 2938 (C-H), 1753, 
1692, 1656 (C=O), 1497, 1455 (C=C), 1163 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.46 – 7.01 (18H, m, Ar-
H), 5.37 – 4.89 and 4.71 – 4.15  (6H, 2xm, 2xNH,  H-2, H-3, H-12 and H-22), 3.76 – 3.56 (3H, m, H-20), 
3.30 – 2.83 and 2.76 – 2.55 (10H, 2xm, NH, H-4, H-13, H-19  and H-23), 1.47 – 1.26 (18H, m, H-11 and 
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H-30); 13C NMR (75 MHz, CDCl3) δ 171.15, 170.91 and 166.73 (C-21, C-18 and C-1), 155.37 and 155.15 
(C-28 and C-9), 137.37 (Ar-C), 136.09 (Ar-C), 135.95 (Ar-C), 129.47 (Ar-C), 129.36 (Ar-C), 129.16 (Ar-C), 
128.79 (Ar-C), 128.44 (Ar-C), 128.26 (Ar-C), 127.23 (Ar-C), 126.93 (Ar-C), 126.40 (Ar-C), 80.47 and 79.45 
(C-29 and C-10), 75.05 (C-2), 61.57 (C-20), 55.46, 52.66 and 50.29 (C-22, C-12 and C-3), 38.01, 37.86 
and 35.96 (C-23, C-13 and C-4), 32.18 (C-19), 28.32 (C-30 and C-11); HRMS m/z: calculated for 
C40H53N4O9: 733.3813, found [M + H]+: 733.3824. 
4.4.17 Synthesis of (2R)-(5S,9R)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-dioxa-
3,6,10-triazatetradecan-8-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 37 
 
L-phenylalanine isocyanide (125 mg, 0.57 mmol), N-Boc-D-phenylalaninal (142 mg, 0.57 mmol) and N-
Boc-D-phenylalanine (151 mg, 0.57 mmol) were stirred in CH2Cl2 (4 ml) at room temperature for 5 d. 
The preparation was completed using the same procedure as described in 4.4.9 to yield 37 (0.37 g, 
89%) as a (1.90 : 1.00) mixture of diastereomers. The mixture was then separated by preparative HPLC 
to obtain two pure diastereomers, the major being 37A and the minor 37B. 
(2R)-(5S,8S,9R)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-dioxa-3,6,10-
triazatetradecan-8-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 37A 
 
Rf = 0.62 (50% EtOAc/Hexane); m.p. 104 – 107 ˚C; IR (vmax/cm-1): 3354 (NH), 2973, 2938 (C-H), 1756, 
1690, 1656 (C=O), 1514, 1497 (C=C), 1165 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.38 – 7.11 (18H, m, Ar-
H), 6.96 – 6.53 (1H, m, NH), 5.32 – 5.09 (2H, m, H-2 and H-12), 4.99 – 4.83 (1H, m, NH), 4.66 – 4.53 and 
4.43 – 4.24 (2H, 2xm, H-22 and H-3), 3.61 (3H, s, H-20), 3.24 – 2.89 and 2.78 – 2.41 (10H, 2xm, NH, H-
4, H-13, H-19 and H-23), 1.51 – 1.21 (18H, m, H-11 and H-30); 13C NMR (75 MHz, CDCl3) δ 171.63, 
170.66 and 167.56 (C-21, C-18 and C-1), 155.44 and 154.84 (C-28 and C-9), 137.32 (Ar-C), 136.57 (Ar-
C), 135.84 (Ar-C), 129.45 (Ar-C), 129.40 (Ar-C), 129.18 (Ar-C), 128.86 (Ar-C), 128.46 (Ar-C), 128.32 (Ar-
C), 127.24 (Ar-C), 127.08 (Ar-C), 126.37 (Ar-C), 80.57 and 79.29 (C-29 and C-10), 74.13 (C-2), 61.41 (C-
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20), 55.14, 52.72 and 50.59 (C-22, C-12 and C-3), 37.85, 37.78 and 37.42 (C-23, C-13 and C-4), 32.02 
(C-19), 28.32 (C-30 and C-11). HRMS m/z: calculated for C40H53N4O9: 733.3813, found [M + H]+: 
733.3822. 
 
(2R)-(5S,8R,9R)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-dioxa-3,6,10-
triazatetradecan-8-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 37B 
 
Rf = 0.62 (50% EtOAc/Hexane); m.p. 98 – 102 ˚C; IR (vmax/cm-1): 3356 (NH), 2973, 2937 (C-H), 1755, 
1690, 1656 (C=O), 1526, 1497 (C=C), 1165 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.45 – 6.99 (18H, m, Ar-
H), 5.38 – 4.89 and 4.69 – 4.15  (6H, 2xm, 2xNH, H-2, H-3, H-12 and H-22), 3.76 – 3.56 (3H, m, H-20), 
3.29 – 2.83 and 2.75 – 2.45 (10H, 2xm, NH, H-4, H-13, H-19  and H-23), 1.47 – 1.26 (18H, m, H-11 and 
H-30); 13C NMR (75 MHz, CDCl3) δ 171.16, 170.66 and 167.37 (C-21, C-18 and C-1), 155.57 and 154.83 
(C-28 and C-9), 137.40 (Ar-C), 136.42 (Ar-C), 135.69 (Ar-C), 129.46 (Ar-C), 129.39 (Ar-C), 129.18 (Ar-C), 
128.86 (Ar-C), 128.46 (Ar-C), 128.33 (Ar-C), 127.30 (Ar-C), 126.93 (Ar-C), 126.41 (Ar-C), 80.56 and 79.39 
(C-29 and C-10), 74.19 (C-2), 61.56 (C-20), 55.14, 52.91 and 50.60 (C-22, C-12 and C-3), 37.93, 37.81 
and 37.52 (C-23, C-13 and C-4), 32.09 (C-19), 28.35 (C-30 and C-11); HRMS m/z: calculated for 
C40H53N4O9: 733.3813, found [M + H]+: 733.3822. 
4.4.18 Synthesis of (2S)-(5S,9S)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-dioxa-
3,6,10-triazatetradecan-8-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 38 
 
L-phenylalanine isocyanide (125 mg, 0.57 mmol), N-Boc-L-phenylalaninal (142 mg, 0.57 mmol) and N-
Boc-L-phenylalanine (151 mg, 0.57 mmol) were stirred in CH2Cl2 (4 ml) at room temperature for 5 d. 
The preparation was completed using the same procedure as described in 4.4.9 to yield 38 (0.32 g, 
77%) as a (1.78 : 1.00) mixture of diastereomers. The mixture was then separated by preparative HPLC 
to obtain two pure diastereomers, the major being 38A and the minor 38B. 
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(2S)-(5S,8R,9S)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-dioxa-3,6,10-
triazatetradecan-8-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 38A 
 
Rf = 0.62 (50% EtOAc/Hexane); m.p. 136 – 139 ˚C; IR (vmax/cm-1): 3358 (NH), 2973, 2938 (C-H), 1755, 
1691, 1660 (C=O), 1527, 1497 (C=C), 1165 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.39 – 7.10 (18H, m, Ar-
H), 5.32 – 5.15 (2H, m, H-2 and H-12), 5.12 – 5.00 (1H, m, NH), 4.98 – 4.90 (1H, m, NH), 4.48 – 4.35  
and 4.29 – 4.13 (2H, 2xm, H-22  and H-3), 3.62 (3H, s, H-20), 3.23 – 2.85 and 2.61 – 2.46 (10H, 2xm, 
NH, H-4, H-13, H-19  and H-23), 1.47 – 1.27 (18H, m, H-11 and H-30); 13C NMR (75 MHz, CDCl3) δ 
171.20, 170.81 and 167.43 (C-21, C-18 and C-1), 155.45 and 154.78 (C-28 and C-9), 137.39 (Ar-C), 
136.48 (Ar-C), 135.61 (Ar-C), 129.44 (Ar-C), 129.39 (Ar-C), 129.14 (Ar-C), 128.91 (Ar-C), 128.39 (Ar-C), 
128.34 (Ar-C), 127.41 (Ar-C), 126.83 (Ar-C), 126.43 (Ar-C), 80.63 and 79.27 (C-29 and C-10), 73.97 (C-
2), 61.56 (C-20), 55.22, 52.90 and 50.23 (C-22, C-12 and C-3), 37.99, 37.71 and 37.40 (C-23, C-13 and 
C-4), 32.08 (C-19), 28.32 (C-30 and C-11); HRMS m/z: calculated for C40H53N4O9: 733.3813, found [M + 
H]+: 733.3802. 
(2S)-(5S,8S,9S)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-dioxa-3,6,10-
triazatetradecan-8-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 38B 
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Rf = 0.62 (50% EtOAc/Hexane); m.p. 119 – 122 ˚C; IR (vmax/cm-1): 3357 (NH), 2971, 2939 (C-H), 1756, 
1692, 1659 (C=O), 1519, 1497 (C=C), 1164 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.45 – 6.99 (17H, m, Ar-
H), 5.38 – 4.86 and 4.70 – 4.13  (6H, 2xm, 2xNH,  H-2, H-3, H-12  and H-22), 3.81 – 3.55 (3H, m, H-20), 
3.30 – 2.76 and 2.75 – 2.46 (10H, 2xm, NH, H-4, H-13, H-19  and H-23), 1.50 – 1.20 (18H, m, H-11 and 
H-30); 13C NMR (75 MHz, CDCl3) δ 171.15, 170.91 and 166.73 (C-21, C-18 and C-1), 155.37 and 155.15 
(C-28 and C-9), 137.37 (Ar-C), 136.09 (Ar-C), 135.95 (Ar-C), 129.47 (Ar-C), 129.36 (Ar-C), 129.16 (Ar-C), 
128.79 (Ar-C), 128.44 (Ar-C), 128.26 (Ar-C), 127.23 (Ar-C), 126.93 (Ar-C), 126.40 (Ar-C), 80.47 and 79.45 
(C-29 and C-10), 75.05 (C-2), 61.57 (C-20), 55.46, 52.66 and 50.29 (C-22, C-12 and C-3), 38.01, 37.86 
and 35.96 (C-23, C-13 and C-4), 32.18 (C-19), 28.32 (C-30 and C-11); HRMS m/z: calculated for 
C40H53N4O9: 733.3813, found [M + H]+: 733.3802. 
4.4.19 Synthesis of (2S)-(5S,9R)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-dioxa-
3,6,10-triazatetradecan-8-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 39 
 
L-phenylalanine isocyanide (125 mg, 0.57 mmol), N-Boc-D-phenylalaninal (142 mg, 0.57 mmol) and N-
Boc-L-phenylalanine (151 mg, 0.57 mmol) were stirred in CH2Cl2 (4 ml) at room temperature for 5 d. 
The preparation was completed using the same procedure as described in 4.4.9 to yield 39 (0.37 g, 
89%) as a (1.85 : 1.00) mixture of diastereomers. The mixture was then separated by preparative HPLC 
to obtain two pure diastereomers, the major being 39A and the minor 39B. 
(2S)-(5S,8S,9R)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-dioxa-3,6,10-
triazatetradecan-8-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 39A 
 
Rf = 0.62 (50% EtOAc/Hexane); m.p. 68 – 70 ˚C; IR (vmax/cm-1): 3320 (NH), 2976, 2936 (C-H), 1753, 
1690, 1655 (C=O), 1522, 1497 (C=C), 1163 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.38 – 7.10 (18H, m, Ar-
H), 6.97 – 6.83 (1H, m, NH), 5.32 – 5.09 (2H, m, H-2 and H-12), 4.99 – 4.84 (1H, m, NH), 4.66 – 4.53 and 
4.43 – 4.24 (2H, 2xm, H-22 and H-3), 3.61 (3H, s, H-20), 3.24 – 2.89 and 2.78 – 2.41 (10H, 2xm, NH, H-
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4, H-13, H-19 and H-23), 1.51 – 1.21 (18H, m, H-11 and H-30); 13C NMR (75 MHz, CDCl3) δ 171.09, 
170.89 and 167.37 (C-21, C-18 and C-1), 155.18 and 154.38 (C-28 and C-9), 137.34 (Ar-C), 136.04 (Ar-
C), 135.97 (Ar-C), 129.47 (Ar-C), 129.37 (Ar-C), 129.17 (Ar-C), 128.88 (Ar-C), 128.41 (Ar-C), 128.27 (Ar-
C), 127.24 (Ar-C), 126.95 (Ar-C), 126.41 (Ar-C), 80.50 and 79.40 (C-29 and C-10), 75.09 (C-2), 61.51 (C-
20), 54.73, 52.56 and 50.25 (C-22, C-12 and C-3), 37.86, 37.72 and 37.35 (C-23, C-13 and C-4), 32.13 
(C-19), 28.33 (C-30 and C-11); HRMS m/z: calculated for C40H53N4O9: 733.3813, found [M + H]+: 
733.3799. 
 
(2S)-(5S,8R,9R)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-dioxa-3,6,10-
triazatetradecan-8-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 39B 
 
Rf = 0.62 (50% EtOAc/Hexane); m.p. 71 – 74 ˚C; IR (vmax/cm-1): 3311 (NH), 2974, 2938 (C-H), 1753, 
1689, 1655 (C=O), 1497 (C=C), 1160 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.48 – 7.08 (17H, m, Ar-H), 5.46 
– 4.83 and 4.76 – 4.28  (6H, 2xm, 2xNH,  H-2, H-3, H-12  and H-22), 3.75 – 3.66 (3H, m, H-20), 3.22 – 
2.87 and 2.79 – 2.58 (10H, 2xm, NH, H-4, H-13, H-19  and H-23), 1.55 – 1.21 (18H, m, H-11 and H-30); 
13C NMR (75 MHz, CDCl3) δ 171.09, 170.94 and 167.39 (C-21, C-18 and C-1), 155.18 and 154.39 (C-28 
and C-9), 137.36 (Ar-C), 136.66 (Ar-C), 136.07 (Ar-C), 129.47 (Ar-C), 129.37 (Ar-C), 129.17 (Ar-C), 128.88 
(Ar-C), 128.46 (Ar-C), 128.27 (Ar-C), 127.26 (Ar-C), 126.95 (Ar-C), 126.41 (Ar-C), 80.47 and 79.44 (C-29 
and C-10), 75.03 (C-2), 61.57 (C-20), 54.67, 52.61 and 50.28 (C-22, C-12 and C-3), 38.04, 37.85 and 
37.38 (C-23, C-13 and C-4), 32.13 (C-19), 28.33 (C-30 and C-11); HRMS m/z: calculated for C40H53N4O9: 
733.3813, found [M + H]+: 733.3799. 
4.4.20 Synthesis of (2R)-(5S,9S)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-dioxa-
3,6,10-triazatetradecan-8-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 40 
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L-phenylalanine isocyanide (125 mg, 0.57 mmol), N-Boc-L-phenylalaninal (142 mg, 0.57 mmol) and N-
Boc-D-phenylalanine (151 mg, 0.57 mmol) were stirred in CH2Cl2 (4 ml) at room temperature for 5 d. 
The preparation was completed using the same procedure as described in 4.4.9 to yield 40 (0.41 g, 
98%) as a (2.03 : 1.00) mixture of diastereomers. The mixture was then separated by preparative HPLC 
to obtain two pure diastereomers, the major being 40A and the minor 40B. 
(2R)-(5S,8R,9S)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-dioxa-3,6,10-
triazatetradecan-8-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 40A 
 
Rf = 0.62 (50% EtOAc/Hexane); m.p. 65 – 67 ˚C; IR (vmax/cm-1): 3318 (NH), 2974, 2938 (C-H), 1746, 
1690, 1654 (C=O), 1497 (C=C), 1160 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.43 – 6.96 (17H, m, Ar-H), 5.31 
– 5.05 (2H, m, H-2 and H-12), 4.98 – 4.72 (2H, m, 2xNH), 4.56 – 4.40  and 4.40 – 4.21 (2H, 2xm, H-22  
and H-3), 3.66 (3H, s, H-20), 3.21 – 2.83 and 2.74 – 2.60 (10H, 2xm, NH, H-4, H-13, H-19  and H-23), 
1.53 – 1.19 (18H, m, H-11 and H-30); 13C NMR (75 MHz, CDCl3) δ 171.07, 170.41 and 167.40 (C-21, C-
18 and C-1), 155.59 and 154.77 (C-28 and C-9), 137.33 (Ar-C), 136.38 (Ar-C), 135.95 (Ar-C), 129.45 (Ar-
C), 129.34 (Ar-C), 129.18 (Ar-C), 128.86 (Ar-C), 128.44 (Ar-C), 128.39 (Ar-C), 127.24 (Ar-C), 126.87 (Ar-
C), 126.51 (Ar-C), 80.63 and 79.42 (C-29 and C-10), 74.46 (C-2), 61.52 (C-20), 54.66, 52.87 and 50.67 
(C-22, C-12 and C-3), 37.85, 37.66 and 37.39 (C-23, C-13 and C-4), 32.17 (C-19), 28.35 (C-30 and C-11); 
HRMS m/z: calculated for C40H53N4O9: 733.3813, found [M + H]+: 733.3815. 
 
(2R)-(5S,8S,9S)-5,9-dibenzyl-3,13,13-trimethyl-4,7,11-trioxo-2,12-dioxa-3,6,10-
triazatetradecan-8-yl 2-((tert-butoxycarbonyl)amino)-3-phenylpropanoate 40B 
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Rf = 0.62 (50% EtOAc/Hexane); m.p. 70 – 71 ˚C; IR (vmax/cm-1): 3317 (NH), 2973, 2940 (C-H), 1757, 
1689, 1656 (C=O), 1497 (C=C), 1164, 1055 (C-O); 1H NMR (300 MHz, CDCl3) δ 7.45 – 7.02 (18H, m, Ar-
H), 5.49 – 4.77 and 4.61 – 4.11  (6H, 2xm, 2xNH,  H-2, H-3, H-12 and H-22), 3.71 – 3.58 (3H, m, H-20), 
3.23 – 2.84, 2.82 – 2.60 and 2.59 – 2.40 (10H, 3xm, NH, H-4, H-13, H-19  and H-23), 1.54 – 1.20 (18H, 
m, H-11 and H-30); 13C NMR (75 MHz, CDCl3) δ 171.15, 170.91 and 166.73 (C-21, C-18 and C-1), 155.37 
and 155.15 (C-28 and C-9), 137.37 (Ar-C), 136.09 (Ar-C), 135.95 (Ar-C), 129.47 (Ar-C), 129.36 (Ar-C), 
129.16 (Ar-C), 128.79 (Ar-C), 128.44 (Ar-C), 128.26 (Ar-C), 127.23 (Ar-C), 126.93 (Ar-C), 126.40 (Ar-C), 
80.47 and 79.45 (C-29 and C-10), 75.05 (C-2), 61.57 (C-20), 55.46, 52.66 and 50.29 (C-22, C-12 and C-
3), 38.01, 37.86 and 35.96 (C-23, C-13 and C-4), 32.18 (C-19), 28.32 (C-30 and C-11); HRMS m/z: 
calculated for C40H53N4O9: 733.3813, found [M + H]+: 733.3815. 
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Appendix 
 
A1: Selected 1H, 13C and 19F NMR Spectra 
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19F NMR Spectrum of 18 from Lipase 6Y reaction 
 
 
 
19F NMR Spectrum of 18 from Lipase 6Z reaction 
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A2: Example of an HPLC method used for separation of Passerini compounds (Gradient 
elution) 
 
Pressure.LowerLimit =  0 [bar] 
 Pressure.UpperLimit =  350 [bar] 
 MaximumFlowRampDown =  6.000 [ml/min²] 
 MaximumFlowRampUp =  6.000 [ml/min²] 
 %A.Equate =  "%A" 
 %B.Equate =  "Acetronitrile" 
 %C.Equate =  "Water" 
 %D.Equate =  "%D" 
 Pump_Pressure.Step =  Auto 
 Pump_Pressure.Average =  On 
 Data_Collection_Rate =  10.00 [Hz] 
 Rise_Time =  0.20 [s] 
 UV_VIS_1.Wavelength =  225 [nm] 
 UV_VIS_1.Bandwidth =  4 [nm] 
 UV_VIS_1.RefWavelength =  Off 
 UV_VIS_1.RefBandwidth =  1 [nm] 
 UV_VIS_2.Wavelength =  275 [nm] 
 UV_VIS_2.Bandwidth =  4 [nm] 
 UV_VIS_2.RefWavelength =  Off 
 UV_VIS_2.RefBandwidth =  1 [nm] 
 UV_VIS_3.Wavelength =  330 [nm] 
 UV_VIS_3.Bandwidth =  4 [nm] 
 UV_VIS_3.RefWavelength =  Off 
 UV_VIS_3.RefBandwidth =  1 [nm] 
 UV_VIS_4.Wavelength =  400 [nm] 
 UV_VIS_4.Bandwidth =  4 [nm] 
 UV_VIS_4.RefWavelength =  Off 
 UV_VIS_4.RefBandwidth =  1 [nm] 
 UV_VIS_5.Wavelength =  550 [nm] 
 UV_VIS_5.Bandwidth =  4 [nm] 
 UV_VIS_5.RefWavelength =  Off 
 UV_VIS_5.RefBandwidth =  1 [nm] 
 3DFIELD.RefWavelength =  380 [nm] 
 3DFIELD.RefBandwidth =  50 [nm] 
 3DFIELD.MinWavelength =  300 [nm] 
 3DFIELD.MaxWavelength =  700 [nm] 
 3DFIELD.BunchWidth =  3 [nm] 
 
 0.000 Autozero 
 Wait AZ_Done 
 Flow =  1.000 [ml/min] 
 %B =  60.0 [%] 
 %C =  40.0 [%] 
 %D =  0.0 [%] 
 Inject 
 Pump_Pressure.AcqOn 
 UV_VIS_1.AcqOn 
 UV_VIS_2.AcqOn 
 UV_VIS_3.AcqOn 
 UV_VIS_4.AcqOn 
 UV_VIS_5.AcqOn 
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 3DFIELD.AcqOn 
 Flow =  1.000 [ml/min] 
 %B =  60.0 [%] 
 %C =  40.0 [%] 
 %D =  0.0 [%] 
 
10.000 Flow =  1.000 [ml/min] 
 %B =  60.0 [%] 
 %C =  40.0 [%] 
 %D =  0.0 [%] 
 
12.000 Flow =  1.000 [ml/min] 
 %B =  90.0 [%] 
 %C =  10.0 [%] 
 %D =  0.0 [%] 
 
35.000 Pump_Pressure.AcqOff 
 UV_VIS_1.AcqOff 
 UV_VIS_2.AcqOff 
 UV_VIS_3.AcqOff 
 UV_VIS_4.AcqOff 
 UV_VIS_5.AcqOff 
 3DFIELD.AcqOff 
 Flow =  1.000 [ml/min] 
 %B =  90.0 [%] 
 %C =  10.0 [%] 
 %D =  0.0 [%] 
 
36.000    motor = off 
 End 
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A3: Passerini compound 14 calculations 
 
 
 
Example: At 20 min Lipase 6Y 
 
 
 
 
From HPLC data: 
Peak area % of Product 1: 5.82 
Peak area % of Product 2: 1.60 
Total peak area of Products: 5.82 + 1.60 = 7.42 
Ratio of Product 1: 5.82/7.42 = 0.784 
Ratio of Product 2: 1.60/7.42 = 0.216 
eePRODUCT = 0.784 – 0.216 = 0.568 (56.8%) 
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Peak area % of Substrate 1: 44.06 
Peak area % of Substrate 2: 48.51 
Total peak area of Substrates: 44.06 + 48.51 = 92.57 
Ratio of Substrate 1: 44.06/92.57 = 0.476 
Ratio of Substrate 2: 48.51/92.57 = 0.524 
eeSUBSTRATE = 0.524 – 0.476 = 0.048 (4.80%) 
 
From equation 1:  
Conversion = ees / (ees + eep) = 0.048/(0.048+0.568) = 0.0779 (7.79%) 
 
Equation 2: 
E = Ln[1-c(1+eep)] / Ln[1-c(1-eep)]    
   =Ln[1-0.0779(1+0.568)]/Ln[1-0.0779(1-0.568)] = Ln(0.8779)/Ln(0.9663) = 3.80     
 
Equation 3: 
E = Ln[(1-c)(1-ees)] / Ln[(1-c)(1+ees)]    
   =Ln[(1-0.0779)(1-0.048)]/Ln[(1-0.0779)(1+0.0.048)] = Ln(0.8779)/Ln(0.9663) = 3.80   
 
 
